MXPA99009237A - Compositions and methods forthe treatment and diagnosis of breast cancer - Google Patents

Abstract

Compositions and methods for the detection and therapy of breast cancer are disclosed. The compounds provided include nucleotide sequences that are preferentially expressed in breast tumor tissue, as well as polypeptides encoded by such nucleotide sequences. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of antibodies, which are useful for diagnosing and monitoring the progression of breast cancer patient.

Description

COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER TECHNICAL FIELD The present invention relates generally to the detection and therapy of breast cancer. The invention relates more specifically to nucleotide sequences which are preferentially expressed in breast tumor tissue and to polypeptides encoded by such nucleotide sequences. The nucleotide and polypeptide sequences can be used in vaccines and pharmaceutical compositions for the prevention and treatment of breast cancer. The polypeptides can also be used for the production of compounds, such as antibodies, useful for diagnosing and monitoring the progression of breast cancer in a patient.

BACKGROUND OF THE INVENTION Breast cancer is a major health problem for women in the United States and throughout the world. Although it has excelled in the detection and treatment of the disease, breast cancer remains the second cause of cancer-related deaths in women, affecting more than 1 80,000 women in the United States each year. For women in North America, the probability of having breast cancer is now one in eight. Currently there is no vaccine or other universally successful method for the prevention or treatment of breast cancer. The management of the disease is currently based on a combination of early diagnosis (through routine breast examination procedures) and aggressive treatment, which may include one or more of a variety of treatments, such as surgery, radiation therapy, chemotherapy and hormone therapy. The course of treatment for a particular breast cancer is often selected in a variety of prognostic parameters, including an analysis of specific tumor markers. See, for example, Porter-Jordan and Lippman, Breast Cancer 8: 73-1 00 (1994). However, the use of established markers frequently leads to a result that is difficult to interpret and the high mortality observed in patients with breast cancer indicates that improvements are needed in the treatment, diagnosis and prevention of the disease. Accordingly, there is a need in the art for improved methods for therapy and diagnosis of breast cancer. The present invention satisfies these needs and provides other related advantages.

BRIEF DESCRIPTION OF THE INVENTION Briefly, the present invention provides compositions and methods for the diagnosis and therapy of breast cancer. In one aspect, isolated DNA molecules are provided, comprising (a) a nucleotide sequence preferentially expressed in breast cancer tissue, relative to normal tissue; (b) a variant of such sequence containing one or more substitutions, deletions, insertions and / or nucleotide modifications in no more than 20% (preferably not more than 5%) of the nucleotide positions, so that the properties antigenic and / or immunogenic of the polypeptide encoded by the nucleotide sequence are retained; or (c) a nucleotide sequence encoding an epitope of a polypeptide encoded by at least one of the above sequences. In one embodiment, the isolated DNA molecule comprises a human endogenous retroviral sequence declared in SEQ ID NO: 1. In other embodiments, the isolated DNA molecule comprises a nucleotide sequence declared in any of SEQ ID NO: 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194 -198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273 , 275, 276, 278, 280, 281, 284, 288 and 291-297.

In related embodiments, the isolated DNA molecule encodes an epitope of a polypeptide, wherein the polypeptide is encoded by a nucleotide sequence that: (a) hybridizes to a sequence declared in any of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 197-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297 under severe conditions; and (b) is at least 80% identical to a sequence declared in any of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192 , 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271 -273, 275, 276, 278, 280, 281, 284, 288 and 291-297; and wherein the RNA corresponding to said nucleotide sequence is expressed at a higher level in human breast tumor tissue than in normal breast tissue.

In another embodiment, the present invention provides an isolated DNA molecule encoding an epitope of a polypeptide, the peptide being encoded by: (a) a nucleotide sequence transcribed from the sequence of SEQ I D NO: 141; or (b) a variant of said nucleotide sequence containing one or more substitutions, deletions, insertions and / or modifications of nucleotides, in no more than 20% of the nucleotide positions, so that the antigenic and / or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained. Also provided are DNA and RNA molecules comprising a nucleotide sequence complementary to a DNA molecule as described above. In related aspects, the present invention provides recombinant expression vectors comprising a DNA molecule as described above, and host cells transformed or transfected with such expression vectors. In additional aspects, polypeptides are provided, comprising an amino acid sequence encoded by a DNA molecule as described above, and monoclonal antibodies that bind such polypeptides. In yet another aspect, methods for determining the presence of breast cancer in a patient are provided. In one embodiment, the method comprises detecting, within a biological sample, a polypeptide as described above. In another embodiment, the method comprises detecting, within a biological sample, an RNA molecule encoding a polypeptide as described above. In still another embodiment, the method comprises (a) injecting intradermally a patient with a polypeptide as described above; and (b) detecting an immune response in the patient's skin, and thereby detecting the presence of breast cancer in the patient. In additional embodiments, the present invention provides methods for determining the presence of breast cancer in a patient as described above, wherein the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO.78-86, 144, 145, 1 53, 167, 177, 1 93, 1 99, 205, 208, 21 5, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under severe conditions. In a related aspect, diagnostic sets useful in the determination of breast cancer are provided. The diagnostic sets usually comprise either one or more monoclonal antibodies as described above, or one or more monoclonal antibodies that bind to a polypeptide encoded by a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID NO. 78-89, 144, 145, 1 53, 167, 177, 1 93, 199, 205, 208, 21 5, 217, 220, 241, 242 and 246, 248, 249, 252, 256, 267, 270, 274 , 277, 279, 282, 283, 285-287, 289, 290 and a detection reagent. Within a related aspect, the diagnostic set comprises a first polymerase chain reaction primer and a second polymerase chain reaction primer, at least one of the primers being specific for a RNA molecule described. In Z > In one embodiment, at least one of the primers comprises at least about 10 contiguous nucleotides of an RNA molecule as described above, or an RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO. : 78-86, 144, 145, 1 53, 1 67, 1 77, 193, 199, 205, 208, 21 5, 21 7, 220, 241, 242 246, 248, 249, 252, 256, 267, 270 , 274, 277, 279, 282, 283, 285-287, 289 and 290. Within another related aspect, the diagnostic set comprises at least one oligonucleotide probe, the probe being specific for a DNA molecule described herein. In one embodiment, the probe comprises at least about 1 5 contiguous nucleotides of a DNA molecule as described above, or a DNA molecule selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 1 53, 1 67, 177, 1 93, 1 99, 205, 208, 215, 217, 220, 241, 242 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290. In another related aspect, the present invention provides methods for monitoring the progression of cancer of breast in a patient. In one embodiment, the method comprises: (a) detecting an amount, in a biological sample, of a polypeptide as described above at a first point in time; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of polypeptide detected in step (a) and (b), and hence monitoring the progression of breast cancer in the patient. In another embodiment, the method comprises (a) detecting an amount, within a biological sample, of an RNA molecule encoding a polypeptide as described above at a first point in time; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of RNA molecules detected in steps (a) and (b), and then monitoring the progression of breast cancer in the patient. In still other embodiments, the present invention provides methods for monitoring the progression of breast cancer in a patient as described above, wherein the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86. , 144, 145, 1 53, 167, 177, 1 93, 199, 205, 208, 21 5, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277 , 279, 282, 283, 285-287, 289, 290 and sequences that hybridize to them under severe conditions. In yet other aspects, pharmaceutical compositions are provided, which comprise a polypeptide as described above in combination with a physiologically acceptable carrier, and vaccines, which comprise a polypeptide as described above in combination with an immune response enhancer or helper. . In still other aspects, the present invention provides pharmaceutical compositions and vaccines comprising a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 53, 167, 177, 1 93, 1 99, 205, 208, 21 5, 21 7, 220, 241, 242 and 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize to them under severe conditions. In related aspects, the present invention provides methods for inhibiting the development of breast cancer in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above. These and other aspects of the present invention will become apparent upon reference to the following detailed description and accompanying drawings. All references described herein are incorporated herein by reference in their entirety as if each were incorporated individually.

BRIEF DESCRIPTION OF THE DIAMETERS Figure 1 shows the differential display PCR products, separated by electrophoresis in gei, obtained from cDNA prepared from normal breast tissue (lanes 1 and 2) and from cDNA prepared from breast tumor tissue of the same patient (lanes 3 and 4). The arrow indicates the band corresponding to B 1 8Ag 1. Figure 2 is a Northern blot comparing the mRNA level of B 1 8Ag 1 in breast tumor tissue (lane 1) with the level in normal breast tissue. Figure 3 shows B 18Ag 1 mRNA level in breast tumor tissue compared to that in various normal and non-breast tumor tissues as determined by RNase protection assays. Figure 4 is a map of genomic clones showing the location of additional retroviral sequences obtained from the ends of Xbal restriction digests (provided in SEQ I D NO: 3 - SEQ I D NO: 1 0) in relation to B1 8Ag 1.

Figures 5A and 5B show the sequencing strategy, genomic organization, and predicted open reading frame for the retroviral element containing B18Ag1. Figure 6 shows the nucleotide sequence of B18Ag1 of representative breast tumor-specific cDNA. Figure 7 shows the nucleotide sequence of B17Ag1 of representative breast tumor-specific cDNA. Figure 8 shows the nucleotide sequence of B17Ag2 of representative breast tumor-specific cDNA. Figure 9 shows the nucleotide sequence of B13Ag2a of representative breast tumor-specific cDNA. Figure 10 shows the nucleotide sequence of B13Ag1b of representative breast tumor-specific cDNA. Figure 11 shows the nucleotide sequence of B13Ag1a of representative breast tumor-specific cDNA. Figure 12 shows the nucleotide sequence of B11Ag1 of representative breast tumor-specific cDNA. Figure 13 shows the nucleotide sequence of B3CA3c of representative breast tumor-specific cDNA. Figure 14 shows the nucleotide sequence of B9CG1 of representative breast tumor-specific cDNA. Figure 15 shows the nucleotide sequence of B9CG3 of representative breast tumor-specific cDNA. Figure 16 shows the nucleotide sequence of B2CA2 of representative breast tumor-specific cDNA.

Figure 17 shows the nucleotide sequence of B3CA1 of representative breast tumor-specific cDNA. Figure 1 8 shows the nucleotide sequence of B3CA2 of representative breast tumor-specific cDNA. Figure 1.9 shows the nucleotide sequence of B3CA3 of representative breast tumor-specific cDNA. Figure 20 shows the nucleotide sequence of B4CA1 of representative breast tumor-specific cDNA. Figure 21 shows the RT-PCR analysis of breast tumor genes in breast tumor tissues (lanes 1 -8) and normal breast tissues (lanes 9-1 3) and H20 (lane 14). Figure 21 B shows the RT-PCR analysis of breast tumor genes in prostate tumors (lane 1, 2), colon tumors (lane 3), lung tumor (lane 4), normal prostate (lane 5) , normal colon (lane 6), normal kidney (lane 7), normal liver (lane 8), normal lung (lane 9), normal ovary (lanes 1 0, 1 8), normal pancreas (lane 1 1, 12), normal skeletal muscle (lane 1 3), normal skin (lane 14), normal stomach (lane 1 5), normal testicles (lane 16), normal small bowel (lane 1 7), HBL-1 00 (lane 1 9), MCF-1 2A (lane 20), breast tumors (lanes 21-23), H20 (lane 24) and colon tumor (lane 25).

DETAILED DESCRIPTION OF THE INVENTION As noted above, the present invention is generally directed to compositions and methods for the diagnosis, monitoring and therapy of breast cancer. The compositions described herein include polypeptides, nucleic acid sequences and antibodies. The polypeptides of the present invention generally comprise at least a portion of a protein that is expressed at a higher level of human breast tumor tissue than in normal breast tissue (i.e., the level of RNA encoding the polypeptide is at least 2 times higher in tumor tissue). Such polypeptides are referred to herein as breast tumor-specific polypeptides, and cDNA molecules encoding such polypeptides are referred to as breast tumor-specific cDNAs. The nucleic acid sequences of the present invention generally comprise a DNA or RNA sequence that encodes all or a portion of a polypeptide as described above, or that is complementary to such a sequence. The antibodies are generally immune system proteins, or fragments thereof, which are capable of binding to a portion of a polypeptide as described above. The antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via the transfection of antibody genes in suitable bacterial or mammalian cell hosts, in order to allow the production of antibodies. recombinants. Polypeptides within the scope of this invention include, but are not limited to, polypeptides (and epitopes thereof) encoded by a human endogenous retroviral sequence, such as the sequence designated B 1 8Ag 1 (Figure 5 and S EQ ID NO. : 1 ). Polypeptides encoded by other sequences within the retroviral genome containing B 1 8Ag 1 (SEQ ID NO: 141) are also within the scope of the present invention. Such sequences include, but are not limited to, the sequences reported in SEQ ID NO: 3-SEQ ID NO: 10. B 1 8Ag 1 has homology to the p30 gag gene of the endogenous human retroviral element S71, as described in Werner et al. , Virology 174: 225-238 (1990) and also shows homology with approximately thirty other retroviral gag genes. As discussed in more detail below, the present invention also includes a number of additional breast tumor-specific polypeptides, such as those encoded by the nucleotide sequences reported in SEQ ID NO: 1 1-26, 28-77, 142 , 146, 146-1 52, 1 54-166, 1 68-1 76, 178-1 92, 1 97-1 98, 200-204, 206, 207, 209-214, 21 6, 21 8, 21 9 , 221 -240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271 -273, 275, 276, 278, 280, 281, 284, 288 and 291-297. As used herein, the term "polypeptide" encompasses chains of amino acids of any length, including full length proteins containing the sequences disclosed herein. A polypeptide comprising an epitope of a protein containing a sequence as described herein may consist entirely of the epitope, or may contain additional sequences. The additional sequences may be derived from the natural protein or may be heterologous, and such sequences may (but not necessarily) possess immunogenic or antigenic properties. An "epitope", as used herein, is a portion of a polypeptide that is recognized (i.e., specifically bound) by a T cell and / or B cell surface antigen receptor. Epitopes can be identified generally using well-known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed. , 143-147 (Raven Press, 1993) and references cited therein. Such techniques include classifying polypeptides derived from the native polypeptide by the ability to react with antigen-specific serum and / or clones or T cell lines. An epitope of a polypeptide is a portion that reacts with such antiserum and / or T cells to a level that is similar to the reactivity of the full length polypeptide (e.g., in a T cell and / or ELISA reactivity assay). Such classifications can be made generally using well-known methods for those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual (Antibodies: a laboratory manual), Cold Spring Harbor Laboratory, 1 988. B cell and T cell epitopes can also be predicted via computer analysis. Polypeptides comprising an epitope of a polypeptide that is preferentially expressed in a tumor tissue (with or without additional amino acid sequence) are within the scope of the present invention. The compositions and methods of the present invention also encompass variants of the above polypeptides and nucleic acid sequences encoding such polypeptides. A "variant" of polypeptide, as used herein, is a polypeptide that differs from the natural polypeptide in substitutions and / or modifications, such that the antigenic and / or immunogenic properties of the polypeptide are retained. Such variants can be identified generally by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antiserum and / or T cells as described above. The nucleic acid variants may contain one or more substitutions, deletions, insertions and / or modifications, so that the antigenic and / or immunogenic properties of the polypeptide are retained. Such variants can be identified, in general, by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antiserum and / or T cells as described above. The nucleic acid variants may contain one or more substitutions, deletions, insertions and / or modifications, so that the antigenic and / or immunogenic properties of the encoded polypeptide are retained. A preferred variant of the polypeptides described herein is a variant containing substitutions, deletions, insertions and / or nucleotide modifications in no more than 20% of the nucleotide positions. Preferably, a variant contains conservative substitutions.

A "conservative substitution" is one in which an amino acid is substituted by another amino acid having similar properties, so that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to remain substantially unchanged. . In general, the following amino acid groups represent conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. The variants may also be (or alternatively) modified by, for example, the deletion or addition of amino acids that have minimal influence of the antigenic or immunogenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide can be conjugated to a signal sequence (or leader) at the N-terminus of the protein, which co-translationally or post-translationally directs the transfer of the protein. The polypeptide can also be conjugated to a linker or other sequence to facilitate the synthesis, purification or identification of the polypeptide (eg, poly-His), or to enhance the binding of the polypeptide to a solid support. For example, a polypeptide can be conjugated to an Fc region of immunoglobulin. In general, the nucleotide sequences encoding all or a portion of the polypeptides described herein can be prepared using any of several techniques. For example, the cDNA molecules encoding such polypeptides can be cloned on the basis of breast tumor specific expression of the corresponding mRNAs, using differential display PCR. This technique compares the amplified products from normal tissue and breast tumor RNA templates. The cDNA can be prepared by reverse transcription of RNA using an initiator (dT) 2AG. Following amplification of the cDNA using a random primer, a band corresponding to an amplified product specific for tumor RNA can be cut from a gel stained with silver and subcloned into a suitable vector (e.g., T-vector, Novagen Madison, Wl). The nucleotide sequences encoding all or a portion of the mammalian-specific polypeptides described herein can be amplified from the cDNA prepared as described above using the random primers shown in SEQ ID NO: 87-1 25. Alternatively , a gene encoding a polypeptide as described herein (or a portion thereof) can be amplified from human genomic DNA, or from breast tumor cDNA, via polymerase chain reaction. For this approach, sequence-specific primers B 18Ag 1 can be designed based on the sequence provided in SEQ ID NO: 1, and can be purchased or synthesized. A suitable primer pair for the amplification of breast tumor cDNA is (5 'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO: 1 26) and (5' CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO: 127). An amplified portion of B18Ag1 can then be used to isolate the full length gene from a human genomic DNA library or from a breast tumor cDNA library, using well known techniques, such as those described in Sambrook et al. , Molecular Cloning: A Laboratory Manual (Molecular Cloning: A Laboratory Manual), Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1989). Other sequences within the retroviral genome of which B1 8Ag 1 is a part can be prepared in a similar manner by classifying human genomic libraries using specific sequences of B 1 8Ag 1 as probes. The translated nucleotides in the retroviral genome protein shown in SEQ ID NO: 141 can then be determined by cloning the corresponding cDNAs, predicting open reading frames and cloning the appropriate cDNAs in a vector containing a viral promoter., such as T7. The resulting constructs can be employed in a translation reaction, using techniques known to those of skill in the art, to identify nucleotide sequences which result in the expressed protein. Similarly, the primers specific for the remaining breast tumor-specific polypeptides described herein may be designed based on the nucleotide sequences provided in SEQ ID NO: 1-SEQ ID NO: 86 and SEQ ID NO: 142- S EQ ID NO: 297. The recombinant polypeptides encoded by the DNA sequences described above can be easily prepared from the DNA sequences. For example, supernatants from suitable host / vector systems, which secrete polypeptide or recombinant protein in culture medium can be first concentrated using a commercially available filter. Following the concentration, the concentrate can be applied to a suitable purification matrix, such as an affinity matrix or an ion exchange resin. Finally, one or more steps of reverse phase H PLC can be used to further purify a recombinant polypeptide. In general, any of a variety of expression vectors known to those of ordinary skill in the art can be used to express recombinant polypeptides of this invention. Expression can be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule encoding a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line, such as COS or CHO. Such techniques can also be used to prepare polypeptides comprising epitopes or variants of the natural polypeptides. For example, variants of a natural polypeptide can be prepared in a general manner using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis, and sections of the NDA sequence can be removed to allow the preparation of truncated polypeptides. Portions and other variants having less than about 1 00 amino acids and generally less than about 50 amino acids can also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides can be synthesized using any of the commercially available solid phase techniques, such as the Merrifield solid phase synthesis method, where the amino acids are sequentially added to a chain of growing amino acids. See Merrifield, J. Am. Chem. Soc. 85: 2149-2146 (1 963). The equipment for the self-synthesized polypeptide synthesis is commercially available from suppliers such as Perkin Elmer / Applied BioSystems Division, Foster City, CA and can be operated according to the manufacturer's instructions. In specific embodiments, the polypeptides of the present invention encompass amino acid sequences encoded by a DNA molecule having a sequence declared in any of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-1 52, 1 54-166, 168-1 76, 1 78-1 92, 1 97-1 98, 200-204, 206, 207, 209-214, 216, 21 8, 21 9, 221 -240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271 -273, 275, 276, 278, 280, 281, 284, 288 and 291-297, variants of such polypeptides that are encoded by molecules of DNA containing one or more substitutions, deletions, insertions and / or modifications of nucleotides in no more than 20% of the nucleotide positions, and epitopes of the anti-anterior polypeptides. Polypeptides within the scope of the present invention also include polypeptides (and epitopes thereof) encoded by DNA sequences that hybridize to a DNA molecule having, a sequence declared in any of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-1 52, 1 54-166, 168-176, 1 78-1 92, 194-1 98, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271 -273, 275, 276, 278, 280, 281, 284, 288 and 291 -297 under severe conditions, wherein the DNA sequences are at least 80% identical in the overall sequence for a declared sequence and wherein the RNA corresponding to the nucleotide sequence it is expressed at a higher level in human breast tumor tissue than in normal breast tissue. As used herein, "severe conditions" refers to prewash in a solution of 6X SSC, 0.2% SDS; Hybridization at 65 ° C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1 X SSC, 0. 1% SDS at 65 ° C and two washes of 30 minutes each in 0.2 X SSC, 0. 1% SDS at 65 ° C. DNA molecules according to the present invention include molecules that encode any of the above polypeptides.

In another aspect of the present invention, antibodies are provided. Such antibodies can be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual (Antibodies: a laboratory manual), Cold Spring Harbor Laboratory, 1988. In such a technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals. íferos (for example, mice, rats, rabbits, lamb or goats). In this step, the polypeptides of this invention can serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be produced if the polypeptide is linked to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. The polyclonal polypeptides specific for the polypeptide can then be purified from such antiserum by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support. Monoclonal antibodies specific for the antigenic polypeptide of interest can be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:51 1 -51 9 (1 976) and improvements to it. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines can be produced, for example, from spleen cells obtained from an immunized animal as described above. Spleen cells are then immortalized by, for example, fusion with a fusion partner of myeloma cells, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques can be employed. For example, spleen cells and myeloma cells can be combined with a non-ionic detergent for a few minutes and then plated at low density in a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses a HAT selection (hypoxanthine, aminopterin, thymidine). After a sufficient time, usually about 1 to 2 weeks, hybrid colonies are observed. The single colonies are selected and their culture supernatants are tested for ligation activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred. Monoclonal antibodies can be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques can be employed to enhance performance, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies can then be collected from ascites fluid or blood. The contaminants can be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation and extraction. The polypeptides of this invention can be used in the purification process in, for example, an affinity chromatography step. Antibodies can be used, for example, in methods for detecting breast cancer in a patient. Such methods involve using an antibody to detect the presence or absence of a breast tumor-specific polypeptide as described herein in a suitable biological sample. As used herein, suitable biological samples include tissue or normal tissue biopsy, mastectomy, blood, lymph node, serum or urine samples, or another tissue, homogenate or extract thereof obtained from a patient. There are a variety of assay formats known to those of ordinary skill in the art to use an antibody to detect polypeptide markers in a sample. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual (Antibodies: a laboratory manual), Cold Spring Harbor Laboratory, 1988. For example, the assay can be performed in a Western blot format, wherein a preparation of Protein from the biological sample is subjected to gel electrophoresis, transferred to a suitable membrane and allowed to react with the antibody. The presence of the antibody in the membrane can then be detected using a suitable detection reagent, as described below. In another embodiment, the assay involves the use of immobilized antibody on a solid support to bind to the polypeptide and remove it from the rest of the sample. The bound polypeptide can then be detected using a second antibody or reagent containing a reporter group. Alternatively, a competitive assay may be used, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized antibody after incubation of the antibody with the sample. The degree to which the components of the sample inhibit the binding of the labeled polypeptide to the anti-serum is indicative of the reactivity of the sample with the immobilized antibody, and as a result, indicative of the concentration of polypeptide in the sample. The solid support can be any material known to those of ordinary skill in the art to which the antibody can be attached. For example, the solid support can be a test cavity in a microtiter plate or a nitrocellulose filter or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material, such as polystyrene or polyvinyl chloride. The support can also be a magnetic particle or a fiber optic sensor, such as that described, for example, in US Pat. 5, 359.681. The antibody can be immobilized on the solid support using a variety of techniques known to those in the art, which are widely described in scientific literature and patents. In the context of the present invention, the term "immobilization" refers to both a non-covalent association, such as adsorption, and a covalent bond (which may be a direct link between the antigen and functional groups on the support, or may be a link in the form of a crosslinking agent). Immobilization by adsorption to a cavity in a microtiter plate or to a membrane is preferred. In such cases, adsorption can be achieved by contacting the antibody, in a suitable buffer, with the solid support for a sufficient amount of time. The contact time varies with the temperature, but normally it is between approximately 1 hour and 1 day. In general, contact with a cavity of a plastic microtiter plate (such as polystyrene or polyvinyl chloride) with an amount of antibody ranging from about 10 ng to about 1 μg, and preferably about 100-200 ng, it is sufficient to immobilize an adequate amount of polypeptide. The covalent binding of the antibody to a solid support can also be achieved, in general, by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the antibody . For example, the antibody can be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen in the binding partner (see, for example, Pierce I mm. unotechnology Catalog and Handbook (1991) in A1 2-A1 3). In certain modalities, the assay for the detection of polypeptide in a sample is a "sandwich" assay of two antibodies. This assay can be performed by first contacting an antibody that has been immobilized on a solid support, commonly the cavity of a microtiter plate, with the biological sample, so that the polypeptide within the sample is allowed to bind to the antibody immobilized.

The unbound sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site in the polypeptide is added. The amount of second antibody remaining bound to the solid support is then determined using a method appropriate for the specific reporter group. More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites in the support are normally blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20MR (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and the polypeptide is allowed to bind to the antibody. The sample can be diluted with a suitable diluent, such as phosphate buffered saline (PBS) before incubation. Generally, an appropriate contact time (i.e., incubation time) is that period which is sufficient to detect the presence of polypeptide within a sample obtained from an individual with breast cancer. Preferably, the contact time is sufficient to achieve a binding level that is at least 95% of that achieved in equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium can be easily determined by testing the level of ligation that occurs over a period. At room temperature, an incubation time of approximately 30 minutes is usually sufficient.

The unbound sample can then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20M R. The second antibody, which contains a reporter group, can then be added to the solid support. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of antibody to the reporter group can be achieved using standard methods known to those of ordinary skill in the art. The second antibody is then incubated with the immobilized antibody-polypeptide complex for a sufficient amount of time to detect the bound polypeptide. An appropriate amount of time can usually be determined by testing the level of binding that occurs over a period of time. The unbound second antibody is then removed and the second bound antibody is detected using the reporter group. The method used to detect the reporting group depends on the nature of the reporting group. For radioactive groups, auto-radiographic or scintillation counting methods are generally appropriate. The spectroscopic methods can be used to detect dyes, luminescent groups and fluorescent groups. Biotin can be detected using avidin, coupled to a different replenishing group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups can generally be detected by the addition of substrate (usually for a specific period), followed by a spectroscopic analysis or other analysis of the reaction products. To determine the presence or absence of breast cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal corresponding to a predetermined established cutoff value of non-tumor tissue. In a preferred embodiment, the cutoff value is the average signal obtained when immobilized antibody is incubated with samples from patients without breast cancer. In general, a sample generating a signal that is three standard deviations from the predetermined cut-off value can be considered positive for breast cancer. In an alternative preferred modality, the cutoff value is determined using a Receiver ator Curve, according to the method of Sackett et al. , Clinical Epidemiology: A Basic Science for Clinical Medicine (Clinical Epidemiology: A Basic Science for Clinical Medicine), p. 106-7 (Little Brown and Co., 1985). Briefly, in this modality, the cut-off value can be determined from a graph of pairs of real positive proportions (ie, sensitivity) and false positive proportions (1 00% -specificity) that correspond to each of the possible values of cuts for the result of the diagnostic test. The cutoff value on the graph that is closest to the upper left corner (that is, the value that covers the largest area) is the most accurate cutoff value, and a sample that generates a signal that is greater than the value of Cut determined by this method can be considered positive. Alternatively, the cut-off value can be moved to the left along the graph, to minimize the false positive proportion, or to the right, to minimize the false negative proportion. In general, a sample generating a signal that is greater than the cut-off value determined by this method is considered positive for breast cancer. In a related embodiment, the assay is performed in a strip or flow through test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow-through test, the polypeptide within the sample binds to the immobilized antibody as the sample passes through the membrane. A labeled second antibody is then bound to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of bound second antibody can then be performed as described above. In the strip test format, one end of the membrane to which the antibody is attached is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing the second antibody and the area of immobilized antibody. The concentration of the second antibody in the area of the immobilized antibody indicates the presence of breast cancer. Normally, the concentration of the second antibody in the site generates a pattern, such as a line, that can be read visually. The absence of such pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the sandwich assay of two antibodies, in the format discussed before. Preferably, the amount of antibody immobilized on the membrane varies from 25 ng to about 1 μg, and more preferably from 50 ng to about 1 μg. Such tests can usually be done with a very small amount of the biological sample. The presence or absence of breast cancer in a patient can also be determined by evaluating the level of mRNA encoding a breast tumor-specific polypeptide as described herein, within the biological sample (e.g., a biopsy, mastectomy and / or or patient's blood sample) in relation to a predetermined cut-off value. Such an evaluation can be accomplished using any of a variety of methods known to those of ordinary skill in the art, such as, for example, in situ hybridization and polymerase chain reaction amplification. For example, the polymerase chain reaction can be used to amplify cDNA sequences prepared from RNA that is isolated from one of the above biological samples. Sequence-specific primers for use in such amplification can be designed based on the sequences provided in any of SEQ I D NO: 1, 1 1-86 and 142-297, and can be purchased or synthesized. In the case of B 1 8Ag 1, as noted herein, a suitable initiator pair is B1 8Ag 1 -2 (5 'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO: 1 26) and B 1 8Ag 1 -3 (5' CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO: 1 27). The PCR reaction products can then be separated by gel electrophoresis and visualized according to methods well known to those of ordinary skill in the art. Amplification is usually performed on samples obtained from matched pairs of tissue (tumor and non-tumor tissue from the same individual) or unmatched pairs of tissue (tumor and non-tumor tissue from different individuals). The amplification reaction is preferably carried out in several dilutions of cDNA extending two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the tumor sample as compared to the same sample of the non-tumor sample is considered positive. As used herein, the term "specific primer / probe for a DNA / RNA molecule" means an oligonucleotide sequence having at least about 80% identity, preferably at least about 90% and more preferably at least about 95%, identity for the DNA / RNA molecule in question. The primers and / or probes that can be usefully employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the polymerase chain reaction primers comprise at least about 10 contiguous nucleotides of a DNA / RNA molecule encoding one of the polypeptides described herein. Preferably, the oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 continuous oligonucleotides of a DNA / RNA molecule encoding one of the polypeptides described herein. Techniques for both PCR-based assays and in situ hybridization assays are well known in the art. Conventional RT-PCR protocols using spotting with ethidium bromide and agarose while being important to define the specificity of the genes, do not provide for the development of diagnostic sets due to the time and effort required to make them quantitative (ie, construction of saturation and / or titration curves), and its sample performance. This problem is overcome by the development of procedures such as real-time RT-PCR, which allows testing in simple tubes, and in turn can be modified for use in 96-well plate formats. The instrumentation to perform such methodologies are available from Perkin Elmer / Applied Biosystems Division. Alternatively, other high throughput assays using labeled probes (eg, digoxigenin) in combination with labeled antibodies (eg, fluorescent, radioactive enzymes) can also be used for such probes in the development of 96-well plate assays. . In yet another method for determining the presence or absence of breast cancer in a patient, one or more of the described breast tumor-specific polypeptides can be used in a skin test. As used herein, a "skin test" is any test performed directly on a patient, in which a delayed-type hypersensitivity (DTH) reaction (such as swelling, redness or dermatitis) is measured following intradermal injection of one or more polypeptides as described above. Such an injection can be accomplished using any suitable device sufficient to contact the polypeptides or polypeptides with skin cells of the patient, such as a tuberculin syringe or a 1 ml syringe. Preferably, the reaction is measured at least 48 hours after the injection, more preferably 48-72 hours. The DTH reaction is a cell-mediated immune response, which is higher in patients who have been previously exposed to a test antigen (i.e., an immunogenic portion of a polypeptide employed or a variant thereof). The answer can be measured visually, using a rule. Generally, a response of more than about 0.5 cm in diameter, preferably greater than about 5.0 cm in diameter, is a positive response, indicative of breast cancer. The breast tumor specific polypeptides described herein are preferably formulated for use in a skin test, according to pharmaceutical compositions containing at least one polypeptide and a physiologically acceptable carrier, such as water, saline, alcohol, or a shock absorber Such compositions typically contain one or more of the above polypeptides in an amount ranging from about 1 μg to 1 00 μg, preferably from about 10 μg to 50 μg in a volume of 0.1 ml. Preferably, the carrier employed in such pharmaceutical compositions is a saline solution with appropriate preservatives, such as phenol and / or Tween 80M R.

In other aspects of the invention, the progression and / or response to treatment of a breast cancer can be monitored by performing any of the above tests over a period, and evaluating the change in the level of the response (i.e., the amount of polypeptide or mRNA detected or, in the case of a skin test, the degree of the immune response detected). For example, trials can be conducted every month for a period of 1 to 2 years. In general, breast cancer is progressing in those patients in whom the level of response increases over time. In contrast, breast cancer is not progressing when the detected signal either remains constant or decreases over time. In additional aspects of the present invention, the compounds described herein can be used for the breast cancer immunotherapy. In these aspects, the compounds (which may be polypeptides, antibodies or nucleic acid molecules) are incorporated in pharmaceutical compositions or vaccines. The pharmaceutical compositions comprise one or more such compounds and a physiologically acceptable carrier. The vaccines may comprise one or more polypeptides and an immune response enhancer, such as an assistant or a liposome (in which the compound is incorporated). The pharmaceutical compositions and vaccines may additionally contain a delivery system, such as biodegradable microspheres which are described, for example, in US Pat. 4, 897, 268 and 5, 075, 1 09. Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, including one or more polypeptides separately. Alternatively, a vaccine may contain DNA encoding one or more of the polypeptides as described above, so that the polypeptide is generated in situ. In such vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, and viral and bacterial expression systems. Suitable nucleic acid expression systems contain the DNA sequences necessary for expression in the patient (such as a suitable termination signal and promoter). Bacterial delivery systems involve the administration of a bacterium (such as, Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA can be introduced using a viral expression system (e.g., vaccinia or other post-eruption virus, retrovirus, or adenovirus), which may involve the use of a competent virus of non-pathogenic replication (defective ). Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA can also be "naked", as described, for example, in Ulmer et al. , Science 259: 1745-1749 (1 993), and reviewed by Cohen, Science 259: 1691 -1 692 (1 993). The uptake of naked DNA can be increased by coating the DNA on biodegradable beads, which are transported efficiently to the cells.

Although any suitable carrier known to those of ordinary skill in the art can be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, and magnesium carbonate may be employed. Biodegradable microspheres (eg, polylactate polyglycolate) can also be employed as carriers for the pharmaceutical compositions of this invention.

Any of a variety of auxiliaries can be employed in the vaccines of this invention to non-specifically enhance the immune response. Most auxiliaries contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as, lipid A, proteins derived from Bortadella pertussis or Mycobacterium tuberculosis. Suitable auxiliaries are commercially available as, for example, incomplete Freund's auxiliary and Freund's complete assistant (Difco Laboratories, Detroit, Ml), Merck Adjuvant 65 (Merck and Company, I nc., Rahway, NJ), alum, biodegradable microspheres, lipid A of monophosphoryl and quil A. Cytokines, such as GM-CSF or interleukin-2, -7 or -1 2, can also be used as auxiliaries.

The above pharmaceutical compositions and vaccines can be used, for example, for the therapy of breast cancer in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with breast cancer. Accordingly, previous pharmaceutic compositions and vaccines can be used to prevent the development of breast cancer or to treat a patient afflicted with breast cancer. To prevent the development of breast cancer, a pharmaceutical composition or vaccine comprising one or more polypeptides as described herein may be administered to a patient. Alternatively, the naked DNA or plasmid or viral vector encoding the polypeptide can be administered. To treat a patient with breast cancer, the pharmaceutical composition or vaccine may comprise one or more polypeptides, antibodies or nucleotide sequences complementary to DNA encoding a polypeptide as described herein (e.g., antisense RNA or antisense deoxyribonucleotide oligonucleotides). ). The routes and frequency of administration, as well as dosage, will vary from individual to individual. In general, the pharmaceutical compositions and vaccines can be administered by injection (eg, intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (eg, by aspiration) or orally. Between 1 to 10 doses can be administered over a period of 52 weeks. Preferably, 6 doses are administered at 1 month intervals, and booster vaccinations can be given periodically thereafter.

Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response. Such a response can be monitored by measuring anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells in vitro. Such vaccines should also be capable of eliciting an immune response that leads to an improved clinical outcome (e.g., more frequent remissions, full or partial survival or longer disease free) in vaccinated patients as compared to unvaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 100 μg to 5 mg. Suitable dose sizes will vary with the size of the patient, but usually vary from about 0.1 ml to about 5 ml. The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES EXAMPLE 1 PR E PARTI TION D E C D ES ES PE CITY FI E S T E M O MAMA U SAN DO RT-PCR OF DI FERENTIAL EXHIBITION This example illustrates the preparation of cDNA molecules encoding breast tumor-specific polypeptides using a differential display screen.

A. Preparation of B 18Ag 1 cDNA and characterization of mRNA expression Tissue samples were prepared from normal tissue and from breast tumor of a patient with breast cancer that was confirmed by pathology after removal of the patient . Normal RNA and tumor RNA were extracted from the samples and the mRNA was isolated and converted to cDNA using an anchored 3 '(dT) 12AG primer (SEQ ID NO: 1 30). Then the differential display PCR was run using a randomly chosen primer (CTTCAACCTC) (SEQ ID NO: 1 03). Amplification conditions were standard buffer containing 1.5 mM MgCi2, 20 pmol of primer, 50 pmol of dNTP, and 1 unit of Taq DNA polymerase (Perkin-Elmer, Branchburg, NJ). 40 cycles of amplification were performed using 94 ° C of denaturation for 30 seconds, 42 ° C of annealing for 1 minute and 72 ° C of extension for 30 seconds. An RNA fingerprint containing 76 amplified products was obtained. Although the RNA fingerprint of breast tumor tissue was about 98% identical to that of normal breast tissue, it was repeatedly observed that one band was specific for the tumor fingerprint pattern of the tumor. This band was cut from a gel stained with silver, subcloned into the T-vector (Novagen, M adison, Wl) and sequenced.

The cDNA sequence, referred to as B18Ag1, is provided in SEQ ID NO: 1. A database search of GENBANK and EMBL revealed that the initially cloned B18Ag1 fragment is 77% identical to the endogenous human retroviral element S71, which is a truncated retroviral element homologous to the Simian Sarcoma Virus (SSV). S71 contains an incomplete gene gag, a portion of the gene pol and a structure similar to LTR at the 3 'end (see Werner et al., Virology 174: 225-238 (1990)). B18Ag1 is also 64% identical to SSV in the region corresponding to the P30 site (gag). B18Ag1 contains three incomplete and separate reading frames that cover a region which shares homology with a wide variety of retrovirus gag proteins, which infect mammals. In addition, S71 homology is not only within the gene gag, but extends several kb of sequence including an LTR: B18Ag-specific PCR primers were synthesized using computer analysis guide lines. Amplification of RT-PCR (94 ° C), 30 seconds; 60 ° C? 42 ° C, 30 seconds; 72 ° C, 30 seconds for 40 cycles) confirmed that B18Ag1 represents a real mRNA sequence present at relatively high levels in the patient's breast tumor tissue. The primers used in the amplification were B18Ag1-1 (CTC CCT GAG CCA CAA ATG) (SEQ ID NO: 128) and B18Ag1-4 (CCG GAG GAG GAA GCT AGA GGA ATA) (SEQ ID NO: 129) at a concentration of magnesium 3.5 mM and a pH of 8.5, and B18Ag1-2 (ATG GCT ATT TTC GGG GCC TGA CA) (SEQ ID NO: 126) and B18Ag1-3 (CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO: 127) to 2 mM magnesium at pH 9.5. The same experiments showed excessively low or non-existent levels of expression in this patient's normal breast tissue (see Figure 1). RT-PCR experiments were then used to show that 18Ag 1 B mRNA is present in nine other tumor samples (from Brazilian and US patients) but absent from, or at excessively low levels in, the normal breast tissue corresponding to each cancer patient . RT-PCR analysis has also shown that B1 8Ag 1 transcript is not present in several normal tissues (including lymph node, myocardium and liver) and present at relatively low levels in PBMC and lung tissue. The presence of B 18Ag 1 mRNA in breast tumor samples, and its absence of normal breast tissue, has been confirmed by Northern blot analysis, as shown in Figure 2. The differential expression of B1 8Ag 1 in tumor tissue of breast was also confirmed by RNase protection trials. Figure 3 shows the B 1 8Ag 1 mRNA level in various tissue types as determined in four different RNase protection assays. Lanes 1 -1 2 represent several samples of normal breast tissue, lanes 13-25 represent several samples of breast tumor; lanes 26-27 represent normal prostate samples, lanes 38-39 represent prostate tumor samples, lanes 30-32 represent colon tumor samples; lane 33 represents normal aorta; lane 34 represents a normal small intestine; lane 35 represents normal skin, lane 36 represents normal lymph node; lane 37 represents normal ovary; lane 38 represents normal liver, lane 39 represents normal skeletal muscle; lane 40 represents a first normal stomach sample, lane 41 represents a second normal stomach sample; lane 42 represents a normal lung; lane 43 represents normal kidney; and lane 44 represents normal pancreas. The inter-experimental comparison was facilitated by including a positive control RNA of message abundance of β-actin known in each test and normalizing the results of the different tests with respect to this positive control. RT-PCR and Southern blot analysis have shown that the B18Ag 1 site is present in human genomic DNA as a single copy endogenous retroviral element. A genomic clone of approximately 12-1 8 kg was isolated using the initial B 18Ag 1 sequence as a probe. Four additional subclones were also isolated by Xbal digestion. Additional retroviral sequences obtained from the ends of the Xbal digestions of these clones (located as shown in Figure 4) are shown as SEQ ID NO: 3 - SEQ ID NO: 1 0, where SEQ ID NO: 3 shows the location of the sequence marked 1 0 in Figure 4, SEQ ID NO: 4 shows the location of the sequence marked 1 1 -29, SEQ ID NO: 5 shows the location of the sequence marked 3, SEQ ID NO: 6 shows the location of the sequence marked 6, SEQ ID NO: 7 shows the location of the sequence marked 12, SEQ ID NO: 8 shows the location of the sequence marked 1 3, SEQ ID NO: 9 shows the location of the sequence marked 14 and SEQ ID NO: 10 shows the location of the sequence marked 1 1 -22.

Subsequent studies demonstrated that the 12-18 kg genomic clone contains a retroviral element of approximately 7.75 kg, as shown in Figures 5A and 5B. The sequence of this retroviral element is shown in SEQ I D NO.141. The line numbered in the upper part of Figure 5A represents the sense filament sequence of the retroviral genomic clone. The box below this line shows the position of the selected restriction sites. The arrows show the different overlapping clones used to sequence the retroviral element. The direction of the arrow shows whether the single pass subclone sequence corresponded to the sense or anti-sense filament. Figure 5B is a schematic diagram of the retroviral element containing B18Ag 1 showing the organization of viral genes within the element. The open boxes correspond to predicted reading frames, starting with a methionine, found along the element. Each of the six probable reading frames is shown, as indicated to the left of the boxes, with frames 1 -3 corresponding to those found in the sense filament. Using the cDNA of SEQ ID NO: 1 as a probe, a longer cDNA was obtained (SEQ ID NO: 227), which contains fewer nucleotide differences (less than 1%) compared to the genomic sequence shown in SEQ ID NO. : 141 B. Preparation of cDNA molecules encoding other breast tumor-specific polypeptides. Normal RNA and tumor RNA were prepared and mRNA was isolated and converted to cDNA using an anchored 3 '(dT) 12AG primer, as described above. Then the differential display PCR was run using the randomly chosen primers SEQ I D NO: 87-125. The amplification conditions were as noted above and the bands observed as specific to the tumor fingerprint pattern of the tumor were cut from a silver stained cn gel, subcloned either in the T-vector (Novagen, Madison, Wl) or the vector pCRH (I nvitrogen, San Diego, CA) and sequenced. The sequences are provided in SEQ ID NO: 1-SEQ ID NO: 86. Of the 79 isolated sequences, 67 were found to be novel (SEQ I D NO: 1 1 -26 and 28-77) (see also Figures 6-20). An extended DNA sequence (SEQ ID NO: 290) was obtained for the B1 antigen 5Ag 1 (originally identified partial sequence provided in SEQ ID NO: 27) in further studies. The comparison of the sequence of SEQ I D NO: 290 with that in the gene bank as described above, revealed homology with the known human activin β-A gene. Subsequent studies identified an additional 146 sequences (SEQ ID NOS: 142-289), of which 15 appeared to be novel (SEQ ID NOS: 142, 143, 146-152, 1 54-166, 168-176, 178-1 92, 1 94-1 98, 200-204, 206, 207, 209-214, 216, 21 8, 21 9, 221 -240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291). According to the knowledge of the inventors none of the previously identified sequences has been shown so far to be expressed at a higher level in human breast tumor tissue than in normal breast tissue. In additional studies, six different splice forms of the B 1 1 Ag 1 antigen were isolated, with each of the various splice forms containing slightly different versions of the B1 1 Ag 1 coding framework. The splicing junction sequences define individual exons which, in various patterns and arrangements, make the various splice forms. The primers were designed to examine the expression pattern of each of the exons using RT-PCR as described below. It was found that each exon shows the same expression pattern as the original B 1 1 Ag 1 clone, being specific expression of breast tumor, prostate and testes. The cDNA sequences determined for the isolated protein coding exons are provided in SEQ ID NO: 292-297, respectively.

EX EMPLO 2 PREPARATION OF B 1 8AG 1 DNA OF HUMAN GENOMIC DNA This example illustrates the preparation of B1 8Ag1 DNA by amplification of human genomic DNA. The DNA of B 1 8Ag 1 can be prepared from 250 ng of human genomic DNA using 20 pmol of specific primers of B1 8Ag1, 500 pmol of dNTPS and 1 unit of Taq DNA polymerase (Perkin Elmer, Branchbur, NJ) using the following amplification parameters: denaturation of 94 ° C for 30 seconds, tempered landing of 30 seconds 60 ° C to 42 ° C in increments of 2 ° C every two cycles and 72 ° C extension for 30 seconds. The last increment (a tempering temperature of 42 ° C) should cycle 25 times. The primers were selected using computer analysis. The primers synthesized were B 1 8Ag 1 -1, B1 8Ag 1 -2, B 1 8Ag 1 -3 and B 18Ag 1 -4. The primer pairs that can be used are 1 +, 1 +4, 2 + 3 and 2 + 4. Following gel electrophoresis, the band corresponding to B 1 8Ag 1 DNA can be cut and cloned into a suitable vector.

EXAMPLE 3 PREPARATION OF B 1 8AG 1 DNA FROM BREAST TUMOR CNA This example illustrates the preparation of B18Ag 1 DNA by amplification of human breast tumor cDNA. The first filament cDNA is synthesized from Rna prepared from human breast tumor tissue in a reaction mixture containing 500 ng of poly A + RNA, 200 pmol of primer (T) 12AG (ie, TTT TTT TTT TTT AG ) (SEQ ID NO. 30), 1 X first filament reverse transcriptase buffer, 6.7 mM DTT, 500 mmol dNTPS, and 1 unit of AMV or MMLV reverse transcriptase (from any supplier, such as Gibco-BRL (Grand Island NY)) in a final volume of 30 μl. After synthesis of the first strand, the cDNA is diluted approximately 25-fold and 1 μl is used for amplification as described in Example 2. Although some primer pairs may result in a heterogeneous population of transcripts, the primers B18Ag1-2 ( 5 'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO: 126) and B18Ag1-3 (5' CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO: 127) produce a simple 151 bp amplification product .

EXAMPLE 4 IDENTIFICATION OF EPITOPES OF CELLS B AND CELLS T OF B18AG1 This example illustrates the identification of epitopes B18Ag1. The sequence B18Ag1 can be classified using a variety of computer algorithms. To determine B cell epitopes, the sequence can be classified by hydrophobicity and hydrophilicity values using the method of Hopp, Prog. Clin. Biol. Res. 172B: 367-77 (1985) or, alternatively, Ceases et al., J. Exp. Med. 164: 1779-86 (1986) or Spouge et al., J. Immunol. 138: 204-12 (1987). Additional MHC Class II epitopes (antibodies or B cells) can be predicted using programs such as AMPHI (eg Margalit et al., J. Immunol. 138: 2213 (1987)) or the Rothbard and Taylor methods (e.g. , EMBO J.7: 93 (1988)). Once the peptides (15-20 amino acids long) are identified using these techniques, individual peptides can be synthesized using automated peptide synthesis equipment (available from manufacturers such as Perkin Elmer / Applied Biosystems Division, Foster City, CA) and techniques such as Merrifield. Following the synthesis, the peptides can also be used to classify the collected serum from either normal patients or breast cancer to determine whether breast cancer patients possess antibodies reactive with the peptides. The presence of such antibodies in a patient with breast cancer would confirm the immunogenicity of the specific B-cell epitope in question. The peptides can also be tested for their ability to generate a serological or humoral immunization in animals (mice, rats, rabbits, chimpanzees, etc.) following immunization in vivo. The generation of a specific peptide antiserum following the immunization further confirms the immunogenicity of the specific B cell epitope in question. To identify T cell epitopes, the B 1 8Ag 1 sequence can be classified using different computer algorithms, which are useful to identify 8-10 amino acid motifs within the B 1 8Ag 1 sequence, which are capable of binding to MHC Class I molecules. HLA (see for example, Rammensee et al., Immunogenetics 41: 178-228 (1995)). Following the synthesis, such peptides can be tested for their ability to generate antigen reactive cytotoxic T cells following in vitro stimulation of patient or normal peripheral mononuclear cells using, for example, the methods of Bakker et al. , Cancer Res. 55: 5330-34 (1,995); Visseren et al. , J. Immunol. 154: 3991-98 (1995); Kawakami et al. , J. Immunol. 1 54: 3961-68 (1995); and Kast et al. , J. Immunol. 1 52: 3904-1 2 (1994). The successful in vitro generation of T cells capable of killing autologous tumor cells (supporting the same MHC Class I molecules) following the stimulation of in vitro peptides, further confirms the immunogenicity of the B18Ag 1 antigen. In addition, such peptides can be used to generate murine peptides and reactive cytotoxic T cells of B18Ag1 following immunization in vivo in mice that become transgenic for the expression of a particular human MHC class I halpotype (Vitiello et al., J. Exp. Med. 173: 1007-15 (1991) A representative list of T cell and B cell epitopes.

B18Ag1 predicted, decomposed according to the HLA class I MHC binding antigen predicted, is shown below: Predicted Th motifs (B cell epitopes) (SEQ ID NOS: 131-133) SSGGRTFDDFGRYLLVGI QGAAQKPINLSKXIEVVQGHDE SPGVFLEHLQUEAYRIYTPFDLSA HLA A2.2 predicted motifs (T cell epitopes) (SEQ ID NOS: 134-140) YLLVGIQGA GAAQKPINL NLSKXIEVV EVVQGHDES HLQEAYRIY NLAFVAQAA FVAQAAPDS EXAMPLE 5 CHARACTERIZATION OF BREAST TUMOR GENES DISCOVERED BY PCR OF EXH I BI C ION D I FERENC IAL The specificity and sensitivity of the breast tumor genes discovered by differential display PCR were determined using RT-PCR. This procedure allowed the rapid evaluation of mRNA expression of breast tumor gene semiquantitatively without using large amounts of RNA. Using the gene-specific primers, mRNA expression levels were examined in a variety of tissues, including 8 breast tumors, 5 normal mammals, 2 prostate tumors, 2 colon tumors, 1 lung tumor and 14 other human tissues. normal adults, including normal prostate, colon, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, stomach and testes. To ensure the semi-quantitative nature of the RT-PCR, a ß-actin template was used, which was sensitive enough to reflect the difference in the number of initial copies. Using this condition, the β-actin levels were determined for each reverse transcription reaction of each tissue. DNA contamination was minimized by DNase treatment and by ensuring a negative result when using first filament cDNA that was prepared without adding reverse transcriptase. Using the gene-specific primers, the levels of mRNA expression in a variety of tissues were determined. To date, 38 genes have been successfully screened by RT-PCR, five of which exhibit good specificity and sensitivity for breast tumors (B1 5AG-1, B31 GA1 b, G38GA2a, B1 1 A1 a and B 1 8AG 1 a ). Figures 21 A and 21 B show the results for three of these genes: B1 5AG-1 (SEQ I D NO: 27), B31 GA1 b (SEQ I D NO: 148) and B38GA2a (SEQ ID NO: 157). Table I summarizes the level of expression of all genes tested in normal breast tissue and breast tumors, and also in other tissues.

TABLE I Percentage of breast cancer antigens that are expressed in various tissues Overexpressed tissues in breast 84% breast tumors Equally expressed in normal and 16% tumors Other tissues Overexpressed in breast tumors but not 9% in any normal tissue Overexpressed in breast tumors but 30% expressed in some normal tissues Overexpressed in breast tumors but 61% equally expressed in all other tissues From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention.

LIST OF SEQUENCES (1) GENERAL INFORMATION: (i) APPLICANT: Frudakis, Tony N. Smith, John M. Reed, Steven G. (ii) TITLE OF THE INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER (iii) NUMBER OF SEQUENCES: 297 (iv) ADDRESS FOR CORRESPONDENCE: (A) DESTINY: SEED and BERRY LLP (B) STREET: 6300 Columbia Center, 701 Fifth Avenue (C) CITY: Seattle ( D) STATE: Washington (E) COUNTRY: USA (F) POSTAL CODE: 98104-7092 (v) LEGIBLE COMPUTER FORM: (A) TYPE OF MEDIA: FLEXIBLE DISC (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM : PC-DOS / MS-DOS (D) PACKAGE: Release Patent # 1.0, Version # 1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) SUBMISSION DATE: April 4, 1997 ( C) CLASSIFICATION: (viii) ATTORNEY / AGENT INFORMATION: (A) NAME: Maki, David J. (B) REGISTRATION NUMBER: 31,392 (C) REFERENCE NUMBER / CASE: 210121.419C2 (ix) TELECOMMUNICATIONS INFORMATION: ( A) TELEPHONE: (206) 622-4900 (B) TELEFAX: (206) 682-6031 (2) INFORMATION FOR SEQ ID NO: 1: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (ix) ) FEATURE: (A) NAME / KEY: CDS (B) LOCATION: 1 ..363 (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 1 TTA GAG ACC CAA TTG GGA CCT AAT TGG GAC CCA AAT TTC TCA AGT GGA 48 Leu Glu Thr Gln Leu Gly Pro Asn Trp Asp Pro Asn Phe Ser Ser Gly 1 S 10 15 GGG AGA ACT TTT GAC GAT TTC CAC CGG TAT CTC CTC GTG GGT ATT CAG 96 Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val Gly He Gln 20 25 30 GGA GCT GCC CAG AAA CCT ATA AAC TTG TCT AAG GCG ATT GAA GTC GTC 144 Gly Ala Wing Gln Lys Pro He Asn Leu Ser Lys Wing He Glu Val Val 35 40 45 CAG GGG CAT GAT GAG TCA CCA GGA GTG TTT TTA GAG CAC CTC CAG GAG 192 Gln Gly His Asp Glu Ser Pro Gly Val Phe Leu Glu His Leu Gln Glu 50 55 60 GCT TAT CGG ATT TAC ACC CCT TTT GAC CTG GCA GCC CCC GAA AAT AGC 240 Wing Tyr Arg He Tyr Thr Pro Phe Asp Leu Wing Wing Pro Glu Asn Ser 65 70 75 80 CAT GCT CTT AAT TTG GCA TTT GTG GCT CAG GCA GCC CCA GAT AGT AAA 288 His Wing Leu Asn Leu Wing Phe Val Wing Gln Wing Wing Pro Asp Ser Lys 85 90 95 AGG AAA CTC CAA AAA CTA GAG GGA TTT TGC TGG AAT GAA TAC CAG TCA 336 Arg Lys Leu Gln Lys Leu Glu Gly Phe Cys Trp Asn Glu Tyr Gln Ser 100 105 110 GCT TTT AGA GAT AGC CTA AAA GGT TTT 363 Wing Phe Arg Asp Ser Leu Lys Gly Phe 115 120 (2) I NFORMATION FOR SEQ ID NO: 2: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 21 amino acids (B) TI PO: amino acid (D) TOPOLOGY: linear (ii) TI PO DE MOLECULA: protein (xí) SECURITY DESCRITION: SEQ ID NO: 2: Leu Glu Thr Gln Leu Gly Pro Asn Trp Asp Pro Asn Phe Be Ser Gly 1 5 10 15 Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val Gly He Gln 20 25 30 Gly Wing Wing Gln Lys Pro He Asn Leu Ser Lys Wing He Glu Val Val 35 40 45 Gln Gly His Asp Glu Ser Pro Gly Val Phe Leu Glu His Leu Gln Glu 50 55 60 Wing Tyr Arg He Tyr Thr Pro Phe Asp Leu Ala Wing Pro Glu Asn Ser 65 70 75 80 His Ala Leu Asn Leu Wing Phe Val Wing Gln Wing Wing Pro Asp Ser Lys 85 90 95 Arg Lys Leu Gln Lys Leu Glu Gly Phe Cys Trp Asn Glu Tyr Gln Ser 100 105 110 Wing Phe Arg Asp Ser Leu Lys Gly Phe 115 120 (2) I NFORMATION FOR SEQ ID NO: 3: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 1 101 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 3: TCTTAGAATC TTCATACCCC GAACTCTTGG GAAAACTTTA ATCAGTCACC TACAGTCTAC 60 CACCCATTTA GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTTTTA AGATCCCCCA 120 TCTTCAAAGC CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC AGGTAAATGC 180 CAAAAAAGGT CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC CAGGAGAAAA 240 GTGGGAAATT GACTTTACAG AAGTAAAACC ACACCGGGCT GGGTACAAAT ACCTTCTAGT 300 ACTGGTAGAC ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG AAACTGTCAA 360 TATGGTAGTT AAGTTTTTAC TCAATGAAAT CATCCCTCGA CGTGGGCTGC CTGTTGCCAT 420 AGGGTCTGAT AATGGAACGG CCTTCGCCTT GTCTATAGTT TAATCAGTCA GTAAGGCGTT 480 AAACATTCAA TGGAAGCTCC ATTGTGCCTA TCGACCCAGA GCTCTGGGCA AGTAGAACGC 540 ATGAACTGCA CCCTAAAAAA ACACTCTTAC AAAATTAATC TTAAAAACCG GTGTTAATTG 600 TGTTAGTCTC CTTCCCTTAG CCCTACTTAG AGTTAAGGTG CACCCCTTAC TGGGCTGGGT 660 TCTTTTACCTT TTGAAATCAT NTTTNGGAAG GGGCTGCCTA TCTTTNCTTA ACTAAAAAA 720 GCCCATTTGG CAAAAATTTC NCAACTAATT TNTACGTNCC TACGTCTCCC CAACAGGTAN 780 AAAAATCTNC TGCCCTTTTC AAGGAACCAT CCCATCCATT CCTNAACAAA AGGCCTGCCN 840 TTCTTCCCCC AGTTAACTNT TTTTTTNTTAA AATTCCCAAA AAANGAACCN CCTGCTGGAA 900 AAACNCCCCC CTCCAA CCC CGGCC AAGN GGAAGGTTCC CTTGAATCCC NCCCCCNCNA 960 ANGGCCCGGA ACCNTTAAAN TNGTTCCNGG GGGTNNGGCC TAAAAGNCCN ATTTGGTAAA 1020 CCTANAAATT TTTTCTTTTN TAAAAACCAC NNTTT NTTT TTCTTAAACA AAACCCTNTT 1080 T TAGNANCN TATTTCCCNC C 1101 (2) I NFORMATION FOR SEQ ID NO: 4: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 087 pairs of bses (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 4:CGCCTGGATC CCGCCACAGT GAGGAGACCT GAAGACCAGA GAAAACACAG 60 CAAGTAGGCC CTTTAAACTA CTCACCTGTG TTGTCTTCTA ATTTATTCTG TTTTATTTTG 120 TTTCCATCAT TTTAAGGGGT TAAAATCATC TTGTTCAGAC CTCAGCATAT AAAATGACCC 180 ATCTGTAGAC CTCAGGCTCC AACCATACCC CAAGAGTTGT CTGGTTTTGT TTAAATTACT 240 GCCAGGTTTC AGCTGCAGAT ATCCCTGGAA GGAATATTCC AGATTCCCTG AGTAGTTTCC 300 AGGTTAAAAT CCTATAGGCT TCTTCTGTTT TGAGGAAGAG TTCCTGTCAG AGAAAAACAT 360 GATTTTGGAT TTTTAACTTT AATGCTTGTG AAACGCTATA AAAAAAATTT TCTACCCCTA 420 GCTTTAAAGT ACTGTTAGTG AGAAAT AAA ATTCCTTCAG GAGGATTAAA CTGCCATTTC 480 AGTTACCCTA ATTCCAAATG TTTTGGTGGT TAGAATCTTC TTTAATGTTC TTGAAGAAGT 540 GTTTTATATT TTCCCATCNA GATAAATTCT CTCNCNCCTT NNTTTTNTNT CTMNTTTTTT 600 AAAACGGANT CTTGCTCCGT TGTCCANGCT GGGAATTTTN TTTTGGCCAA TCTCCGCTNC 660 CTTGCAANAA TNCTGCNTCC CAAAATTACC NCCTTTTTCC CACCTCCACC CCNNGGAATT 720 ACCTGGAATT ANAGGCCCCC NCCCCCCCCC CGGCTAATTT GTTTTTGTTT TTAGTAAAAA 780 ACGGGTTTCC TGTTTTAGTT AGGATGGCCC ANNTCTGACC CCNTNATCNT CCCCCTCNGC 840 CCTCNAATNT TNGGNNTANG GCTTACCCCC CCCNGNNGTT TTTCCTCCAT TNAAATTTTC 900 TNTGGANTCT TGAATNNCGG GTTTTCCCTT TTAAACCNAT TTTTTTTTTN NNNCCCCCAN 960 TTTTNCCTCC CCCNTNTNTA ANGGGGGTTT CCCAANCCGG GTCCNCCCCC ANGTCCCCAA 1020 TTTTCTCCC CCCCCCTCTT TTTTCTTTNC CCCAAAANTC CTATCTTTTC CTNNAAATAT 1080 CNANTNT 1087 (2) I NFORMATION FOR SEQ ID NO: 5: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 101 0 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 5: TCTAGACCAA GAAATGGGAG GATTTTAGAG TGACTGATGA TTTCTCTATC ATCTGCAGTT 60 AGTAAACATT CTCCACAGTT TATGCAAAAA GTAACAAAAC CACTGCAGAT GACAAACACT 120 AGGTAACACA CATACTATCT CCCAAATACC TACCCACAAG CTCAACAATT TTAAACTGTT 180 AGGATCACTG GCTCTAATCA CCATGACATG AGGTCACCAC CAAACCATCA AGCGCTAAAC 240 AGACAGAATG TTTCCACTCC TGATCCACTG TGTGGGAAGA AGCACCGAAC TTACCCACTG 300 GGGGGCCTGC NTCANAANAA AAGCCCATGC CCCCGGGTNT NCCTTTNAAC CGGAACGAAT 360 NAACCCACCA TCCCCACANC TCCTCTGTTC NTGGGCCCTG CATCTTGTGG CCTCNTNTNC 420 TTTNGGGGAN ACNTGGGGAA GGTACCCCAT TTCNTTGACC CCNCNANAAA ACCCCNGTGG 480 CCCTTTGCCC TGATTCNCNT GGGCCTTTTC CTTTTCCCT TTTGGGTTGT TTAAATTCCC 540 AATGTCCCCN GAACCCTCTC CNTNCTGCCC AAAACCTACC TAAATTNCTC NCTANGNNTT 600 TTCTTGGTGT TNCTTTTCAA AGGTNACCTT NCCTGTTCAN NCCCNACNAA AATTTNTTCC 660 NTATNNTGGN CCCNNAAAAA NNNATCNNCC CNAATTGCCC GAATTGGTTN GGTTTTTCCT 720 NCTGGGGGAA ACCCTTTAAA TTTCCCCCTT GGCCGGCCCC CCTTTTTTTCC CCCCTTTNGA 780 AGGCAGGNGG TTCTTCCCGA ACTTCCAATT NCAACAGCCN TGCCCATTGN TGAAACCCTT 840 TTCCTAAAAT TAAAAAATAN CCGGTTNNGG NNGGCCTCTT TCCCCTCCNG GNGGGNNGNG 900 AAANTCCTTA CCCCNAAAAA GGTTGCTTAG CCCCCNGTCC CCACTCCCCC NGGAAAAATN 960 AACCTTTTCN AAAAAAGGAA TATAANTTTN CCACTCCTTN GTTCTCTTCC 1010 (2) I NFORMATION FOR SEQ ID NO: 6: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 950 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: TCTAGAGCTC GCGGCCGCGA GCTCTAATAC GACTCACTAT AGGGCGTCGA CTCGATCTCA 6 GCTCACTGCA ATCTCTGCCC CCGGGGTCAT GCGATTCTCC TGCCTCAGCC TTCCAAGTAG_12_CTGGGATTAC AGGCGTGCAA CACCACACCC GGCTAATTTT GTATTTTTAA TAGAGATGGG 18 GTTTTCCCTT GTTGGCCANN ATGGTCTCNA ACCCCTGACC TCNNGTGATC CCCCCNCCCN 24 NGANCTCNNA CTGCTGGGGA TNNCCGNNNN NNNCCTCCCN NCNCNNNNNN NCNCNNTCCN 30 TNNTCCTTNC TCNNNNNNNN CNNTCNNTCC NNCTTCTCNC CNNNTNTTNT CNNCNNCCNN 36 CNNNCCNCNT NCCCNCNNNT TCNCNTNCNN TNTCCNNCNN NNTCNNCNNN CNNNNCNTNN 42 CCNNTACNTC NTNNNCNNNT CCNTCTNTNN CCTCNNCNNT CNCTNCNCNT TNTCTCCTCN 48 NTNNNNNNNCT CCNNNNNTCT CNTCNCNNCN TNCCTCNNTN NCCNCNCCCC NCCTCNCNNC 54 CTNNTTTNNN CNNCNNNTCC NTNCCNTTCN NNTCCNNTNN CNNCNTCNCN NNCNTTNTTC 60 CCNCCNNTTC CTTNCNCNTN NNNTNTCNNN CNCNTCNNTC NTTTNCTCCT NNNTCCCNNC 66 TCNNTTCNCC CNNNTCCNCC CCCCNCCTNT CTCTCNCCCN NNTNNNTNTN NNNCNTCCNC 72 TNTCNCNTTC NTCNNTNCNT TNCTNTCNNC NNCNNTNCNC TNCCNTNTNT CTNNNTCNCN 78 TCNCNTNTCN CCNTCCNTTN CTNTCTCCTN TNTCCTTCCC CTCNCCTNCT CNTTCNCCNC 84 CCNNTNTNTN TNNCNCCNNT NCTNNNCNNC CNTCNTTTCN TCTCTNCTNN NNNTNNCCTC 90 NNCCCNTNCC CTNNTNCNCT NCTNNTACCN TNCTNCTCCN TCTTCCTTCC 95 (2) IN TRAINING FOR SEQ ID NO: 7: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 1 086 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 7: TCTAGAGCTC GCGGCCGCGA GCTCAATTAA CCCTCACTAA AGGGAGTCsA CTCGATCAGA 60 CTGTTACTGT GTCTATGTAG AAAGAAGTAG ACATAAGAGA TTCCATTTTG TTCTGTACTA 120 AGAAAAATTC TTCTGCCTTG AGATGCTGTT AATCTGTAAC CCTAGCCCCA ACCCTGTGCT 180 CACAGAGACA TGTGCTGTGT TGACTCAAGG TTCAATGGAT TTAGGGCTAT GCTTTGTTAA 240 AAAAGTGCTT GAAGATAATA TGCTTGTTAA AAGTCATCAC CATTCTCTAA TCTCAAGTAC 300 CCAGGGACAC AATACACTGC GGAAGGCCGC AGGGACCTCT GTCTAGGAAA GCCAGGTATT 360 GTCCAAGATT TCTCCCCATG TGATAGCCTG AGATATGGCC TCATGGGAAG GGTAAGACCT 420 GACTGTCCCC CAGCCCGACA TCCCCCAGCC CGACATCCCC CAGCCCGACA CCCGAAAAGC 480 GTCTGTGCTG AGGAAGATTA NTAAAAGAGG AAGGCTCTTT GCATTGAAGT AAGAAGAAGG 540 CTCTGTCTCC TGCTCGTCCC TGGGCAATAA AATGTCTTGG TGTTAAACCC GAATGTATGT 600 TCTACTTACT GAGAATAGGA GAAAACATCC TTAGGGCTGG AGGTGAGACA CCCTGGCGGC 660 ATACTGCTCT TTAATGCACG AGATGTTTGT NTAATTGCCA TCCAGGGCCA NCCCCTTTCC 720 TTAACTTTTT ATGANACAAA AACTTTGTTC NCTTTTTCCTG CGAACCTCTC CCCCTATTAN 780 CCTATTGGCC TGCCCATCCC CTCCCCAAAN GGTGAAAANA TGTTCNTAAA TNCGAGGGAA 840 TCCAAAACNT TTTCCCGTTG GTCCCCTTTC CAACCCCGTC CCTGGGCCNN TTTCCTCCCC 900 AACNTGTCCC GGNTCCTTCN TTCCCNCCCC CTTCCCNGAN AAAAAACCCC GTNTGANGGN 960 GCCCCCTCAA ATTATAACCT TTCCNAAACA AANNGGTTCN AAGGTGGTTT GNTTCCGGTG 1020 CGGCTGGCCT TGAGGTCCCC CCTNCACCCC AATTTGGAAN CCNGTTTTTT TTATTGCCCN 1080 NTCCCC 1086 (2) I NFORMATION FOR SEQ ID NO: 8: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 1 77 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 8: NCCNTTTAGA TGTTGACAAN NTAAACAAGC NGCTCAGGCA GCTGAAAAAA GCCACTGATA 60 AAGCATCCTG GAGTATCAGA GTTTACTGTT AGATCAGCCT CATTTGACTT CCCCTCCCAC 120 ATGGTGTTTA AATCCAGCTA CACTACTTCC TGACTCAAAC TCCACTATTC CTGTTCATGA 180 CTGTCAGGAA CTGTTGGAAA CTACTGAAAC TGGCCGACCT GATCTTCAAA ATGTGCCCCT 240 AGGAAAGGTG GATGCCACCG TGTTCACAGA CAGTACCNCC TTCCTCGAGA AGGGACTACG 300 AGGGGCCGGT GCANCTGTTA CCAAGGAGAC TNATGTGTTG TGGGCTCAGG CTTTACCANC 360 AAACACCTCA NCNCNNAAGG CTGAATTGAT CGCCCTCACT CAGGCTCTCG GATGGGGTAA 420 GGGATATTAA CGTTAACACT GACAGCAGGT ACGCCTTTGC TACTGTGCAT GTACGTGGAG 480 CCATCTACCA GGAGCGTGGG CTACTCACTC GGCAGGTGGC TGTNATCCAC TGTAAANGGA 540 CATCAAAAGG AAAACNNGGC TGTTGCCCGT GGTAACCANA AANCTGATCN NCAGCTCNAA 600 GATGCTGTGT TGACTTTC? C TCNCNCCTCT TAAACTTGCT GCCCACANTC TCCTTTCCCA 660 ACCAGATCTG CCTGACAATC CCCATACTCA AAAAAAAAAN AANACTGGCC CCGAACCCNA 720 ACCAATAAAA ACGGGGANGG TNGGTNGANC NNCCTGACCC AAAAATAATG GATCCCCCGG 780 GCTGCAGGAA TTCAATTCAN CCTTATCNAT ACCCCCAACN NGGNGGGGGG GGCCNGTNCC 840 CATTNCCCCT NTATTNATTC TTTNNCCCCC CCCCCGGCNT CCTTTTTNAA CTCGTGAAAG 900 GGAAAACCTG NCTTACCAAN TTATCNCCTG GACCNTCCCC TTCCNCGGTN GNTTANAAAA 960 AAAAGCCCNC ANTCCCNTCC NAAATTTGCA CNGAAAGGNA AGGAATTTAA CCTTTATTTT 1020 TTNNTCCTTT ANTTTGTNNN CCCCCTTTTA CCCAGGCGAA CNGCCATCNT TTAANAAAAA 1080 AAANAGAANG TTTATTTTTC CTTNGAACCA TCCCAATANA AANCACCCGC NGGGGAACGG 1140 GGNGGNAGGC CNCTCACCCC CTTTÑTGTNG GNGGGNC 1177 (2) I NFORMATION FOR SEQ ID NO: 9: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 1 146 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 9: NCCNNTTNNT GATGTTGTCT TTTTGGCCTC TCTTTGGATA CTTTCCCTCT CTTCAGAGGT 60 GAAAAGGGTC AAAAGGAGCT GTTGACAGTC ATCCCAGGTG GGCCAATGTG TCCAGAGTAC 120 AGACTCCATC AGTGAGGTCA AAGCCTGGGG CTTTTCAGAG AAGGGAGGAT TATGGGTTTT 180 CCAATTATAC AAGTCAGAAG TAGAAAGAAG GGACATAAAC CAGGAAGGGG GTGGAGCACT 240 CATCACCCAG AGGGACTTGT GCCTCTCTCA GTGGTAGTAG AGGGGCTACT TCCTCCCACC 300 ACGGTTGCAA CCAAGAGGCA ATGGGTGATG AGCCTACAGG GGACATANCC GAGGAGACAT 360 GGGATGACCC TAAGGGAGTA GGCTGGTTTT AAGGCGGTGG GACTGGGTGA GGGAAACTCT 420 CCTCTTCTTC AGAGAGAAGC AGTACAGGGC GAGCTGAACC- GGCTGAAGGT CGAGGCGAAA 480 ACACGGTCTG GCTCAGGAAG ACCTTGGAAG TAAAATTATG AATGGTGCAT GAATGGAGCC 540 ATGGAAGGGG TGCTCCTGAC CAAACTCAGC CATTGATCAA TGTTAGGGAA ACTGATCAGG 600 GAAGCCGGGA ATTTCATTAA CAACCCGCCA CACAGCTTGA ACATTGTGAG GTTCAGTGAC 660 CCTTCAAGGG GCCACTCCAC TCCAACTTTG GCCATTCTAC TTTGCNAAAT TTCCAAAACT 720 TCCTTTTTTA AGGCCGAATC CNTANTCCCT NAAAAACNAA AAAAAATCTG CNCCTATTCT 780 GGAAAAGGCC CANCCCTTAC CAGGCTGGAA GAAATTTTNC CTTTTTTTTT TTTTTGAAGG 840 CNTTTNTTAA ATTGAACCTN AATTCNCCCC CCCAAAAAAA AACCCNCCNG GGGGGCGGAT 900 TTCCAAAAAC NAATTCCCTT ACCAAAAAAC AAAAACCCNC CCTTNTTCCC TTCCNCCCTN 960 TTCTTTTAAT TAGGGAGAGA TNAAGCCCCC CAATTTCCNG GNCTNGATNN GTTTCCCCCC 1020 CCCCCATTTT CCNAAACTTT TTCCCANCNA GGAANCCNCC CTTTTTTTNG GTCNGATTNA 1080 NCAACCTTCC AAACCATTTT TCCNNAAAAA NTTTGNTNGG NGGGAAAAAN ACCTNNTTTT 1140 (2) I NFORMATION FOR SEQ ID NO: 10: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 545 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 0: CTTCATTGGG TACGGGCCCC CTCGAGGTCG ACGGTATCGA TAAGCTTGAT ATCGAATTCC _ _. -SW TGCAGCCCGG GGGATCCACT AGTTCTAGAG TCAGGAAGAA CCACCAACCT TCCTGATTTT 120 TATTGGCTCT GAGTTCTGAG GCCAGTTTTC TTCTTCTGTT GAGTATGCGG GATTGTCAGG 180 CAGATCTGGC TGTGGAAAGG AGACTGTGGG CAGCAAGTTT AGAGGCGTGA CTGAAAGTCA 240 CACTGCATCT TGAGCTGCTG AATCAGCTTT CTGGTTACCA CGGGCAACAG CCGTGTTTTC 300 CTTTTGATGT CCTTTACAGT GGATTACAGC CACCTGCTGA GGTGAGTAGC CCACGCTCCT 360 GGTAGATGGC TCCACGTACA TGCACAGTAG CAAAGGCGTA CCTGCTGTCA GTGTTAACGT 420 TAATATCCTT ACCCCATCGG AGAGCCTGAG TGAGGGCGAT CAATTCAGCC CTTTTGTGCT 480 GAGGTGTTTG CTGGTTAAGC CCTGAACCCA CAACACATCT GTCTCCATGG TAACAGCTGC 540 ACCGG 545 (2) INFORMATION FOR SEQ ID NO: 11: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 196 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 1: TCTCCTAGGC TGGGCACAGT GGCTCATACC TGTAATCCTG ACCGTTTCAG AGGCTCAGGT 60 GGGGGGGATCG CTTGAGCCCA AGATTTCAAG ACTAGTCTGG GTAACATAGT GAGACCCTAT 120 CTCTACGAAA AAATAAAAAA ATGAGCCTGG TGTAGTGGCA CACACCAGCT GAGGAGGGAG 180 AATCGAGCCT AGGAGA 196 (2) IN TRAINING FOR SEQ ID NO: 12: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 388 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 2: TCTCCTAGGC TTGGGGGCTC TGACTAGAAA TTCAAGGAAC CTGGGATTCA AGTCCAACTG 60 TGACACCAAC TTACACTGTG GNCTCCAATA AACTGCTTCT TTCCTATTCC CTCTCTATTA 120 AATAAAATAA GGAAAACGAT GTCTGTGTAT AGCCAAGTCA GNTATCCTAA AAGGAGATAC 180 TAAGTGACAT TAAATATCAG AATGTAAAAC CTGGGAACCA GGTTCCCAGC CTGGGATTAA 240 ACTGACAGCA AGAAGACTGA ACAGTACTAC TGTGAAAAGC CCGAAGNGGC AATATGTTCA 300 CTCTACCGTT GAAGGATGGC TGGGAGAATG AATGCTCTGT CCCCCAGTCC CAAGCTCACT 360 TACTATACCT CCTTTATAGC CTÁGGAGA 388 (2) I NFORMATION FOR SEQ ID NO: 13: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 13: TAGTAGTTGC CTATAATCAT GTTTCTCATT ATTTTCACAT TTTATTAACC AATTTCTGTT 60 TACCCTGAAA AATATGAGGG AAATATATGA AACAGGGAGG CAATGTTCAG ATAATTGATC 120 ACAAGATATG ATTTCTACAT CAGATGCTCT TTCCTTTCCT GTTTATTTCC TTTTTATTTC 180 GGTTGTGGGG TCGAATGTAA TAGCTTTGTT TCAAGAGAGA GTTTTGGCAG TTTCTGTAGC 240 TTCTGACACT GCTCATGTCT CCAGGCATCT ATTTGCACTT TAGGAGGTGT CGTGGGAGAC 300 TGAGAGGTCT ATTTTTTCCA TATTTGGGCA ACTACTA 337 (2) INFORMATION FOR SEQ ID NO: 14: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 571 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 14: TAGTAGTTGC CATACAGTGC CTTTCCATTT ATTTAACCCC CACCTGAACG GCATAAACTG 60 AGTGTTCAGC TGGTGTTTTT TACTGTAAAC AATAAGGAGA CTTTGCTCTT CATTTAAACC 120 AAAATCATAT TTCATATTTT ACGCTCGAGG GTTTTTTACCG GTTCCTTTTT ACACTCCTTA 180 AAACAGTTTT TAAGTCGTTT GGAACAAGAT ATTTTTTCTT TCCTGGCAGC TTTTAACATT 240 ATAGCAAATT TGTGTCTGGG GGACTGCTGG TCACTGTTTC TCACAGTTGC AAATCAAGGC 300 ATTTGCAACC AAGAAAAAAA AATTTTTTTG TTTTATTTGA AACTGGACCG GATAAACGGT 360 GTTTGGAGCG GCTGCTGTAT ATAGTTTTAA ATGGTTTATT GCACCTCCTT AAGTTGCACT 420 TATGTGGGGG GGGGNTTTTG NATAGAAAGT NTTTANTCAC ANAGTCACAG GGACTTTTNT 480 CTTTTGGNNA CTGAGCTAAA AAGGGCTGNT TTTCGGGTGG GGGCAGATGA AGGCTCACAG 540 GAGGCCTTTC TCTTAGAGGG GGGAACTNCT A 571 (2) I NFORMATION FOR SEQ ID NO: 1 5: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 548 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) descri PTION Secu GUM: SEQ ID NO: 1 5: TATATATTTA ATAACTTAAA TATATTTTGA TCACCCACTG GGGTGATAAG ACAATAGATA 60 TAAAAGTATT TCCAAAAAGC ATAAAACCAA AGTATCATAC CAAACCAAAT TCATACTGCT 120 TCCCCCACCC GCACTGAAAC TTCACCTTCT AACTGTCTAC CTAACCAAAT TCTACCCTTC 180 AAGTCTTTGG TGCGTGCTCA CTACTCTTTT TTTNTTTTGG AGATGGAGTC 240 TGGCTGTGCA GCCCAGGGGT GGAGTACAAT GGCACAACCT CAGCTCACTG NAACCTCCGC 300 CTCCCAGGTT CATGAGATTC TCCTGNTTCA GCCTTCCCAG TAGCTGGGAC TACAGGTGTG 360 CATCACCATG CCTGGNTAAT CTTTTTTNGT TTTNGGGTAG AGATGGGGGT TTTACATGTT 420 GGCCAGGNTG GTNTCGAACT CCTGACCTCA AGTGATCCAC CCACCTCAGG CTCCCAAAGT 480 GCTAGGATTA CAGACATGAG CCACTGNGCC CAGNCCTGGT GCATGCTCAC TTCTCTAGGC AACTACTA 540 548 (2) IN TRAINING FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 638 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 16: TTCCGTTATG CACATGCAGA ATATTCTATC GGTACTTCAG CTATTACTCA TTTTGATGGC 60 GCAATCCGAG CCTATCCTCA AGATGAGTAT TTAGAAAGAA TTGATTTAGC GATAGACCAA 120 GCTGGTAAGC ACTCTGACTA CACGAAATTG TTCAGATGTG ATGGATTTAT GACAGTTGAT 180 CTTTGGAAGA GATTATTAAG TGATTATTTT AAAGGGAATC CATTAAT CC AGAATATCTT 240 GGTTTAGCTC AAGATGATAT AGAAATAGAA CAGAAAGAGA CTACAAATGA AGATGTATCA 300 CCAACTGATA TTGAAGAGCC TATAGTAGAA AATGAATTAG CTGCATTTAT TAGCCTTACA 360 CATAGCGATT TTCCTGATGA ATCTTATATT CAGCCATCGA CATAGCATTA CCTGATGGGC 420 AACCTTACGA ATAATAGAAA CTGGGTGCGG GGCTATTGAT GAATTCATCC NCAGTAAATT 480 TGGATATNAC AAAATATAAC TCGATTGCAT TTGGATGATG GAATACTAAA TCTGGCAAAA 540 GTAACTTTGG AGCTACTAGT AACCTCTCTT TTTGAGATGC AAAATTTTCT TTTAGGGTTT 600 CTTATTCTCT ACTTTACGGA TATTGGAGCA TAACGGGA 638 (2) I NFORMATION FOR SEQ ID NO: 17: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 286 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 7: ACTGATGGAT GTCGCCGGAG GCGAGGGGCC TTATCTGATG CTCGGCTGCC TGTTCGTGAT 6 GTGCGCGGCG ATTGGGCTGT TTATCTCAAA CACCGCCACG GCGGTGCTGA TGGCGCCTAT 12 TGCCTTAGCG GCGGCGAAGT CAATGGGCGT CTCACCCTAT CCTTTTGCCA TGGTGGTGGC 18 GATGGCGGCT TCGGCGGCGT TTATGACCCC GGTCTCCTCG CCGGTTAACA CCCTGGTGCT 24 TGGCCCTGGC AAGTACTCAT TTAGCGATTT TGTCAAAATA GGCGTG 28 (2) I NFORMATION FOR SEQ ID NO: 18: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 262 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: TCGGTCATAG CAGCCCCTTC TTCTCAATTT CATCTGTCAC TACCCTGGTG TAGTATCTCA 60 TAGCCTTACA TTTTTATAGC CTCCTCCCTG GTCTGTCTTT TGATTTTCCT GCCTGTAATC 120 CATATCACAC ATAACTGCAA GTAAACATTT CTAAAGTGTG GTTATGCTCA TGTCACTCCT 180 GTGNCAAGAA ATAGTTTCCA TTACCGTCTT AATAAAATTC GGATTTGTTC TTTNCTATTN 240 TCACTCTTCA CCTATGACCG AA 262 (2) I NFORMATION FOR SEQ ID NO: 19: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 261 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 19: TCGGTCATAG CAAAGCCAGT GGTTTGAGCT CTCTACTGTG TAAACTCCTA AACCAAGGCC 60 ATTTATGATA AATGGTGGCA GGATTTTTAT TATAAACATG TACCCATGCA AATTTCCTAT 120 AACTCTGAGA TATATTCTTC TACATTTAAA CAATAAAAAT AATCTATTTT TAAAAGCCTA 180 ATTTGCGTAG TTAGGTAAGA GTGTTTAATG AGAGGGTATA AGGTATAAAT CACCAGTCAA 240 CGTTTCTCTG CCTATGACCG A 261 (2) IN TRAINING FOR SEQ ID NO: 20: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 294 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 20: TACAACGAGG CGACGTCGGT AAAATCGGAC ATGAAGCCAC CGCTGGTCTT TTCGTCCGAG 6 CGATAGGCGC CGGCCAGCCA GCGGAACGGT TGCCCGGATG GCGAAGCGAG CCGGAGTTCT 12 TCGGACTGAG TATGAATCTT GTTGTGAAAA TACTCGCCGC CTTCGTTCGA CGACGTCGCG 18 TCGAAATCTT CGANCTCCTT ACGATCGAAG TCTTCGTGGG CGACGATCGC GGTCAGTTCC 24 GCCCCACCGA AATCATGGTT GAGCCGGATG CTGNCCCCGA AGNCCTCGTT TGTN 29 (2) I NFORMATION FOR SEQ ID NO: 21: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 208 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 21: TTGGTAAAGG GCATGGACGC AGACGCCTGA CGTTTGGCTG AAAATCTTTC ATTGATTCGT 6 ATCAATGAAT AGGAAAATTC CCAAAGAGGG AATGTCCTGT TGCTCGCCAG TTTTTNTGTT 12 GTTCTCATGG ANAAGGCAAN GAGCTCTTCA GACTATTGGN ATTNTCGTTC GGTCTTCTGC 18 CAACTAGTCG NCTTGCNANG ATCTTCAT 20 (2) I NFORMATION FOR SEQ ID NO: 22: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 287 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: Linear (xí) SEQUENCE DESCRITION: SEQ ID NO: 22: NCCNTTGAGC TGAGTGATTG AGATNTGTAA TGGTTGTAAG GGTGATTCAG GCGGATTAGG 6 GTGGCGGGTC ACCCGGCAGT GGGTCTCCCG ACAGGCCAGC AGGATTTGGG GCAGGTACGG 12 NGTGCGCATC GCTCGACTAT ATGCTATGGC AGGCGAGCCG TGGAAGGNGG ATCAGGTCAC 18 GGCGCTGGAG CTTTCCACGG TCCATGNATT GNGATGGCTG TTCTAGGCGG CTGTTGCCAA 24 GCGTGATGGT ACGCTGGCTG GAGCATTGAT TTCTGGTGCC AAGGTGG 28 (2) INFORMATION FOR SEQ ID NO: 23: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 204 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 23: TTGGGTAAAG GGAGCAAGGA GAAGGCATGG AGAGGCTCAN GCTGGTCCTG GCCTACGACT 6 GGGCCAAGCT GTCGCCGGGG ATGGTGGAGA ACTGAAGCGG GACCTCCTCG AGGTCCTCCG 12 NCGTTACTTC NCCGTCCAGG AGGAGGGTCT TTCCGTGGTC TNGGAGGAGC GGGGGGAGAA 18 GATNCTCCTC ATGGTCNACA TCCC 20 (2) IN TRAINING FOR SEQ ID NO: 24: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 264 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 24: TGGATTGGTC AGGAGCGGGT AGAGTGGCAC CATTGAGGGG ATATTCAAAA ATATTATTTT 6 GTCCTAAATG ATAGTTGCTG AGTTTTTCTT TGACCCATGA GTTATATTGG AGTTTATTTT 12 TTAACTTTCC AATCGCATGG ACATGTTAGA CTTATTTTCT GTTAATGATT NCTATTTTTA 18 TTAAATTGGA TTTGAGAAAT TGGTTNTTAT TATATCAATT TTTGGTATTT GTTGAGTTTG 24 ACATTATAGC TTAGTATGTG ACCA 26 (2) IN TRAINING FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 25: TTACAACGAG GGGAAACTCC GTCTCTACAA AAATTAAAAA ATTAGCCAGG TGTGGTGGTG 6 TGCACCCGCA ATCCCAGCTA CTTGGGAGGT TGAGACACAA GANTCACCTA NATGTGGGAG 12 GTCAAGGTTs CATGAGTCAT GATTGTGCCA CTGCACTCCA GCCTGGGTGA CAGACCGAGA 18 CCCTGCCTCA ANAGANAANG AATAGGAAGT TCAGAAATCN TGGNTGTGGN GCCCAGCAAT 24 CTGCATCTAT NCAACCCCTG CAGGCAANGC TGATGCAGCC TANGTTCAAG AGCTGCTGTT 30 TCTGGAGGCA GCAGTTNGGG CTTCCATCCA GTATCACGGC CACACTCGCA CNAGCCATCT 36 GTCCTCCGTN TGTNAC 37 (2) INFORMATION FOR SÉQ ID NÓ: 26: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 372 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 26: TTACAACGAG GGGAAACTCC GTCTCTACAA AAATTAAAAA ATTAGCCAGG TGTGGTGGTG 6 TGCACCTGTA ATCCCAGCTA CTTGGGCGGC TGAGACACAA GAACCACCTA AATGTGGGAG 12 GGTCAAGGTT GCATGAGTCA TGATCGCGCC ACTGCACTCC AGCCTGGGTG ACAGACTGAG 18 ACCCTGCCTC AAAAGAAAAA GAATAGGAAG TTCAGAAACC CTGGGTGTGG NGCCCAGCAA 24 TCTGCATTTA AACAATCCCT GCAGGCAATG CTGATGCAGC CTAAGTTCAA GAGCTGCTGT 30 TCTGGAGGCA GNAGTAAGGG CTTCCATCCA GCATCACGGN CAACACTGCA AAAGCACCTG 36 TCCTCGTTGG TA 37 (2) INFORMATION FOR SEQ ID NO: 27: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 477 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 27: TTCTGTCCAC ATCTACAAGT TTTATTTATT TTGTGGGTTT TCAGGGTGAC TAAGTTTTTC 6 CCTACATTGA AAAGAGAAGT TGCTAAAAGG TGCACAGGAA ATCATTTTTT TAAGTGAATA 12 TGATAATATG GGTCCGTGCT TJVATACAACT GAGACATATT TGTTCTCTGT TTTTTTAGAG 18 TCACCTCTTA AAGTCCAATC CCACAATGGT GAAAAAAAAA TAGAAAGTAT TTGTTCTACC 24 TTTAAGGAGA CTGCAGGGAT TCTCCTTGAA AACGGAGTAT GGAATCAATC TTAAATAAAT 30 ATGAAATTGG TTGGTCTTCT GGGATAAGAA ATTCCCAACT CAGTGTGCTG AAATTCACCT 36 GACTTTTTTT GGGAAAAAAT AGTCGAAAAT GTCAATTTGG TCCATAAAAT ACATGTTACT 42 ATTAAAAGAT ATTTAAAGAC AAATTCTTTC AGAGCTCTAA GATTGGTGTG GACAGAA 47 (2) I NFORMATION FOR SEQ ID NO: 28: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 438 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 28: TCTNCAACCT CTTGANTGTC AAAAACCTTN TAGGCTATCT CTAAAAGCTG ACTGGTATTC 60 ATTCCAGCAA AATCCCTCTA GTTTTTGGAG TTTCCTTTTA CTATCTGGGG CTGCCTGAGC 120 CACAAATGCC AAATTAAGAG CATGGCTATT TTCGGGGGCT GACAGGTCAA AAGGGGTGTA 180 AATCCGATAA GCCTCCTGGA GGTGCTCTAA AAACACTCCT GGTGACTCAT CATGCCCCTG 240 GACGACTTCA ATCGNCTTAG ACAAGTTTAT AGGTTTCTGG GCAGCTCCCT GAATACCCAC 300 GAGGAGATAC CGGTGGAAAT CGTCAAAAGT TCTCCCTCCA CTTGAGAAAT TTGGGTCCCA 360 ATTAGGTCCC AATTGGGTCT CTAATCACTA TTCCTCTAGC TTCCTCCTCC GGNCTATTGG 420 TTGATGTGAG GTTGAAGA 438 (2) I NFORMATION FOR SEQ ID NO: 29: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 620 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 29: AAGAGGGTAC CAGCCCCAAG CCTTGACAAC TTCCATAGGG TGTCAAGCCT GTGGGTGCAC 60 AGAAGTCAAA AATTGAGTTT TGGGATCCTC AGCCTAGATT TCAGAGGATA TAAAGAAACA 120 CCTAACACCT AGATATTCAG ACAAAAGTTT ACTACAGGGA TGAAGCTTTC ACGGAAAACC 180 TCTACTAGGA AAGTACAGAA GAGAAATGTG GGTTTGGAGC CCCCAAACAG AATCCCCTCT 240 AGAACACTGC CTAATGAAAC TGTGAGAAGA TGGCCACTGT CATCCAGACA CCAGAATGAT 300 AGACCCACCA AAAACTTATG CCATATTGCC TATAAAACCT ACAGACACTC AATGCCAGCC 360 CCATGAAAAA AAAACTGAGA AGAAGACTGT NCCCTACAAT GCCACCGGAG CAGAACTGCC 420 CCAGGCCATG GAAGCACAGC TCTTATATCA ATGTGACCTG GATGTTGAGA CATGGAATCC 480 NANGAAATCN TTTTAANACT TCCACGGTTN AATGACTGCC CTATTANATT CNGAACTTAN 540 ATCCNGGCCT GTGACCTCTT TGCTTTGGCC ATTCCCCCTT TTTGGAATGG CTNTTTTTTT 600 CCCATGCCTG TNCCCTCTTA 620 (2) INFORMATION FOR SEQ ID NO: 30: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 100 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 30: TTACAACGAG GGGGTCAATG TCATAAATGT CACAATAAAA CAATCTCTTC TTTTTTTTTTT 6 TTTTTTTTTTT TTTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 10 (2) I NFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 762 base pairs (B) TI PO: nucleic acid (C) FILAM ENTO: simple (D) TOPOLOGY: linear [xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: TAGTCTATGC GCCGGACAGA GCAGAATTAA ATTGGAAGTT GCCCTCCGGA CTTTCTACCC 60 ACACTCTTCC TGAAAAGAGA AAGAAAAGAG GCAGGAAAGA GGTTAGGATT TCATTTTCAA 120 GAGTCAGCTA ATTAGGAGAG CAGAGTTTAG ACAGCAGTAG GCACCCCATG ATACAAACCA 180 TGGACAAAGT CCCTGTTTAG TAACTGCCAG ACATGATCCT GCTCAGGTTT TGAAATCTCT 240 CTGCCCATAA AAGATGGAGA GCAGGAGTGC CATCCACATC AACACGTGTC CAAGAAAGAG 300 TCTCAGGGAG ACAAGGGTAT CAAAAAACAA GATTCTTAAT GGGAAGGAAA TCAAACCAAA 360 AAATTAGATT TTTCTCTACA TATATATAAT ATACAGATAT TTAACACATT ATTCCAGAGG 420 TGGCTCCAGT CCTTGGGGCT TGAGAGATGG TGAAAACTTT TGTTCCACAT TAACTTCTGC 480 TCTCAAATTC TGAAGTATAT CAGAATGGGA CAGGCAATGT TTTGCTCCAC ACTGGGGCAC 540 AGACCCAAAT GGTTCTGTGC CCGAAGAAGA GAAGCCCGAA AGACATGAAG GATGCTTAAG 600 GGGGGTTGGG AAAGCCAAAT TGGTANTATC TTTTCCTCCT GCCTGTGTTC CNGAAGTCTC 660 CNCTGAAGGA ATTCTTAAAA CCCTTTGTGA GGAAATGCCC CCTTACCATG ACAANTGGTC 720 CCATTGCTTT TAGGGNGATG GAAACACCAA GGGTTTTGAT CC 762 (2) I NFORMATION FOR SEQ ID NO: 32: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 276 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: TAGTCTATGC GTGTATTAAC CTCCCCTCCC TCAGTAACAA CCAAAGAGGC AGGAGCTGTT 60CCATTTTACA GATGCATCAA TAATGACAGA GAAGTGAAGT GACTTGCGCA 120 CACAACCAGT AAATTGGCAG AGTCAGATTT GAATCCATGG AGTCTGGTCT GCACTTTCAA 180 TCACCGAATA CCCTTTCTAA GAAACGTGTG CTGAATGAGT GCATGGATAA ATCAGTGTCT 240 ACTCAACATC TTTGCC GA TATCCCGCAT AGACTA 276 (2) IN TRAINING FOR SEQ ID NO: 33: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 477 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 33: TAGTAGTTGC CAAATATTTG AAAATTTACC CAGAAGTGAT TGAAAACTTT TTGGAAACAA 60 AAACAAATAA AGCCAAAAGG TAAAATAAAA ATATCTTTGC ACTCTCGTTA TTACCTATCC 120 ATAACTTTTT CACCOTAAGC TCTCCTGCTT GTTAGTGTAG TGTGGTTATA TTAAACTTTT 180 TAGTTATTAT TTTTTATTCA CTTTTCCACT AGAAAGTCAT TATTGATTTA GCACACATGT 240 TGATCTCATT TCATTTTTTC TTTTTATAGG CAAAATTTGA TGCTATGCAA CAAAAATACT 300 CAAGCCCATT ATCTTTTTTC CCCCCGAAAT CTGAAAATTG CAGGGGACAG AGGGAAGTTA 360 TCCCATTAAA AAATTGTAAA TATGTTCAGT TTATGTTTAA AAATGCACAA AACATAAGAA 420 AATTGTGTTT ACTTGAGCTG CTGATTGTAA GCAGTTTTAT CTCAGGGGCA ACTACTA 477 (2) I NFORMATION FOR SEQ ID NO: 34: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 631 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 34: TAGTAGTTGC CAATTCAGAT GATCAGAAAT GCTGCTTTCC TCAGCATTGT CTTGTTAAAC 60 CGCATGCCAT TTGGAACTTT GGCAGTGAGA AGCCAAAAGG AAGAGGTGAA TGACATATAT 120 ATATATATAT ATTCAATGAA AGTAAAATGT ATATGCTCAT ATACTTTCTA GTTATCAGAA 180 TGAGTTAAGC TTTATGCCAT TGGGCTGCTG CATATTTTAA TCAGAAGATA AAAGAAAATC 240 TGGGCATTTT TAGAATGTGA TACATGTTTT TTTAAAACTG TTAAATATTA TTTCGATATT 300 TGTCTAAGAA CCGGAATGTT CTTAAAATTT ACTAAAACAG TATTGTTTGA GGAAGAGAAA 360 ACTGTACTGT TTGCCATTAT TACAGTCGTA CAAGTGCATG TCAAGTCACC CACTCTCTCA 420 GGCATCAGTA TCCACCTCAT AGCTTTACAC ATTTTGACGG GGAATATTGC. ..AGCATCCTCA 480 GGCCTGACAT CTGGGAAAGG CTCAGATCCA CCTACTGCTC CTTGCTCGTT GATTTGTTTT 540 AAAATATTGT GCCTGGTGTC ACTTTTAAGC CACAGCCCTG CCTAAAAGCC AGCAGAGAAC 600 AGAACCCGCA CCATTCTATA GGCAACTACT A 631 (2) I NFORMATION FOR SEQ ID NO: 35: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 578 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: TAGTAGTTGC CATCCCATAT TACAGAAGGC TCTGTATACA TGACTTATTT GGAAGTGATC 60 TGTTTTCTCT CCAAACCCAT TTATCGTAAT TTCACCAGTC TTGGATCAAT CTTGGTTTCC 12 ACTGATACCA TGAAACCTAC TTGGAGCAOA CATTGCACAG TTTTCTGTGG TAAAAACTAA 18 AGGTTTATTT GCTAAGCTGT CATCTTATGC TTAGTATTTT TTTTTTTACAG TGGGGAATTG 24 CTGAGATTAC ATTTTGTTAT TCATTAGATA CTTTGGGATA ACTTGACACT GTCTTCTTTT 30 TTTCGCTTTT AATTGCTATC ATCATGCTTT TGAAACAAGA ACACATTAGT CCTCAAGTAT 36 TACATAAGCT TGCTTGTTAC GCCTGGTGGT TTAAAGGACT ATCTTTGGCC TCAGGTTCAC 420 AAGAATGGGC AAAGTGTTTC CTTATGTTCT GTAGTTCTCA ATAAAAGATT GCCAGGGGCC 480 GGGTACTGTG GCTCGCACTG TAATCCCAGC ACTTTGGGAA GCTGAGGCTG GCGGATCATG 540 TTAGGGCAGG TGTTCGAAAC CAGCCTGGGC AACTACTA 578 (2) I NFORMATION FOR SEQ ID NO: 36: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 583 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) descri PTION Secu GUM: SEQ ID NO: 36: TAGTAGTTGC CTGTAATCCC AGCAACTCAG GAGGCTGGGG CAGGAGAATC AGTTGAACCT 60 GGGAGGCAGA AGTTGTAATT AGCAAAGATC GCACCATTGC ACTTCAGCCT GGGCAACAAG 120 AGTGAGATTC CATCTCAAAA ACAAAAAAAA GAAAAAGAAA AGAAAAGGAA AAAACGTATA 180 AACCCAGCCA AAACAAAATG ATCATTCTTT TAATAAGCAA GACTAATTTA ATGTGTTTAT 240 TTAATCAAAG CAGTTGAATC TTCTGAGTTA TTGGTGAAAA TACCCATGTA GTTAATTTAG_300_GGTTCTTACT TGGGTGAACG TTTGATGTTC ACAGGTTATA AAATGGTTAA CAAGGAAAAT 360 GATGCATAAA GAATCTTATA AACTACTAAA AATAAATAAA ATATAAATGG ATAGGTGCTA 420 TGGATGGAGT TTTTGTGTAA TTTAAAATCT TGAAGTCATT TTGGATGCTC ATTGGTTGTC 480 TGGTAATTTC CATTAGGAAA AGGTTATGAT ATGGGGAAAC TGTTTCTGGA AATTGCGGAA 540 TGTTTCTCAT CTGTAAAATG CTAGTATCTC AGGGCAACTA CTA 583 (2) IN TRAINING FOR S EQ ID NO: 37: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 716 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 37: GATCTACTAG TCATNTGGAT TCTATCCATG GCAGCTAAGC CTTTCTGAAT GGATTCTACT 60TCTTTAATCC AGACCCTTAT ATATGTTTAT GTTCACAGGC AGGGCAATGT 120 TTAGTGAAAA CAATTCTAAA TTTTTTATTT TGCATTTTCA TGCTAATTTC CGTCACACTC 180 CAGCAGGCTT CCTGGGAGAA TAAGGAGAAA TACAGCTAAA GACATTGTCC CTGCTTACTT 240 ACAGCC AAT GGTATGCAAA ACCACTTCAA TAAAGTAACA GGAAAAGTAC TAACCAGGTA 300 GAATGGACCA AAACTGATAT AGAAAAATCA GAGGAAGAGA GGAACAAATA TTTACTGAGT 360 CCTAGAATGT ACAAGGCTTT TTAATTACAT ATTTTATGTA AGGCCTGCAA AAAACAGGTG 420 AGTAATCAAC ATTTGTCCCA TTTTACATAT AAGGAAACTG AAGCTTAAAT TGAATAATTT 480 AATGCATAGA TTTTATAGTT AGACCATGTT CAGGTCCCTA TGTTATACTT ACTAGCTGTA 540 TGAATATGAG AAAATAATTT TGTTATTTTC TTGGCATCAG TATTTTCATC TGCAAAATAA 600 AGCTAAAGTT ATTTAGCAAA CAGTCAGCAT AGTGCCTGAT ACATAGTAGG TGCTCCAAAC 660 ATGATTACNC TANTATTNGG TATTANAAAA ATCCAATATA GGCNTGGATA AAACCG 716 (2) INFORMATION FOR SEQ ID NO: 38: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 688 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 38: TTCTGTCCAC ATATCATCCC ACTTTAATTG TTAATCAGCA AAACTTTCAA TGAAAAATCA 60 TCCATTTTAA CCAGGATCAC ACCAGGAAAC TGAAGGTGTA TTTTTTTTTA CCTTAAAAAA 120 AAAAAAAAAA ACCAAACAAA CCAAAACAGA TTAACAGCAA AGAGTTCTAA AAAATTTACA 180 TTTCTCTTAC AACTGTCATT CAGAGAACAA TAGTTCTTAA GTCTGTTAAA TCTTGGCATT 240 AACAGAGAAA CTTGATGAAN AGTTGTACTT GGAATATTGT GGATTTTTTT TTTTGTCTAA 300 TCTCCCCCTA TTGTTTTGCC AACAGTAATT TAAGTTTGTG TGGAACATCC CCGTAGTTGA 360 AGTGTAAACA ATGTATAGGA AGGAATATAT GATAAGATGA TGCATCACAX-ATGCAT ACA - 430 TGTAGGGACC TTCACAACTT CATGCACTCA GAAAACATGC TTGAAGAGGA GGAGAGGACG 480 GCCCAGGGTC ACCATCCAGG TGCCTTGAGG ACAGAGAATG CAGAAGTGGC ACTGTTGAAA 540 TTTAGAAGAC CATGTGTGAA TGGTTTCAGG CCTGGGATGT TTGCCACCAA GAAGTGCCTC 600 CGAGAAATTT CTTTCCCATT TGGAATACAG GGTGGCTTGA TGGGTACGGT GGGTGACCCA 660 ACGAAGAAAA TGAAATTCTG CCCTTTCC 688 (2) I NFORMATION FOR SEQ ID NO: 39: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 585 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 39: TAGTAGTTGC CGCNNACCTA AAANTTGGAA AGCATGATGT CTAGGAAACA TANTAAAATA 60 GGGTATGCCT ATGTGCTACA GAGAGATGTT AGCATTTAAA GTGCATANTT TTATGTATTT 120 TGACAAATGC ATATNCCTCT ATAATCCACA ACTGATTACG AAGCTATTAC AATT AAAAG 180 TTTGGCCGGG CGTGGTGGGC GGTGGCTGAC GCCTGTAATC CCAGCACTTT GGGAGGCCGA 240 GGCACGCGGA TCACGAGGTC GGGAGTTCAA GACCATCCTG GCTAACACGG tQAAAGTCCÁ "300 TCTCTACTAA AAATACGAAA AAATTACCCC GGCGTGGTGG CGGGCGCCTG TAGTCCCAGC 360 TACTCCGGAG GCTGAGGCAG GAGAATGGCG TGAACCCAGG ACACGGAGCT TGCAGTGTGC 420 CAACATCACG TCACTGCCCT CCAGCCTGGG GGACAGGAAC AAGANTCCCG TCCTCANAAA 480 AGAAAAATAC TACTNATANT TTCNACTTTA TTTTAANTTA CACAGAACTN CCTCTTGGTA 540 CCCCCTTACC ATTCATCTCA CCCACCTCCT ATAGGGCACN NCTAA 585 (2) I NFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 475 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 40: TCTGTCCACA CCAATCTTAG AAGCTCTGAA AAGAATTTGT CTTTAAATAT CTTTTAATAG_60_TAACATGTAT TTTATGGACC AAATTGACAT TTTCGACTGT TTTTTCCAAA AAAGTCAGGT 120 GAATTTCAGC ACACTGAGTT GGGAATTTCT TATCCCAGAA GACCAACCAA TTTCATATTT 180 ATTTAAGATT GATTCCATAC TCCGTTTTCA AGGAGAATCC CTGCAGTCTC CTTAAAGGTA 240 GAACAAATAC TTCCTATTTT TTTTTCACCA TTGTGGGATT GGACTTTAAG AGGTGACTCT 300 AAAAAAACAG AGAACAAATA TGTCTCAGTT GTATTAAGCA CGGACCCATA TTATCATATT 360 CACTTAAAAA AATGATTTCC TGTGCACCTT TTGGCAACTT CTCTTTTCAA TGTAGGGAAA 420 AACTTAGTCA CCCTGAAAAC CCACAAAATA AATAAAACTT GTAGATGTGG ACAGA 475 (2) INFORMATION FOR SEQ ID NO: 41: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 423 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRITION: SEQ ID NO: 41: TAAGAGGGTA CATCGGGTAA GAACGTAGGC ACATCTAGAG CTTAGAGAAG TCTGGGGTAG_60_GAAAAAAATC TAAGTATTTA TAAGGGTATA GGTAACATTT AAAAGTAGGG CTAGCTGACA 120 TTATTTAGAA AGAACACATA CGGAGAGATA AGGGCAAAGG ACTAAGACCA GAGGAACACT 180 AATATTTAGT GATCACTTCC ATTCTTGGTA AAAATAGTAA CTTTTAAGTT AGCTTCAAGG 240 AAGATTTTTG GCCATGATTA GTTGTCAAAA GTTAGTTCTC TTGGGTTTAT ATTACTAATT 300 TTGTTTTAAG ATCCTTGTTA GTGCTTTAAT AAAGTCATGT TATATCAAAC GCTCTAAAAC 360 ATTGTAGCAT GT AAATGTC ACAATATACT TACCATTTGT TGTATATGGC TGTACCCTCT 420 CTA 423 (2) I NFORMATION FOR SEQ ID NO: 42: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 527 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 42: TCTCCTAGGC TAATGTGTGT GTTTCTGTAA AAGTAAAAAG TTAAAAATTT TAAAAATAGA 60 AAAAAGCTTA TAGAATAAGA ATATGAAGAA AGAAAATATT TTTGTACATT TGCACAATGA 120 GTTTATGTTT TAAGCTAAGT GTTATTACAA AAGAGCCAAA AAGGTTTTAA AAATTAAAAC 180 GTTTGTAAAG TTACAGTACC CTTATGTTAA TTTATAATTG AAGAAAGAAA AACTTTTTTT 240 TATAAATGTA GTGTAGCCTA AGCATACAGT ATTTATAAAG TCTGGCAGTG TTCAATAATG 300 TCCTAGGCCT TCACATTCAC TCACTGACTC ACCCAGAGCA ACTTCCAGTC CTGTAAGCTC 360 CATTCGTGGT AAGTGCCCTA TACAGGTGCA CCATTTATTT TACAGTATTT TTACTGTACC 420 TTCTCTATGT TTCCATATGT TTCGATATAC AAATACCACT GGTTACTATN GCCCNACAGG 480 TAATTCCAGT AACACGGCCT GTATACGTCT GGTANCCCTA GNGAAGA 527 (2) I NFORMATION FOR S EQ ID NO: 43: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 331 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 43: TCTTCAACCT CGTAGGACAA CTCTCATATG CCTGGGCACT ATTTTTAGGT TACTACCTTG 60 GCTGCCCTTC TTTAAGAAAA AAAAAAGAAG AAAAAAGAAC TTTTCCACAA GTTTCTCTTC 120 CTCTAGTTGG AAAATTAGAG AAATCATGTT TTTAATTTTG TGTTATTTCA GATCACAAAT 180 TCAAACACTT GTAAACATTA AGCTTCTGTT CAATCCCCTG GGAAGAGGAT TCATTCTGAT 240 ATTTACGGTT CAAAAGAAGT TGTAATATTG TGCTTGGAAC ACAGAGAACC AGTTATTAAC 300 TTCCTACTAC TATTATATAA TAAATAATAA C 331 (2) I NFORMATION FOR SEQ ID NO: 44: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 592 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) DESCRIPTION OF SECTION: SEQ ID NO: 44: GGCTTAGTAG TTGCCAGGCA AAATARCGTT GATTCTCCTC AGGAGCCACC CCCAACACCC - 60 CTGTTTGCTT CTAGACCTAT ACCTAGACTA AAGTCCCAGC AGACCCCTAG AGGTGAGGTT 120 CAGAGTGACC CTTGAGGAGA TGTGCTACAC TAGAAAAGAA CTGCTTGAGT TTTCTAATTT 180 ATATAAGCAG AAATCTGGAG AAGAGTCATA GGAATGGATA TTAAGGGTGT GAGATAATGG 240 CGGAAGGAAT ATAGAGTTGG ATCAGGCTGG ACTTATTGAT TTGAACCCAC TAAGTAOAGA 300 TTCTGCTTTT GATGTTGCAG CTCAGGGAGT TAAAAAAGGT TTTAATGGTT CTAATAGTTT 360 ATTTGCTTGG TTAGCTGAAA TATGGATAAA AGATGGCCCA CTGTGAGCAA GCTGGAAATG 420 CCTGATCTCT CTCAGTTTAA TGTAGAGGAA GGGATCCAAA AGTTTAGGGA GANTTGGATG 480 CTGGRAKTGG ATTGGTCACT TTGRGACCTA CCC TCCCAG CTGGGAGGGT CCAGAAGATA 540 CACCCTTGAC CAACGCTTTG CGAAATGGAT TTGTGATGGC GGCAACTACT AA 592 (2) I NFORMATION FOR SEQ ID NO: 45: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 567 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: GGCTTAGTAG TTGCCATTGC GAGTGCTTGC TCAACGAGCG TTGAACATGG CGGATTGTCT 60 AGATTCAACG GATTTGAGTT TTACCAGCAA AGCGAACCAA GCGCGGCCCA GAGAATTATG 120 GGTTGGTTGG CTTTGAAAAG ATGGAAATCC TGTAGGCCTA GTCAGAAAAG CCTTCTTGCA 180 GAACAGTTGG TTCTCGGGCG AACGCTCATC AAGATGCCCA TTGGAAAGGC TAGCGTGTAT 240 TTGGGAGAGC CTGATAGCGT GTCTTCTGAT GATGTTTGTG CTTGGACAGT GACAAAAGAT 300 ATGCAAAGCA AGTCCGAACT AGACGTCAAG CTTCGTGAGC AAATTATTGT AGACTCCTAC 360 TTATACTGTG AGGAATGATA GCCAAGGGTG GGGACTTTAA GACTAAGGTG GTTTGTACTT 420 GCGCCGATGA TCCCAGGCAG AAAGAMCTGA TCGCTAGTTT TATACGGGCA ACTACTAAGC 480 CGAATTCCAG CACACTGGCG GCCGTTACTA ATTGGATCCG ANCTCGGTAC CAGCTTGATG 540 CATASCTTGA GTTWTCTATA NTGTCNC 567 (2) INFORMATION FOR SEQ ID NO: 46: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 908 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: GAGCGAAAGA CCGAGGGCAG NGNNTANGNG CGANGAAGCG GAGAGGGCCA AAAAGCAACC 6 GCTTTCCCCG GGGGGTGCCG ATTCATTAAG GCAGGTGGAG GACAGGTTTC CCGATGGAAG 12CGCAAGCAAT TAATGTGAGT AGGCCATTCA TTAGCACCCG GGCTTAACAT 18 TTAAGCTTCG GGTTGGTATG TGGTGGGAAT TGTGAGCGGA TAACAATTTC ACACAGGAAA 24 CAGCTATGAC CATGATTACG CCAAGCTATT TAGGTGACAT TATAGAATAA CTCAAGTTAT 300 GCATCAAGCT TGGTACCGAG TTCGGATCCA CTAGTAACGG CCGCCAGTGT GTGGAATTCG 360 GCTTAGTAGT TGCCGACCAT GGAGTGCTAC CTAGGCTAGA ATACCTGAGY TCCTCCCTAG_420_CCTCACTCAC AT AAATTGT ATCTTTTCTA CATTAGATGT CCTCAGCGCC TTATTTCTGC 480 TGGAC ATCG ATAAATTAAT CCTGATAGGA TGATAGCAGC AGATTAATTA CTGAGAGTAT 540 GTTJ_ATGTGT CATCCCTCCT ATATAACGTA TTTGCATTTT AATGGAGCAA TTCTGGAGAT 600 AATCCCTGAA GGCAAAGGAA TGAATCTTGA GGGTGAGAAA GCCAGAATCA GTGTCCAGCT 660 GCAGTTGTGG GAGAAGGTGA TATTATGTAT GTCTCAGAAG TGACACCATA TGGGCAACTA 720 CTAAGCCCGA ATTCCAGCAC ACTGGCGGGC GTTACTAATG GATCCGAGCT CGGTACCAAG 780 CTTGATGCAT AGCTTGAGTA TCTATAGTGT CACTAAATAG CCTGGCGTTA TCATGGTCAT 840 AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCCCAATTCC CCCCACCATA CGAGCCGGAA 900 CATAAAGT 908 (2) I NFORMATION FOR SEQ ID NO: 47: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 480 base pairs (B) TYPE: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 47: TGCCAACAAG GAAAGTTTTA AATTTCCCCT TGAGGATTCT TGGTGATCAT CAAATTCAGT 60 GGTTTTTTAAG GTTGTTTTCT GTCAAATAAC TCTAACTTTA AGCCAAACAG TATATGGAAG 120 CACAGATAKA ATATTACACA GATAAAAGAG GAGTTGATCT AAAGTARAGA TAGTTGGGGG 180 CTTTAATTTC TGGAACCTAG GTCTCCCCAT CTTCTTCTGT GCTGAGGAAC TTCTTGGAAG 240 CGGGGATTCT AAAGTTCTTT GGAAGACAGT TTGAAAACCA CCATGTTGTT CTCAGTACCT 300 TTATTTTTAA AAAGTAGGTG AACATTTTGA GAGAGAAAAG GGCTTGGTTG AGATGAAGTC 360 CCCCCCCCCC CTTTTTTTTT TTTTAGCTGA AATAGATACC CTATGTTNAA RGAARGGATT 420 ATTATTTACC ATGCCAYTAR SCACATGCTC TTTGATGGGC NYCTCCSTAC CCTCCTTAAG 480 (2) I NFORMATION FOR SEQ ID NO: 48: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 591 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 48: AAGAGGGTAC CGAGTGGAAT TTCCGCTTCA CTAGTCTGGT GTGGCTAGTC GGTTTCGTGG 6 TGGCCAACAT TACGAACTTC CAACTCAACC GTTCTTGGAC GTTCAAGCGG GAGTACCGGC 12 GAGGATGGTG GCGTGAATTC TGGCCTTTCT TTGCCGTGGG ATCGGTAGCC GCCATCATCG 18 GTATGTTTAT CAAGATCTTC TTTACTAACC CGACCTCTCC GATTTACCTG CCCGAGCCGT 24 GGTTTAACGA GGGGAGGGGG ATCCAGTCAC GCGAGTACTG GTCCCAGATC TTCGCCATCG 30 TCGTGACAAT GCCTATCAAC TTCGTCGTCA ATAAGTTGTG GACCTTCCGA ACGGTGAAGC 36 ACTCCGAAAA CGTCCGGTGG CTGCTGTGCG GTGACTCCCA AAATCTTGAT AACAACAAGG 42 TAACCGAATC GCGCTAAGGA ACCCCGGCAT CTCGGGTACT CTGCATATGC GTACCCCTTA 48 AGCCGAATTC CAGCACACTG GCGGCCGTTA CTAATTGGAT CCGAACTCCG TAACCAAGCC 54 TGATGCGTAA CTTGAGTTAT TCTATAGTGT CCCTAAAATA ACCTCGCGTT A 59 (2) I NFORMATION FOR SEQ ID NO: 49: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 454 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 49: AAGAGGGTAC CTGCCTTGAA ATTTAAATGT CTAAGGAAAR TGGGAGATGA TTAAGAGTTG 6 GTGTGGCYTA GTCACACCAA AATGTATTTA TTACATCCTG CTCCTTTCTA GTTGACAGGA 12 AAGAAAGCTG CTGTGGGGAA AGGAGGGATA AATACTGAAG GGATTTACTA AACAAATGTC 18 CATCACAGAG TTTTCCTTTT TTTTTTTTTTG AGACAGAGTC TTGCTCTGTC ACCCAGGCTG 24 GAATGAAGWG GTATGATCTC AGTTGAATGC AACCTCTACC TCCTAGGTTC AAGCGATTCT 30 CATGCCTCAG CCTCCTGAGC AGCTGGGACT ATAGGCGCAT GCTACCATGC CAGGCTAATT 36 TTTATATTTT TATTAGAGAC GGGGTGTTGC CATGTTGGCC AGGCAGGTCT CGAACTCCTG 42 GGCCTCAGAT GATCTGCCCC ACCGTACCCT CTTA - 45 (2) I NFORMATION FOR SEQ ID NO: 50: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 463 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: AAGAGGGTAC CAAAAAAAAG AAAAAGGAAA AAAAGAAAAA CAACTTGTAT AAGGCTTTCT 6 GCTGCATACA GCTTTTTTTT TTTAAATAAA TGGTGCCAAC AAATGTTTTT GCATTCACAC 12 CAATTGCTGG TTTTGAAATC GTACTCTTCA AAGGTATTTG TGCAGATCAA TCCAATAGTG 18 ATGCCCCGTA GGTTTTGTGG ACTGCCCACG TTGTCTACCT TCTCATGTAG GAGCCATTGA 24 GAGACTGTTT GGACATGCCT GTGTTCATGT AGCCGTGATG TCCGGGGGCC GTGTACATCA 30 TGTTACCGTG GGGTGGGGTC TGCATTGGCT GCTGGGCATA TGGCTGGGTG CCCATCATGC 36 CCATCTGCAT CTGCATAGGG TATTGGGGCG TTTGATCCAT ATAGCCATGA TTGCTGTGGT 42 AGCCACTGTT CATCATTGGC TGGGACATGC TGTTACCCTC TTA 46 (2) INFORMATION FOR SEQ ID NO: 51: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 399 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: CTTCAACCTC CCAAAGTGCT GGGATTACAG GACTGAGCCA CCACGCTCAG CCTAAGCCTC 6 TTTTTCTCTA CCCTCTAAGC GATCTACCAC AGTGATGAGG GGCTAAAGAG CAGTGCAATT 12 TGATTACAAT J_ATGGAACTT AGATTTATTA ATTAACAATT TTTCCTTAGC ATGTTGGTTC 18 CATAATTATT AAGAGTATGG ACTTACTTAG AAATGAGCTT TCATTT AAG AATTTCATCT 24 TTGACCTTCT CTATTAGTCT GAGCAGTATG ACACTATACG TATTTTATTT AACTAACCTA 30 CCTTGAGCTA TTACTTTTTA AAAGGCTATA TACATGAATG TGTATTGTCA ACTGTAAAGC 36 CCCACAGTAT TTAATTATAT CATGATGTCT TTGAGGTTG 39 (2) INFORMATION FOR SEQ ID NO: 52: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 392 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear < i) SEQUENCE DESCRIPTION: SEQ ID NO: 52: CTTCAACCTC AATCAACCTT GGTAATTGAT AAAATCATCA CTTAACTTTC TGATATAATG 6 GCAATAATTA TCTGAGAAAA AAAAGTGGTG AAAGATTAAA CTTGCATTTC TCTCAGAATC 12 TTGAAGGATA TTTGAATAAT TCAAAAGCGG AATCAGTAGT ATCAGCCGAA GAAACTCACT 18 TAGCTAGAAC GTTGGACCCA TGGATCTAAG TCCCTGCCCT TCCACTAACC AGCTGATTGG 24 TTTTGTGTAA ACCTCCTACA CGCTTGGGCT TGGTCGCCTC ATTTGTCAAA GTAAAGGCTG 30 AAATAGGAAG ATAATGAACC GTGTCTTTTT GGTCTCTTTT CCATCCATTA CTCTGATTTT 36 ACAAAGAGGC CTGTATTCCC CTGGTGAGGT TG 39 (2) INFORMATION FOR SEQ ID NO: 53: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 179 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 53: TTCGGGTGAT GCCTCCTCAG GCTACAGTGA AGACTGGATT ACAGAAAGGT GCCAGCGAGA 60 TTTCAGATTC CTGTAAACCT CTAAAGAAAA GGAGTCGCGC CTCAACTGAT GTAGAAATGA 12 CTAGTTCAGC ATACNGAGAC ACNTCTGACT CCGATTCTAG AGGACTGAGT GACCTGCAN 17 (2) I NFORMATION FOR SEQ ID NO: 54: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 12 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 54: TTCGGGTGAT GCCTCCTCAG GCTACATCAT NATAGAAGCA AAGTAGAANA ATCNNGTTTG 6 TGCATTTTCC CAC NACAAA ATTCAAATGA NTGGAAGAAA TTGGGANAGT AT 11 (2) I NFORMATION FOR SEQ ID NO: 55: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 55: TGAGCTTCCG CTTCTGACAA CTCAATAGAT AATCAAAGGA CAACTTTAAC AGGGATTCAC 6 AAAGGAGTAT ATCCAAATGC CAATAAACAT ATAAAAAGGA ATTCAGCTTC ATCATCATCA 12 GAAGWATGCA AATTAAAACC ATAATGAGAA ACCACTATGT CCCACTAGAA TAGATAAAAT 18 CTTAAAAGAC TGGTAAAACC AAGTGTTGGT AAGGCAAGAG GAGCA 22 (2) INFORMATION FOR SEQ ID NO: 56: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 1 75 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 56: GCTCCTCTTG CCTTACCAAC ACATTCTCAA AAACCTGTTA GAGTCCTAAG CATTCTCCTG 6 TTAGTATTGG GATTTTACCC CTGTCCTATA AAGATGTTAT GTACCAAAAA TGAAGTGGAG 12 GGCCATACCC TGAGGGAGGG GAGGGATCTC TAGTGTTGTC AGAAsCGGAA GCTCA 17 (2) I NFORMATION FOR SEQ ID NO: 57: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 223 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 57: AGCCATTTAC CACCCATGGA TGAATGGATT TTGTAATTCT AGCTGTTGTA TTTTGTGAAT 6 TTGTTAATTT TGTTGTTTTT CTGTGAAACA CATACATTGG ATATGGGAGG TAAAGGAGTG 120 TCCCAGTTGC TCCTGGTCAC TCCCTTTATA GCCATTACTG TCTTGTTTCT TGTAACTCAG 180 GTTAGGTTTT GGTCTCTCTT GCTCCACTGC AAAAAAAAAA AAA 223 (2) I NFORMATION FOR SEQ ID NO: 58: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 1 base pair (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58: GTTCGAAGGT GAACGTGTAG GTAGCGGATC TCACAACTGG GGAACTGTCA AAGACGAATT 60 AACTGACTTG GATCAATCAA ATGTGACTGA GGAAACACCT GAAGGTsAAG AACATCATCC 120 AGTGGCAGAC ACTGAAAATA AGGAGAATGA AGTTGAAGAG GTAAAAGAGG AGGGTCCAAA 180 AGAGATGACT TTGGATGGGT GGTAAATGGC T 211 (2) I NFORMATION FOR SEQ ID NO: 59: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 208 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 59: GCTCCTCTTG CCTTACCAAC TTTGCACCCA TCATCAACCA TGTGGCCAGG TTTGCAGCCC 60 AGGCTGCACA TCAGGGGACT GCCTCGCAAT ACTTCATGCT GTTGCTGCTG ACTGATGGTG 12 CTGTGACGGA TGTGGAAGCC ACACGTGAGG CTGTGGTGCG TGCCTCGAAC CTGCCCATGT 18 CAGTGATCAT TATGGGTGGT AAATGGCT 20 (2) I NFORMATION FOR SEQ ID NO: 60: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 71 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 60: AGCCATTTAC CACCCATACT AAATTCTAGT TCAAACTCCA ACTTCTTCCA TAAAACATCT 6 AACCACTGAC ACCAGTTGGC AATAGCTTCT TCCTTCTTTA ACCTCTTAGA GTATTTATGG 12 TCAATGCCAC ACATTTCTGC AACTGAATAA AGTTGGTAAG GCAAGAGGAG C 17 (2) I NFORMATION FOR SEQ ID NO: 61: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 34 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 61: CGGGTGATGC CTCCTCAGGC TTTGGTGTGT CCACTCNACT CACTGGCCTC TTCTCCAGCA 6 ACTGGTGAAN ATGTCCTCAN GAAAANCNCC ACACGCNGCT CAGGGTGGGG TGGGAANCAT 12 CANAATCATC NGGC 13 (2) I NFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 145 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 62: AGAGGGTACA TATGCAACAG TATATAAAGG AAGAAGTGCA CTGAGAGGAA CTTCATCAAG 6 GCCATTTAAT CAATAAGTGA TAGAGTCAAG GCTCAACCCA GGTGTGACGG ATTCCAGGTC 12 CCAAGCTCCT TACTGGTACC CTCTT 14 (2) IN TRAINING FOR SEQ ID NO: 63: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 297 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 63: TGCACTGAGA GGAATTCAAA GGGTTTATGC CAAAGAACAA ACCAGTCCTC TGCAGCCTAA 6 CTCATTTGTT TTTGGGCTGC GAAGCCATGT AGAGGGCGAT CAGGCAGTAG ATGGTCCCTC 12 CCACAGTCAG CGCCATGGTG GTCCGGTAAA GCATTTGGTC AGGCAGGCCT CGTTTCAGGT 18 AGACGGGCAC ACATCAGCTT TCTGGAAAAA CTTTTGTAGC TCTGGAGCTT TGTTTTTCCC 24 AGCATAATCA TACACTGTGG AATCGGAGGT CAGTTTAGTT GGTAAGGCAA GAGGAGC 29 (2) IN TRAINING FOR SEQ ID NO: 64: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 300 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 64: GCACTGAGAG GAACTTCCAA TACTATGTTG AATAGGAGTG GTGAGAGAGG GCATCCTTGT 60 CTTGTGCCGG TTTTCAAAGG GAATGCTTCC AGCTTTTGCC CATTCAGTAT AATATTAAAG 12 AATGTTTTAC CATTTTCTGT CTTGCCTGTT TTTCTGTGTT TTTGTTGGTC TCTTCATTCT 18 CCATTTTTAG GCCTTTACAT GTTAGGAATA TATTTCTTTT AATGATACTT CACCTTTGGT 24 ATACTTTTGTG AGACTCTACT CATAGTGTGA TAAGCACTGG GTTGGTAAGG CAAGAGGAGC 30 (2) I NFORMATION FOR SEQ ID NO: 65: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 203 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) descri PTION Secu GUM: SEQ ID NO: 65: GCTCCTCTTG CCTTACCAAC TCACCCAGTA TGTCAGCAAT TTTATCRGCT TTACCTACGA 60 AACAGCCTGT ATCCAAACAC TTAACACACT CACCTGAAAA GTTCAGGCAA CAATCGCCTT 120 CTCATGGGTC TCTCTGCTCC AGTTCTGAAC CTTTCTCTTT TCCTAGAACA TGCATTTARG 180 203 TGC TCGATAGAAG TTCCTCTCAG (2) I NFORMATION FOR SEQ ID NO: 66: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 344 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 66: TACGGGGACC CCTGCATTGA GAAAGCGAGA CTCACTCTGA AGCTGAAATG CTGTTGCCCT 60 TGCAGTGCTG GTAGCAGGAG TTCTGTGCTT TGTGGGCTAA GGCTCCTGGA TGACCCCTGA 120 CATGGAGAAG GCAGAGTTGT GTGCCCCTTC TCATGGCCTC GTCAAGGCAT CATGGACTGC 180 CACACACAAA ATGCCGTTTT TATTAACGAC ATGAAATTGA AGGAGAGAAC ACAATTCACT 240 GATGTGGCTC GTAACCATGG ATATGGTCAC ATACAGAGGT GTGATTATGT AAAGGTTAAT 300 TCCACCCACC TCATGTGGAA ACTAGCCTCA ATGCAGGGGT CCCA 344 (2) I NFORMATION FOR SEQ ID NO: 67: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 57 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: GCACTGAGAG GAACTTCGTA GGGAGGTTGA ACTGGCTGCT GAGGAGGGGG AACAACAGGG 60 TAACCAGACT GATAGCCATT GGATGGATAA TATGGTGGTT sAGGAGGGAC ACTACTTATA 120 GCAGAGGGTT GTGTATAGCC TGAGGAGGCA TCACCCG 157 (2) I NFORMATION FOR SEQ ID NO: 68: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 1 37 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: GCACTGAGAG GAACTTCTAG AAAGTGAAAG TCTAGACATA AAATAAAATA AAAATTTAAA 60 ACTCAGGAGA GACAGCCCAG CACGGTGGCT CACGCCTGTA ATCCCAGAAC TTTGGGAGCC 120 TGAGGAGGCA TCACCCG 137 (2) INFORMATION FOR SEQ ID NO: 69: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 137 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: CGGGTGATGC CTCCTCAGGC TGTATTTTGA AGACTATCGA CTGGACTTCT TATCAACTGA 60 AGAATCCGTT AAAAATACCA GTTGTATTAT TTCTACCTGT CAAAATCCAT TTCAAATGTT 120 GAAGTTCCTC TCAGTGC • 137 (2) INFORMATION FOR SEQ ID NO: 70: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 220 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: AGCATGTTGA GCCCAGACAC GCAATCTGAA TGAGTGTGCA CCTCAAGTAA ATGTCTACAC 6 GCTGCCTGGT CTGACATGGC ACACCATCNC GTGGAGGGCA CASCTCTGCT CNGCCTACWA 120 CGAGGGCANT CTCAT GACA GGTTCCACCC ACCAAACTGC AAGAGGCTCA NNAAGTACTR 180 CCAGGGTMYA SGGACMASGG TGGGAYTYCA YCACWCATCT 22 (2) INFORMATION FOR SEQ ID NO: 71: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 353 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) descri PTION OF SEt U GUM: SEQ ID NO: 71 CGTTAGGGTC TCTATCCACT GCTAAACCAT ACACCTGGGT AAACAGGGAC CATTTAACAT TCCCANCTAA ATATGCCAAG TGACTTCACA TGTTTATCTT AAAGATGTCC AAAACGCAAC 1 TGATTTTCTC CCCTAAACCT GTGATGGTGG GATGATTAAN CCTGAGTGGT CTACAGCAAG 1 TTAAGTGCAA GGTGCTAAAT GAANGTGACC TGAGATACAG CATCTACAAG GCAGTACCTC 2 TCAACNCAGG GCAACTTTGC TTCTCANAGG GCATTTAGCA GTGTCTGAAG TAATTTCTGT 3 ATTACAACTC ACGGGGCGGG GGGTGAATAT CTANTGGANA GNAGACCCTA ACG 3 (2) I NFORMATION FOR SEQ ID NO: 72: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 343 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 72: GCACTGAGAG GAACTTCCAA TACYATKATC AGAGTGAACA RGCARCCYAC AGAACAGGAG AAAATGTTYG CAATCTCTCC ATCTGACAAA AGGCTAATAT CCAGAWTCTA AWAGGAACTT 1 AAACAAATTT ATGAGAAAAG AACARACAAC CTCAWCAAAA AGTGGGTGAA GGAWATGCTS 1 AAARGAAGAC ATYTATTCAG CCAGTAAACA YATGAAAAAA AGGCTCATSA TCACTGAWCA 2 TTAGAGAAAT GCAAATCAAA ACCACAATGA GATACCATCT YAYRCCAGTT AGAAYGGTGA 3 TCATTAAAAR STCAGGAAAC AACAGATGCT GGACAAGGTG TCA 3 (2) INFORMATION FOR SEQ ID NO: 73: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 321 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRI SEQUENCE PCI: SEQ ID NO: 73: GCACTGAGAG GAACTTCAGA GAGAGAGAGA GAGTTCCACC CTGTACTTGG GGAGAGAAAC AGAAGGTGAG AAAGTCTTTG GTTCTGAAGC AGCTTCTAAG ATCTTTTCAT T GCTTCATT 1 TCAAAGTTCC CATGCTGCCA AAGTGCCATC CTTTGGGGTA CTGTTTTCTG AGCTCCAGTG 1 ATAACTCATT TATACAAGGG AGATACCCAG AAAAAAAGTs AGCAAATCTT AAAAAGGTGG 2 CTTGAGTTCA GCCTTAAATA CCATCTTGAA ATGACACAGA GAAAGAANGA TGTTGGGTGG 3 GAGTGGATAG AGACCCTAAC G 3 (2) IN TRAINING FOR S EQ ID NO: 74: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 321 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: GCACTGAGAG GAACTTCAGA GAGAGAGAGA GAGTTCCACC CTGTACTTGG GGAGAGAAAC AGAAGGTGAG AAAGTCTTTG GTTCTGAAGC AGCTTCTAAG ATCTTTTCAT TTGCTTCATT 1 TCAAAGTTCC CATGCTGCCA AAGTGCCATC CTTTGGGGTA CTGTTTTCTG AGCTCCAGTG 1TATACAAGGG AGATACCCAG AAAAAAAGTG AGCAAATCTT AAAAAGGTGG 2 CTTGAGTTCA GYCTTAAATA CCATCTTGAA ATGAMACAGA GAAAGAAGGA TGTTGGGTGG 3 GAGTGGATAG AGACCCTAAC G 3 (2) INFORMATION FOR SEQ ID NO: 75: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: GCACTGAGAG GAACTTCCAC ATGCACTGAG AAATGCATGT TCACAAGGAC TGAAGTCTGG AACTCAGTTT CTCAGTTCCA ATCCTGATTC AGGTGTTTAC CAGCTACACA ACCTTAAGCA 1 AGTCAGATAA CCTTAGCTTC CTCATATGCA AAATGAGAAT GAAAAGTACT CATCGCTGAA 1 TTGTTTTGAG GATTAGAAAA ACATCTGGCA TGCAGTAGAA ATTCAATTAG TATTCATTTT 2 CATTCTTCTA AATTAAACAA ATAGGATTTT TAGTGGTGGA ACTTCAGACA CCAGAAATGG 3 GAGTGGATAG AGACCCT 3 (2) I NFORMATION FOR SEQ ID NO: 76: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 244 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 76: CGTTAGGGTC TCTATCCACT CCCACT ACTG ATCAAACTCT ATTTATTTAA TTATTTTTAT CATACTTTAA GTTCTGGGAT ACACGTGCAG CATGCGCAGG TTTGTTGCAT AGGTATACAC 1 TTGCC ATGGT GGTTTGCTGC ACCCATCAGT CCATCATCTA CATTAGGTAT TTCTCCTAAT 1 GCTATCCCTC CCCTAGCCCC TTACACCCCC AACAGGCTCT AGTGTGTGAA GTTCCTCTCA 2 GTGC 2 (2) I NFORMATION FOR SEQ ID NO: 77: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 254 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 77: CGTTAGGGTC TCTATCCACT GAAATCTGAA GCACAGGAGG AAGAGAAGCA GTYCTAGTGA GATGGCAAGT TCWTTTACCA CACTCTTTAA CATTTYGTTT AGTTTTAACC TTTATTTATG 12 GATAATAAAG GTTAATATTA ATAATGATTT ATTTTAAGGC ATTCCCRAAT TTGCATAATT 18 CTCCTTTTGG AGATACCCTT TTATCTCCAG TGCAAGTCTG GATCAAAGTG ATASAMAGAA 24 GTTCCTCTCA GTGC 25 (2) I NFORMATION FOR S EQ ID NO: 78: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 355 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) DESC RI PTION Secu GUM: SEQ ID NO: 78: TTCGATACAG GCAAACA.TGA ACTGCAGGAG GGTGGTGACG ATCATGATGT TGCCGATGGT 6 CCGGATGGNC ACGAAGACGC ACTGGANCAC GTGCTTACGT CCTTTTGCTC TGTTGATGGC 12 CCTGAGGGGA CGCAGGACCC TTATGACCCT CAGAATCTTC ACAACGGGAG ATGGCACTGG 18 ATTGANTCCC ANTGACACCA GAGACACCCC AACCACCAGM ATATCANTAT ATTGATGTAG_24_TTCCTGTAGA NGGCCCCCTT GTGGAGGAAA GCTCCATNAG TTGGTCATCT TCAACAGGAT 30 CTCAACAGTT TCCGATGGCT GTGATGGGCA TAGTCATANT TAACCNTGTN TCGAA 35 (2) I NFORMATION FOR SEQ ID NO: 79: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 406 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY; linear (xi) DESC RI PTION OF SEQUENCE: SEQ I D NO: 79: TAAGAGGGTA CCAGCAGAAA GGTTAGTATC ATCAGATAGC ATCTTATACG AGTAATATGC 6 CTGCTATTTG AAGTGTAATT GAGAAGGAAA ATTTTAGCGT GCTCACTGAC CTGCCTGTAG_12_CCCCAGTGAC AGCTAGGATG TGCATTCTCC AGCCATCAAG AGACTGAGTC AAGTTGTTCC 18 TTAAGTCAGA ACAGCAGACT CAGCTCTGAC ATTCTGATTC GAATGACACT GTTCAGGAAT 24 CGGAATCCTG TCGATTAGAC TGGACAGCTT GTGGCAAGTG AATTTGCCTG TAACAAGCCA 30 GATTTTTTAA AATTTATATT GTAAATAATG TGTGTGTGTG TGTGTGTATA TATATATATA 36 TGTACAGTTA TCTAAGTTAA TTTAAAAGTT GTTTGGTACC CTCTTA 40 (2) I NFORMATION FOR SEQ ID NO: 80: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 327 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 80: TTTTTTTTTT TTTACTCGGC TCAGTCTAAT CCTTTTTGTA GTCACTCATA GGCCAGACTT 6 AGGGCTAGGA TGATGATTAA TAAGAGGGAT GACATAACTA TTAGTGGCAG GTTAGTTGTT 12 TGTAGGGCTC ATGGTAGGGG TAAAAGGAGG GCAATTTCTA GATCAAATAA TAAGAAGGTA 1 ATAGCTACTA AGAAGAATTT TATGGAGAAA GGGACGCGGG CG0GGGATAT AGGGTCGAAG 2 CCGCACTCGT AAGGGGTGGA TTTTTCTATG TAGCCGTTGA GTTGTGGTAG TCAAAATGTA 3 ATAATTATTA GTAGTAAGCC TAGGAGA 3 (2) I NFORMATION FOR SEQ ID NO: 81: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 31 8 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81: TAGTCTATGC GGTTGATTCG GCAATCCATT ATTTGCTGGA TTTTGTCATG TGTTTTGCCATCA TAATTTATTA TGCATTTATG CTTGTATCTC CTAAGTCATG GTATATAATC 1 CATGCTTTTT ATGTTTTGTC TGACATAAAC TCTTATCAGA GCCCTTTGCA CACAGGGATT 1 CAATAAATAT TAACACAGTC TACATTTATT TGGTGAATAT TGCATATCTG CTGTACTGAA 2 AGCACATTAA GTAACAAAGG CAAGTGAGAA GAATGAAAAG CACTACTCAC AACAGTTATC 3 ATGATTGCGC ATAGACTA 3 (2) IN TRAINING FOR S EQ ID NO: 82: (i) CHARACTERI STI CASE OF THE SECU ENCIA (A) LENGTH: 338 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 82: TCTTCAACCT CTACTCCCAC TAATAGCTTT TTGATGACTT CTAGCAAGCC TCGCTAACCT 6 CGCCTTACCC CCCACTATTA ACCTACTGGG AGAACTCTCT GTGCTAGTAA CCACTC 12 CTGATCAAAT ATCACTCTCC TACTTACAGG ACTCAACATA CTAGTCACAG CCCTATACTC 18 CCTCTACATA TTTACCACAA CACAATGGGG CTCACTCACC CACCACATTA ACAACATAAA 24 ACCCTCATTC ACACGAGAAA ACACCCTCAT GTTCATACAC CTATCCCCCA TTCTCCTCCT 30 ATCCCTCAAC CCCGACATCA TTACCGGGTT TTCCTCTT 33 (2) INFORMATION FOR SEQ ID NO: 83: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 1 1 base pair (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (i) SEQUENCE DESCRITION: SEQ ID NO: 83: AGCCATTTAC CACCCATCCA CAAAAAAAAA AAAAAAAAAG AAAAATATCA AGGAATAAAA ATAGACTTTG AACAAAAAGG AACATTTGCT GGCCTGAGGA GGCATCACCC G 1 (2) I NFORMATION FOR SEQ ID NO: 84: (i) CHARACTERIZATION OF THE S ECU IN C IA: (A) LENGTH: 224 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 84: TCGGGTGATG CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CATTTCCAAA AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCCGA AGGGTCAGGG AGGAGGAAAT 1 TGAGGTGGAT TCACGAGTTG CGGACAACTC CTTTGATGCC AAGCGAGGTG CAGCCGGAGA 1 CTGGGGAGAG CGAGCCAATC AGGTTTTGAA GTTCCTCTCA GTGC 2 (2) IN FORMATION FOR SEQ ID NO: 85: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85: GCACTGAGAG GAACTT GGAAACGGGT TTTTTTCATG TAAGGCTAGA CAGAAGAATT 6 CTCAGTAACT TCCTTGTGTT GTGTGTATTC AACTCACASA GTTGAACGAT CCTTTACACA 12 GAGCAGACTT GTAACACTCT TWTTGTGGAA TTTGCAAGTG GAGATTTCAG SCGCTTTGAA 18 GTSAAAGGTA GAAAAGGAAA TATCTTCCTA TAAAAACTAG ACAGAATGAT TCTCAGAAAC 24 TCCTTTGTGA TGTGTG CAACTCACAG AGTTTAACCT TTCWTTTCAT AGAAGCAGTT 30 AGGAAACACT CTGTTTGTAA AGTCTGCAAG TGGATAGAGA CCCTAACG 34 (2) INFORMATION FOR SEQ ID NO: 86: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 293 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: GCACTGAGAG GAACTTCYTT GTGWTGTKTG YATTCAACTC ACAGAGTTGA ASSWTSMTTT 6 ACABAGWKCA GGCTTKCAAA CACTCTTTTT GTMGAATYTG CAAGWGGAKA TTTSRRCCRC 12 TTTGWGGYCW WYSKTMGAAW GGRWATATC TTCWYATMRA AMCTAGACAG AAKSATTCTC 18 AKAAWSTYYY YTGTGAWGWS TGCRTTCAAC TCACAGAGKT KAACMWTYCT KYTSATRGAG 24 CAGTTWKGAA ACTCTMTTTC TTTGGATTCT GCAAGTGGAT AGAGACCCTA ACG 29 (2) INFORMATION FOR SEQ ID NO: 87: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87: CTCCTAGGCT 10 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs &8 (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88: AGTAGTTGCC / 10 (2) INFORMATION FOR SEQ ID NO: 89: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89: TTCATG C 11 (2) INFORMATION FOR SEQ ID NO: 90: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: TGGTAAAGGG 10 (2) INFORMATION FOR SEQ ID NO: 91: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91 TCGGTCATAG_10_(2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO : simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92: TACAACGAGG 10 (2) INFORMATION FOR SEQ ID NO: 93: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 pairs of bases (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 93: TGGATTGGTC 10 (2) INFORMATION FOR SEQ ID NO: 94: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94: CTTTCTACCC 10 (2) INFORMATION FOR SEQ ID NO: 95: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95: TTTTGGCTCC 10 (2) INFORMATION FOR SEQ ID NO: 96: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96: GGAACCAATC 10 (2) INFORMATION FOR SEQ ID NO: 97: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) 'SEQUENCE DESCRIPTION: SEQ ID NO: 97: TCGATACAGG 10 (2) INFORMATION FOR SEQ ID NO: 98: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98: GGTACTAAGG 10 (2) INFORMATION FOR SEQ ID NO: 99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99: AGTCTATGCG 10 (2) INFORMATION FOR SEQ ID NO: 100: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100: CTATCCATGG 10 (2) INFORMATION FOR SEQ ID NO: 101: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101: TCTGTCCACA 10 (2) INFORMATION FOR SEQ ID NO: 102: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 102: AAGAGGGTAC 10 (2) INFORMATION FOR SEQ ID NO: 103: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103: CTTCAACCTC 10 (2) INFORMATION FOR SEQ ID NO: 104: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104: GCTCCTCTTG CCTTACCAAC 20 (2) INFORMATION FOR SEQ ID NO: 105: (¡) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE- nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105: GTAAGTCGAG CAGTGTGATG 20 (2) INFORMATION FOR SEQ ID NO: 106: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 106: GTAAGTCGAG CAGTCTGATG 20 (2) INFORMATION FOR SEQ ID NO: 107: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107: GACTTAGTGG AAAGAATGTA 20 (2) INFORMATION FOR SEQ ID NO: 108: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108: GTAATTCCGC CAACCGTAGT 20 (2) INFORMATION FOR SEQ ID NO: 109: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xí) SEQUENCE DESCRIPTION: SEQ ID NO: 109: ATGGTTGATC GATAGTGGAA 20 (2) INFORMATION FOR SEQ ID NO: 110: f (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid ( C) FILAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110: ACGGGGGACCC CTGCATTGAG 20 (2) INFORMATION FOR SEQ ID NO: 111:. (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid 15 (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111 TATTCTAGAC CATTCGCTAC 20 (2) INFORMATION FOR SEQ ID NO: 112: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple 25 (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112: ACATAACCAC TTTAGCGTTC 20 (2) INFORMATION FOR SEQ ID NO: 113: 30 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 113: CGGGTGATGC CTCCTCAGGC 20 (2) INFORMATION FOR SEQ ID NO: 114: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114: AGCATGTTGA GCCCAGACAC 20 (2) INFORMATION FOR SEQ ID NO: 115: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115: GACACCTTGT CCAGCATCTG 20 (2) INFORMATION FOR SEQ ID NO: 116: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116: TACGCTGCAA CACTGTGGAG 20 (2) INFORMATION FOR SEQ ID NO: 117: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) ) FILAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117: CGTTAGGGTC TCTATCCACT 20 (2) INFORMATION FOR SEQ ID NO: 118: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118: AGACTGACTC ATGTCCCCTA 20 (2) INFORMATION FOR SEQ ID NO: 119: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119: TCATCGCTCG GTGACTCAAG 20 (2) INFORMATION FOR SEQ ID NO: 120: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120: CAAGATTCCA TAGGCTGACC 20 (2) INFORMATION FOR SEQ ID NO: 121: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121 ACGTACTGGT CTTGAAGGTC 20 (2) INFORMATION FOR SEQ ID NO: 122: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122: GACGCTTGGC CACTTGACAC 20 (2) INFORMATION FOR SEQ ID NO: 123: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123: GTATCGACGT AGTGGTCTCC 20 (2) INFORMATION FOR SEQ ID NO: 124: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124: TAGTGACATT ACGACGCTGG 20 (2) INFORMATION FOR SEQ ID NO: 125: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125: CGGGTGATGC CTCCTCAGGC 20 (2) INFORMATION FOR SEQ ID NO: 126: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126: ATGGCTATTT TCGGGGGCTG ACA 23TION FOR SEQ ID NO: 127: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127: CCGGTATCTC CTCGTGGGTA TT 22 (2) INFORMATION FOR SEQ ID NO: 128: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128: CTGCCTGAGC CACAAATG 18 (2) INFORMATION FOR SEQ ID NO: 129: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129: CCGGAGGAGG AGGCTAGAGG AATA 24 (2) INFORMATION FOR SEQ ID NO: 130: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 14 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130: TTTTTTTTTT TTAG_14_(2) INFORMATION FOR SEQ ID NO: 131: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 131: Be Ser Gly Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val 1 5 10 15 Gly lie (2) INFORMATION FOR SEQ ID NO: 132: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 132: Gln Gly Ala Ala Gln Lys Pro He Asn Leu Ser Lys Xaa lie Glu Val 1 10 15 Val Gln Gly His Asp Glu 20 (2) INFORMATION FOR SEQ ID NO: 133: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 133: Ser Pro Gly Val Phe Leu Glu His Leu Gln Glu Ala Tyr Arg He Tyr 1 5 10 15 Thr Pro Phe Asp Leu Ser Wing 20 (2) INFORMATION FOR SEQ ID NO: 134: (i) CHARACTERISTICS FROM THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) FILAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134: Tyr Leu Leu Val Gly He Gln Gly Wing 1 5 (2) INFORMATION FOR SEQ ID NO: 135: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) FILAMENT: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 135: Gly Ala Ala Gln Lys Pro He Asn Leu 1 5 (2) INFORMATION FOR SEQ ID NO: 136: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 136: Asn Leu Ser Lys Xaa He Glu Val Val 1 5 (2) INFORMATION FOR SEQ ID NO: 137: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 137: Glu Val Val Gln Gly His Asp Glu Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 138: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) FILAMENTO: simple ( D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138: His Leu Gln Glu Wing Tyr Arg He Tyr 1 5 (2) INFORMATION FOR SEQ ID NO: 139: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 139: Asn Leu Ala Phe Val Ala Ala Gln Ala Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 140: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) FILAMENT: simple (D) TOPOLOGY: linear (xi) DESCRIPTION OF SEQUENCE : SEQ ID NO: 140: Phe Val Ala Gln Ala Ala Pro Asp Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 141 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9388 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 141: GCTCGCGGCC GCGAGCTCAA TTAACCCTCA CTAAAGGGAG TCGACTCGAT CAGACTGTTA 60 CTGTGTCTAT GTAGAAAGAA GTAGACATAA GAGATTCCAT TTTGTTCTGT ACTAAGAAAA 120 ATTCTTCTGC CTTGAGATGC TGTTAATCTG TAACCCTAGC CCCAACCCTG TGCTCACAGA 180 GACATGTGCT GTGTTGACTC AAGGTTCAAT GGATTTAGGG CTATGCTTTG TTAAAAAAGT 240 GCTTGAAGAT AATATGCTTG TTAAAAGTCA TCACCATTCT CTAATCTCAA GTACCCAGGG 300 ACACAATACA CTGCGGAAGG CCGCAGGGAC CTCTGTCTAG GAAAGCCAGG TATTGTCCAA 360 GATTTCTCCC CATGTGATAG CCTGAGATAT GGCCTCATGG GAAGGGTAAG ACCTGACTGT 420 CCCCCAGCCC GACATCCCCC AGCCCGACAT CCCCCAGCCC GACACCCGAA AAGGGTCTGT 480 GCTGAGGAGG ATTAGTAAAA GAGGAAGGCC TCTTTGCAGT TGAGGTAAGA GGAAGGCATC 540 TGTCTCCTGC TCGTCCCTGG GCAATAGAAT GTCTTGGTGT AAAACCCGAT TGTATGTTCT 600 ACTTACTGAG ATAGGAGAAA ACATCCTTAG GGCTGGAGGT GAGACACGCT GGCGGCAATA 660 CTGCTCTTTA ATGCACCGAG ATGTTTGTAT AAGTGCACAT CAAGGCACAG CACCTTTCCT 720 TAAACTTATT TATGACACAG AGACCTTTGT TCACGTTTTC CTGCTGACCC TCTCCCCACT 780 ATTACCCTAT TGGCCTGCCA CATCCCCCTC TCCGAGATGG TAGAGATAAT GATCAATAAA 840 TACTGAGGGA ACTCAGAGAC CAGTGTCCCT GTAGGTCCTC CGTGTGCTGA GCGCCGGTCC 900 CTTGGGCTCA CTTTTCTTTC TCTATACTTT GTCTCTGTGT CTCTTTCTTT TCTCAGTCTC 960 TCGTTCCACC TGACGAGAAA TACCCACAGG TGTGGAGGGG CAGGCCACCC CTTCAATAAT 1020 TTACTAGCCT GTTCGCTGAC AACAAGACTG GTGGTGCAGA AGGTTGGGTC TTGGTGTTCA 1080 CCGGGTGGCA GGCATGGGCC AGGTGGGAGG GTCTCCAGCG CCTGGTGCAA ATCTCCAAGA 1140 AAGTGCAGGA AACAGCACCA AGGGTGATTG TAAATTTTGA TTTGGCGCGG CAGGTAGCCA 1200 TTCCAGCGCA AAAATGCGCA GGAAAGCTTT TGCTGTGCTT GTAGGCAGGT AGGCCCCAAG 1260 CACTTCTTAT TGGCTAATGT GGAGGGAACC TGCACATCCA TTGGCTGAAA TCTCCGTCTA 1320 TTTGAGGCTG ACTGAGCGCG TTCCTTTCTT CTGTGTTGCC TGGAAACGGA CTGTCTGCCT 1380 AGTAACATCT GATCACGTTT CCCATTGGCC GCCGTTTCCG GAAGCCCGCC CTCCCATTTC 1440 CGG AGCCTG GCGCAAGGTT GGTCTGCAGG TGGCCTCCAG GTGCAAAGTG GGAAGTGTGA 1500 GTCCTCAGTC TTGGGCTATT CGGCCACGTG CCTGCCGGAC ATGGGACGCT GGAGGGTCAG 1560 CAGCGTGGAG TCCTGGCCTT TTGCGTCCAC GGGTGGGAAA TTGGCCATTG CCACGGCGGG 1620 AACTGGGACT CAGGCTGCCC CCCGGCCGTT TCTCATCCGT CCACCGGACT CGTGGGCGCT 1680 CGCACTGGCG CTGATGTAGT TTCCTGACCT CTGACCCGTA TTGTCTCCAG ATTAAAGGTA 1740 AAAACGGGGC TTTTTCAGCC CACTCGGGTA AAACGCCTTT TGATTTCTAG GCAGGTGTTT 1800 TGTTGCACGC CTGGGAGGGA GTGACCCGCA GGTTGAGGTT TATTAAAATA CATTCCTGGT 1860 TTATGTTATG TTTATAATAA AGCACCCCAA CCTTTACAAA ATCTCACTTT TTGCCAGTTG 1920 TATTATTTAG TGGACTGTCT CTGATAAGGA CAGCCAGTTA AAATGGAATT TTGTTGTTGC 1980 TAATTAAACC AATTTTTAGT TTTGGTGTTT GTCCTAATAG CAACAACTTC TCAGGCTTTA 2040 TAAAACCATA TTTCTTGGGG GAAATTTCTG TGTAAGGCAC AGCGAGTTAG TTTGGAATTG 2100 TTTTAAAGGA AGTAAGTTCC TGGTTTTGAT ATCTTAGTAG TGTAATGCCC AACCTGGTTT 2160 TTACTAACCC TGTTTTTAGA CTCTCCCTTT CCTTAAATCA CCTAGCCTTG TTTCCACCTG 2220 AATTGACTCT CCCTTAGCTA AGAGCGCCAG ATGGACTCCA TCTTGGCTCT TTCACTGGCA 2280 GCCCCTTCCT CAAGGACTTA ACTTGTGCAA GCTGACTCCC AGCACATCCA AGAATGCAAT 2340 TAACTGTTAA GATACTGTGG CAAGCTATAT CCGCAGTTCC GAGGAATTCA TCCGATTGAT 2400 TATGCCCAAA AGCCCCGCGT CTATCACCTT GTAATAATCT TAAAGCCCCT GCACCTGGAA 2460 CTATTAACTT TCCTGTAACC ATTTATCCTT TTAACTTTTT TGCTTACTTT ATTTCTGTAA 2520 AATTGTTTTA ACTAGACCTC CCCTCCCCTT TCTAAACCAA AGTATAAAAG AAGATCTAGC 2580 CCCTTCTTCA GAGCGGAGAG AATTTTGAGC ATTAGCCATC TCTTGGCGGC CAGCTAAATA 2640 AATGGACTTT TAATTTGTCT CAAAGTGTGG CGTTTTCTCT AACTCGCTCA GGTACGACAT 2700 TTGGAGGCCC CAGCGAGAAA CGTCACCGGG AGAAACGTCA CCGGGCGAGA GCCGGGCCCG 2760 CTGTGTGCTC CCCCGGAAGG ACAGCCAGCT TGTAGGGGGG AGTGCCACCT GAAAAAAAAA 2820 TTTCCAGGTC CCCAAAGGGT GACCGTCTTC CGGAGGACAG CGGATCGACT ACCATGCGGG 2880 TGCCCACCAA AATTCCACCT CTGAGTCCTC AACTGCTGAC CCCGGGGTCA GGTAGGTCAG 2940 ATTTGACTTT GGTTCTGGCA GAGGGAAGCG ACCCTGATGA GGGTGTCCCT CTTTTGACTC 3000 TGCCCATTTC TCTAGGATGC TAGAGGGTAG AGCCCTGGTT TTCTGTTAGA CGCCTCTGTG 3060 TCTCTGTCTG GGAGGGAAGT GGCCCTGACA GGGGCCATCC CTTGAGTCAG TCCACATCCC 3120 AGGATGCTGG GGGACTGAGT CCTGGTTTCT GGCAGACTGG TCTCTCTCTC TCTCTTTTTC 3180 TATCTCTAAT CTTTCCTTGT TCAGGTTTCT TGGAGAATCT CTGGGAAAGA AAAAAGAAAA 3240 ACTGTTATAA ACTCTGTGTG AATGGTGAAT GAATGGGGGA GGACAAGGGC TTOCGCTTGT 3300 CCTCCAGTTT GTAGCTCCAC GGCGAAAGCT ACGGAGTTCA AGTGGGCCCT CACCTGCGGT 3360 TCCGTGGCGA CCTCATAAGG CTTAAGGCAG CATCCGGCAT AGCTCGATCC GAGCCGGGGG 3420 TTTATACCGG CCTGTCAATG CTAAGAGGAG CCCAAGTCCC CTAAGGGGGA GCGGCCAGGC 3480 GGGCATCTGA CTGATCCCAT CACGGGACCC CCTCCCCTTG TTTGTCTAAA AAAAAAAAAA 3540 GAAGAAACTG TCATAACTGT TTACATGCCC TAGGGTCAAC TGTTTGTTTT ATGTTTATTG 3600 TTCTGTTCGG TGTCTATTGT CTTGTTTAGT GGTTGTCAAG GTTTTGCATG TCAGGACGTC 3660 GATATTGCCC AAGACGTCTG GGTAAGAACT TCTGCAAGGT CCTTAGTGCT GATTTTTTGT 3720 CACAGGAGGT TAAATTTCTC ATCAATCATT TAGGCTGGCC ACCACAGTCC TGTCTTTTCT 3780 GCCAGAAGCA AGTCAGGTGT TGTTACGGGA ATGAGTGTAA AAAAACATTC GCCTGATTGG 3840 GATTTCTGGC ACCATGATGG TTGTATTTAG ATTGTCATAC CCCACATCCA GGTTGATTGG 3900 ACCTCCTCTA AACTAAACTG GTGGTGGGTT CAAAACAGCC ACCCTGCAGA TTTCCTTGCT 3960 CACCTCTTTG GTCATTCTGT AACTTTTCCT GTGCCCTTAA ATAGCACACT GTGTAGGGAA 4020 ACCTACCCTC GTACTGCTTT ACTTCGTTTA GATTCTTACT CTGTTCCTCT GTGGCTACTC 4080 TCCCATCTTA AAAACGATCC AAGTGGTCCT TTTCCTCCTC CCTGCCCCCT ACCCCACACA 4140 TCTCGTTTTC CAGTGCGACA GCAAGTTCAG CGTCTCCAGG ACTTGGCTCT GCTCTCACTC 4200 CTTGAACCCT TAAAAGAAAA AGCTGGGTTT GAGCTATTTG CCTTTGAGTC ATGGAGACAC 42 «" 0 AAAAGGTATT TAGGGTACAG ATCTAGAAGA AGAGAGAGAA CACCTAGATC CAACTGACCC 4320 AGGAGATCTC GGGCTGGCCT CTAGTCCTCC TCCCTCAATC TTAAAGCTAC AGTGATGTGG 4380 CAAGTGGTAT TTAGCTGTTG TGGTTTTTCT GCTCTTTCTG GTCATGTTGA TTCTGTTCTT 4440 TCGATACTCC AGCCCCCCAG GGAGTGAGTT TCTCTGTCTG TGCTGGGTTT GATATCTATG 4500 TTCAAATCTT ATTAAATTGC CTTCAAAAAA AAAAAAAAAA GGGAAACACT TCCTCCCAGC 4560 CTTGTAAGGG TTGGAGCCCT CTCCAGTATA TGCTGCAGAA TTTTTCTCTC GGTTTCTCAG 4620 AGGATTATGG AGTCCGCCTT AAAAAAGGCA AGCTCTGGAC ACTCTGCAAA GTAGAATGGC 4680 CAAAGTTTGG AGTTGAGTGG CCCCTTGAAG GGTCACTGAA CCTCACAATT GTTCAAGCTG 4740 TGTGGCGGGT TGTTACTGAA ACTCCCGGCC TCCCTGATCA GTTTCCCTAC ATTGATCAAT 4800 GGCTGAGTTT GGTCAGGAGC ACCCCTTCCA TGGCTCCACT CATGCACCAT TCATAATTTT 4860 ACCTCCAAGG TCCTCCTGAG CCAGACCGTG TTTTCGCCTC GACCCTCAGC CGGTTCAGCT 4920 CGCCCTGTAC TGCCTCTCTC TGAAGAAGAG GAGAGTCTCC CTCACCCAGT CCCACCGCCT 4980 TAAAACCAGC CTACTCCCTT AGGGTCATCC CATGTCTCCT CGGCTATGTC CCCTGTAGGC 5040 TCATCACCCA TTGCCTCTTG GTTGCAACCG TGGTGGGAGG AAGTAGCCCC TCTACTACCA 5100 CTGAGAGAGG CACAAGTCCC TCTGGGTGAT GAGTGCTCCA CCCCCTTCCT GGTTTATGTC 5160 ccTTCTTTct ACTTCTGACT TGTATAATTG GAAAACCCAT AATCCTCCCT TCTCTGAAAA 5220 GCCCCAGGCT TTGACCTCAC TGATGGAGTC TGTACTCTGG ACACATTGGC CCACCTGGGA 5280 TGACTGTCAA CAGCTCCTTT TGACCCTTTT CACCTCTGAA GAGAGGGAAA GTATCCAAAG 5340 AGAGGCCAAA AAGTACAACC TCACATCAAC CAATAGGCCG GAGGAGGAAG CTAGAGGAAT 5400 AGTGATTAGA GACCCAATTG GGACCTAATT GGGACCCAAA TTTCTCAAGT GGAGGGAGAA 5460 CTTTTGACGA TTTCCACCGG TATCTCCTCG TGGGTATTCA GGGAGCTGCT CAGAAACCTA 5520 TAAACTTGTC TAAGGCGACT GAAGTCGTCC AGGGGCATGA TGAGTCACCA GGAGTGTTTT 5530 TAGAGCACCT CCAGGAGGCT TATCGGATTT ACACCCCTTT 'TGACCTGGCA < GCCCCCGAAA 5640 ATAGCCATGC TCTTAATTTG GCATTTGTGG CTCAGGCAGC 'CCCAGATAGT. AAAAGGAAAC 5700 TCCAAAAACT AGAGGGATTT TGCTGGAATG AATACCAGTC. AGCTTTTAGA GATAGCCTAA 5760 AAGGTTTTTG ACAGTCAAGA GGTTGAAAAA CAAAAACAAG CAGCTCAGGC AGCTGAAAAA 5820 AGCCACTGAT AAAGCATCCT GGAGTATCAG AGTTTACTGT TAGATCAGCC TCATTTGACT 5880 TCCCCTCCCA ATGGTGTTT AAATCCAGCT ACACTACTTC CTGACTCAAA CTCCACTATT 5940 CCTGTTCATG ACTGTCAGGA ACTGTTGGAA ACTACTGAAA CTGGCCGACC TGATCTTCAA 6000 AATGTGCCCC TAGGAAAGGT GGATGCCACC GTGTTCACAG ACAGTAGCAG CTTCCTCGAG 6060 AAGGGACTAC GAAAGGCCGG TGCAGCTGTT ACCATGGAGA CAGATGTGTT GTGGGCTCAG 6120 GCTTTACCAG CAAACACCTC AGCACAAAAG GCTGAATTGA TCGCCCTCAC TCAGGCTCTC 6180 CGATGGGGTA AGGATATTAA CGTTAACACT GACAGCAGGT ACGCCTTTGC TACTGTGCAT 6240 GTACGTGGAG CCATCTACCA GGAGCGTGGG CTACTCACCT CAGCAGGTGG CTGTAATCCA 6300 CTGTAAAGGA CATCAAAAGG AAAACACGGC TGTTGCCCGT GGTAACCAGA AAGCTGATTC 6360 AGCAGCTCAA GATGCAGTGT GACTTTCAGT CACGCCTCTA AACTTGCTGC CCACAGTCTC 6420 CTTTCCACAG CCAGATCTGC CTGACAATCC CGCATACTCA ACAGAAGAAG AAAACTGGCC 6480 TCAGAACTCA GAGCCAATAA AAATCAGGAA GGTTGGTGGA TTCTTCCTGA CTCTAGAATC 6540 TTCATACCCC GAACTCTTGG GAAAACTTTA ATCAGTCACC TACAGTCTAC CACCCATTTA 6600 GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTTTTA AGATCCCCCA TCTTCAAAGC 6660 CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC AGGTAAATGC CAAAAAAGGT 6720 CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC CAGGAGAAAA GTGGGAAATT 6780 GACTTTACAG AAGTAAAACC ACACCGGGCT GGGTACAAAT ACCTTCTAGT ACTGGTAGAC 6840 ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG AAACTGTCAA TATGGTAGTT 6900 AAGTTTTTAC TCAATGAAAT CATCCCTCGA CGTGGGCTGC CTGTTGCCAT AGGGTCTGAT 6960 AATGGACCGG CCTTCGCCTT GTCTATAGTT TAGTCAGTCA GTAAGGCGTT AAACATTCAA 7020 TGGAAGCTCC ATTGTGCCTA TCGACCCCAG AGCTCTGGGC AAGTAGAACG CATGAACTGC 7080 ACCCTAAAAA ACACTCTTAC AAAATTAATC TTAGAAACCG GTGTAAATTG TGTAAGTCTC 7140 CTTCCTTTAG CCCTACTTAG AGTAAGGTGC ACCCCTTACT GGGCTGGGTT CTTACCTTTT 7200 GAAATCATGT ATGGGAGGGC GCTGCCTATC TTGCCTAAGC TAAGAGATGC CCAATTGGCA 7260 AAAATATCAC AAACTAATTT ATTACAGTAC CTACAGTCTC CCCAACAGGT ACAAGATATC 7320 ATCCTGCCAC TTGTTCGAGG AACCCATCCC AATCCAATTC CTGAACAGAC AGGGCCCTGC 7380 CATTCATTCC CGCCAGGTGA CCTGTTGTTT GTTAAAAAGT TCCAGAGAGA AGGACTCCCT 7440 CCTGCTTGGA AGAGACCTCA CACCGTCATC ACGATGCCAA CGGCTCTGAA GGTGGATGGC 7500 ATTCCTGCGT GGATTCATCA CTCCCGCATC AAAAAGGCCA ACGGAGCCCA ACTAGAAACA 7560 TGGGTCCCCA GGGCTGGGTC AGGCCCCTTA AAACTGCACC TAAGTTGGGT GAAGCCATTA 7620 GATTAATTCT TTTTCTTAAT TTTGTAAAAC AATGCATAGC TTCTGTCAAA CTTATGTATC 7680 TTAAGACTCA ATATAACCCC CTTGTTATAA CTGAGGAATC AATGATTTGA TTCCCCAAAA 7740 ACACAAGTGG GGAATGTAGT GTCCAACCTG GTTTTTACTA ACCCTGTTTT TAGACTCTCC 7800 CTTTCCTTTA ATCACTCAGC CTTGTTTCCA CCTGAATTGA CTCTCCCTTA GCTAAGAGCG 7860 CCAGATGGAC TCCATCTTGG CTCTTTCACT GGCAGCCGCT TCCTCAAGGA CTTAACTTGT 7920 GCAAGCTGAC TCCCAGCACA TCCAAGAATG CAATTAACTG ATAAGATACT GTGGCAAGCT 7980 ATATCCGCAG TTCCCAGGAA TTCGTCCAAT TGATTACACC CAAAAGCCCC GCGTCTATCA 8040 CCTTGTAATA ATCTTAAAGC CCCTGCACCT GGAACTATTA ACGTTCCTGT AACCATTTAT 8100 CCTTTTAACT TTTTTTGCCTA CTTTATTTCT GTAAAATTGT TTTAACTAGA CCCCCCCTCT 8160 CCTTTCTAAA CCAAAGTATA AAAGCAAATC TAGCCCCTTC TTCAGGCCGA GAGAATTTCG 8220 AGCGTTAGCC GTCTCTTGGC CACCAGCTAA ATAAACGGAT TCTTCATGTG TCTCAAAGTG 8280 XI? ÍI U _.- J. "_ 'TC TC AACTCGC TCAGGTACGA CCGTGGTAGT ATTTTCCCCA ACGTCTTATT 8340 TTTAGGGCAC GTATGTAGAG TAACTTTTAT GAAAGAAACC AGTTAAGGAG GTTTTGGGAT 8400 TTCCTTTATC AACTGTAATA CTGGTTTTGA TTATTTATTT ATTTATTTAT TTTTTTTGAG 8460 AAGGAGTTTC ACTCTTGTTG CCCAGGCTGG AGTGCAATGG TGCGATCTTG GCTCACTGCA 8520 ACTTCCGCCT CCCAGGTTCA AGCGATTCTC CTGCCTCAGC CTCGAGAGTA GCTGGGATTA 8580 TAGGCATGCG CCACCACACC CAGCTAATTT TGTATTTTTA GTAAAGATGG GGTTTCTTCA 8640 TGTTGGTCAA GCTGGTCTGG AACTCCCCGC CTCGGGTGAT CTGCCCGCCT CGGCCTCCGA 8700 AAGTGCTGGG ATTACAGGTG TGATCCACCA CACCCAGCCG ATTTATATGT ATATAAATCA 8760 CATTCCTCTA ACCAAAATGT AGTGTTTCCT TCCATCTTGA ATATAGGCTG TAGACCCCGT 8820 GGGTATGGGA CATTGTTAAC AGTGAGACCA CAGCAGTTTT TATGTCATCT GACAGCATCT 8880 CCAAATAGCC TTCATGGTTG TCACTGCTTC CCAAGACAAT TCCAAATAAC ACTTCCCAGT 8940 GATGACTTGC TACTTGCTAT TGTTACTTAA TGTGTTAAGG TGGCTGTTAC AGACACTATT 9000 AGTATGTCAG GAATTACACC AAAATTTAGT GGCTCAAACA ATCATTTTAT TATGTATGTG 9060 GATTCTCATG GTCAGGTCAG GATTTCAGAC AGGGCACAAG GGTAGCCCAC TTGTCTCTGT 9120 CTATGATGTC TGGCCTCAGC ACAGGAGACT CAACAGCTGG GGTCTGGGAC CATTTGGAGG 9180 CTTGTTCCCT CACATCTGAT ACCTGGCTTG GGATGTTGGA AGAGGGGGTG AGCTGAGACT 9240 GAGTGCCTAT ATGTAGTGTT TCCATATGGC CTTGACTTCC TTACAGCCTG GCAGCCTCAG 9300 GGTAGTCAGA ATTCTTAGGA GGCACAGGGC TCCAGGGCAG ATGCTGAGGG! GTCTTTTATG 9360 AGGTAGCACA GCAAATCCAC CCAGGATC 9388 (2) INFORMATION FOR SEQ ID NO: 142: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 41 9 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 142: TGTAAGTCGA GCAGTGTGAT GGAAGGAATG GTCTTTGGAG AGAGCATATC CATCTCCTCC 60 TCACTGCCTC CTAATGTCAT GAGGTACACT GAGCAGAATT AAACAGGGTA GTCTTAACCA 120 CACTATTTTT AGCTACCTTG TCAAGCTAAT GGTTAAAGAA CACTTTTGGT TTACACTTGT 180 TGGGTCATAG AAGTTGCTTT CCGCCATCAC GCAATAAGTT TGTGTGTAAT CAGAAGGAGT 240 TACCTTATGG TTTCAGTGTC ATTCTTTAGT TAACTTGGGA GCTGTGTAAT TTAGGCTTTG 300 CGTATTATTT CACTTCTGTT CTCCACTTAT GAAGTGATTG TGTGTTCGCG TGTGTGTGCG 360 TGCGCATGTG CTTCCGGCAG TTAACATAAG CAAATACCCA ACATCACACT GCTCGACTT 419 (2) I NFORMATION FOR SEQ ID NO: 143: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) ITU D LONG: 402 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) ) TOPOLOGY: linear (xí) DESC RI SECU ENCE PCI: SEQ ID NO: 143:GCAGTGTGAT GTCCACTGCA GTGTGTTGCT GGGAACAGTT AATGAGCAAA 60 TTGTATACAA TGGCTAGTAC ATTGACCGGG ATTTGTTGAA GCTGGTGAGT GTTATGACTT 120 AGCCTGTTAG ACTAGTCTAT GCACATGGCT CTGGTCAACT CCGCTCTCT CATTTCTCCA 180 GATAAATCCC CCATGCTTTA TATTCTCTTC CAAACATACT ATCCTCATCA CCACATAGTT 240 CCTTTTGTTAA TGCTTTGTTC TAGACTTTCC CTTTTCTGTT TTCTTATTCA AACCTATATC 300 TCTTTGCATA GATTGTAAAT TCAAATGCCC TCAGGGTGCA GGCAGTTCAT GTAAGGGAGG 360 GAGGCTAGCC AGTGAGATCT GCATCACACT GCTCGACTTA CA 402 (2) I NFORMATION FOR SEQ ID NO: 144: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 224 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 144: TCGGGTGATG CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CATTTCCAAA 60 AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCGTTCCGA AGGGTCAGGG AGGAGGAAAT 120 TGAGGTGGAT TCACGAGTTG CGGACAACTC CTTTGATGCC AAGCGAGGTG CAGCCGGAGA 180 CTGGGGAGAG CGAGCCAATC AGGTTTTGAA GTTCCTCTCA GTGC 22 (2) I NFORMATION FOR SEQ ID NO: 145: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 1 1 base pair (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 145: AGCCATTTAC CACCCATCCA CAAAAAAAAA AAAAAAAAAG AAAAATATCA AGGAATAAAA 60 ATAGACTTTG AACAAAAAGG AACATTTGCT GGCCTGAGGA GGCATCACCC G 111 (2) I NFORMATION FOR SEQ ID NO: 146: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 585 base pairs (B) TYPE: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY ÍA: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 146: TAGCATGTTG AGCCCAGACA CTTGTAGAGA GAGGAGGACA GTTAGAAGAA GAAGAAAAGT 60 TTTTAAATGC TGAAAGTTAC TATAAGAAAG CTTTGGCTTT GGATGAGACT TTTAAAGATG 120 CAGAGGATGC TTTGCAGAAA CTTCATAAAT ATATGCAGGT GATTCCTTAT TTCCTCCTAG_180_AAATTTAGTG ATATTTGAAA TAATGCCCAA ACTTAATTTT CTCCTGAGGA AAACTATTCT 240 ACATTACTTA AGTAAGGCAT TATGAAAAGT TTCTTTTTAG GTATAGTTTT TCCTAATTGG 300 GTTTGACATT GCTTCATAOT GCCTCTGTTT TTGTCCATAA TCGAAAGTAA AGATAGCTGT 360 GAGAAAACTA TTACCTAAAT TTGGTATGTT GTTTTGAGAA ATGTCCTTAT AGGGAGCTCA 420 CCTGGTGGTT TTTAAATTAT TGTTGCTACT ATAATTGAGC TAATTATAAA AACCTTTTTG 480 AGACATATTT TAAATTGTCT TTTCCTGTAA TACTGATGAT GATGTTTTCT CATGCATTTT 540 CTTCTGAATT GGGACCATTG CTGCTGTGTC TGGGCTCACA TGCTA 585 (2) I NFORMATION FOR SEQ ID NO: 147: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 579 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 147: TAGCATGTTG AGCCCAGACA CTGGGCAGCG GGGGTGGCCA CGGCAGCTCC TGCCGAGCCC 60 AAGCGTGTTT GTCTGTGAAG GACCCTGACG TCACCTGCCA GGCTAGGGAG GGGTCAATGT 120 GGAGTGAATG TTCACCGACT TTCGCAGGAG TGTGCAGAAG CCAGGTGCAA CTTGGTTTGC 180 TTGTGTTCAT CACCCCTCAA GATATGCACA CTGCTTTCCA AATAAAGCAT CAACTGTCAT 240 CTCCAGATGG GGAAGACTTT TTCTCCAACC AGCAGGCAGG TCCCCATCCA CTCAGACACC 300 AGCACGTCCA CCTTCTCGGG CAGCACCACG TCCTCCACCT TCTGCTGGTA CACGGTGATG 360 ATGTCAGCAA AGCCGTTCTG CANGACCAGC TGCCCCGTGT GCTGTGCCAT CTCACTGGCC 42 TCCACCGCGT ACACCGCTCT AGGCCGCGCA TANTGTGCAC AGAANAAATG ATGATCCAGT 48 CCCACAGCCC ACGTCCAAGA NGACTTTATC CGTCAGGGAT TCTTTATTCT GCAGGATGAC 54 CTGTGGTATT AATTGTTCGT GTCTGGGCTC AACATGCTA 57 (2) I NFORMATION FOR S EQ ID NO: 148: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 249 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) DESCRI SEQUENCE PCI: SEQ ID NO: 148: TGACACCTTG TCCAGCATCT GCAAGCCAGG AAGAGAGTCC TCACCAAGAT CCCCACCCCG 60 TTGGCACCAG GATCTTGGAC TTCCAATCTC CAGAACTGTG AGAAATAAGT ATTTGTCGCT 120 AAATAAATCT TTGTGGTTTC AGATATTTAG CTATAGCAGA TCAGGCTGAC TAAGAGAAAC 180 CCCATAAGAG TTACATACTC ATTAATCTCC GTCTCTATCC CCAGGTCTCA GATGCTGGAC 240 AAGGTGTCA 249 (2) I NFORMATION FOR SEQ ID NO: 149: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 255 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SECU ENCIA: SEQ ID NO: 149: TGACACCTTG TCCAGCATCT GCTATTTTGT GACTTTTTAA TAATAGCCAT TCTGACTGGT 60 GTGAGATGGT AACTCATTGT GGGTTTGGTC TGCATTTCTC TAATGATCAG TGATATTAAG 120 CTTTTTTTTAA ATATGCTTGT TGACCACATG TATATCATCT TTTGAGAAGT GTCTGTTCAT 180 ATCCTTTGCC CACTTTTTAA TTTTTTTATC TTGTAAATTT GTTTAATTTC CTTACAGATG 240 CTGGACAAGG TGTCA 255 (2) I NFORMATION FOR S EQ ID NO: 1 50: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 318 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 1 50: TTACGCTGCA ACACTGTGGA GGCCAAGCTG GGATCACTTC TTCATTCTAA CTGGAGAGGA 60 GGGAAGTTCA AGTCCAGCAG AGGGTGGGTG GGTAGACAGT GGCACTCAGA AATGTCAGCT 120 GGACCCCTGT CCCCGCATAG GCAGGACAGC AAGGCTGTGG CTCTCCAGGG CCAGCTGAAG 180 AACAGGACAC TGTCTCCGCT GCCACAAAGC GTCAGAGACT CCCATCTTTG AAGCACGGCC 240 TTCTTGGTCT TCCTGCACTT CCCTGTTCTG TTAGAGACCT GGTTATAGAC AAGGCTTCTC 300 CACAGTGTTG CAGCGTAA 318 (2) IN TRAINING FOR SEQ ID NO: 1 51: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 323 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 151: TNACGCNGCN ACNNTGTAGA GANGGNAAGG CNTTCCCCAC ATTNCCCCTT CATNANAGAA 60 TTATTCNACC AAGNNTGACC NATGCCNTTT ATGACTTACA TGCNNACTNC NTAATCTGTN 120 TCNNGCCTTA AAAGCNNNTC CACTACATGC NTCANCACTG TNTGTGTNAC NTCATNAACT 180 GTCNGNAATA GGGGCNCATA ACTACAGAAA TGCANTTCAT ACTGCTTCCA NTGCCATCNG 240 CGTGTGGCCT TNCCTACTCT TCTTNTATTC CAAGTAGCAT CTCTGGA1.TG CTTCCCCACT 300 CTCCACATTG TTGCAGCNAT AAT 323 (2) I NFORMATION FOR SEQ ID NO: 152: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 31 1 base pair (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) descri PTION OF SEQUENCE: SEQ ID NO: 1 52: TCAAGATTCC ATAGGCTGAC CAGTCCAAGG AGAGTTGAAA TCATGAAGGA GAGTCTATCT 60 GGAGAGAGCT GTAGTTTTGA GGGTTGCAAA GACTTAGGAT GGAGTTGGTG GGTGTGGTTA 120 GTCTCTAAGG TTGATTTTGT TCATAAATTT CATGCCCTGA ATGCCTTGCT TGCCTCACCC 180 TGGTCCAAGC CTTAGTGAAC ACCTAAAAGT CTCTGTCTTC TTGCTCTCCA AACTTCTCCT 240 GAGGATTTCC TCAGATTGTC TACATTCAGA TCGAAGCCAG TTGGCAAACA AGATGCAGTC 300 CAGAGGGTCA G 311 (2) I NFORMATION FOR SEQ ID NO: 1 53: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 332 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) descri PTION OF SEQUENCE: SEQ ID NO: 1 53: CAAGATTCCA TAGGCTGACC AGGAGGCTAT TCAAGATCTC TGGCAGTTGA GGAAGTCTCT 60 T AAGAAAAT AGTTTAAACA ATTTGTTAAA ATTTTTCTGT CTTACTTCAT TTCTGTAGCA 120 GTTGATATCT GGCTGTCCTT TTTATAATGC AGAGTGGGAA CTTTCCCTAC CATGTTTGAT 180 AAATGTTGTC CAGGCTCCAT TGCCAATAAT GTGTTGTCCA AAATGCCTGT TTAGTTTTTA 240 AAGACGGAAC TCCACCCTTT GCTTGGTCTT AAGTATGTAT GGAATGTTAT GATAGGACAT 300 AGTAGTAGCG GTGGTCAGCC TATGGAATCT TG 332 (2) INFORMATION FOR SEQ ID NO: 154: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple ( D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154: TCAAGATTCC ATAGGCTGAC CTGGACAGAG ATCTCCTGGG TCTGGCCCAG GACAGCAGGC 60 TCAAGCTCAG TGGAGAAGGT TTCCATGACC CTCAGATTCC CCCAAACCTT GGATTGGGTG 120 ACATTGCATC TCCTCAGAGA GGGAGOAGAT GTANGTCTGG GCTTCCACAG GGACCTGGTA 180 TTTTAGGATC AGGGTACCGC TGGCCTGAGG CTTGGATCAT TCANAGCCTG GGGGTGGAAT 240 GGCTGGCAGC CTGTGGCCCC ATTGAAATAG GCTCTGGGGC ACTCCCTCTG TTCCTANTTG 300 AACTTGGGTA AGGAACAGGA ATGTGGTCAN CCTATGGAAT CTTGA 345 (2) INFORMATION FOR SEQ ID NO: 155: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 295 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155: GACGCTTGGC CACTTGACAC ATTAAACAGT TTTGCATAAT CACTANCATG TATTTCTAGT 60 TTGCTGTCTG CTGTGATGCC CTGCCCTGAT TCTCTGGCGT TAATGATGGC AAGCATAATC 120 AAACGCTGTT CTGTTAATTC CAAGTTATAA CTGGCATTGA TTAAAGCATT ATCTTTCACA 180 ACTAAACTGT TCTTCATANA ACAGCCCATA TTATTATCAA ATTAAGAGAC AATGTATTCC 240 AATATCCTTT ANGGCCAATA TATTTNATGT CCCTTAATTA AGAGCTACTG TCCGT 295TION FOR SEQ ID NO: 156: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 406 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156: GACGCTTGGC CACTTGACAC TGCAGTGGGA AAACCAGCAT GAGCCGCTGC CCCCAAGGAA 60 CCTCGAAGCC CAGGCAGAGG ACCAGCCATC CCAGCCTGCA GGTAAA.GTGT GTCACCTGTC 120 AGGTGGGCTT GGGGTGAGTG GGTGGGGGAA GTGTGTGTGC AAAGGGGGTG TNAATGTNTA 180 TGCGTGTGAG CATGAGTGAT GGCTAGTGTG ACTGCATGTC AGGGAGTGTG AACAAGCGTG 240 CGGGGGTGTG TGTGCAAGTG CGTATGCATA TGAGAATATG TGTCTGTGGA TGAGTGCATT 300 TGAAAGTCTG TGTGTGTGCG TGTGGTCATG ANGGTAANTT ANTGACTGCG CAGGATGTGT 360 GAGTGTGCAT GGAACACTCA NTGTGTGTGT CAAGTGGCCN ANCGTC 406 (2) IN TRAINING FOR SEQ ID NO: 1 57: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 208 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 1 57: TGACGCTTGG CCACTTGACA CACTAAAGGG TGTTACTCAT CACTTTCTTC TCTCCTCGGT 60 GGCATGTGAG TGCATCTATT CACTTGGCAC TCATTTGTTT GGCAGTGACT GTAANCCANA 120 TCTGATGCAT ACACCAGCTT GTAAATTGAA TAAATGTCTC TAATACTATG TGCTCACAAT 180 ANGGTANGGG TGAGGAGAAG GGGAGAGA 208 (2) IN TRAINING FOR SEQ ID NO: 1 58: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 547 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 1 58: CTTCAACCTC CTTCAACCTC CTTCAACCTC CTGGATTCAA ACAATCATCC CACCTCAGAC 60 TCCTTAGTAG CTGAGACTAC AGACTCACGC CACTACATCT GGCTAAATTT TTGTAGAGAT 120 AGGGTTTCAT CATGTTGCCC TGGCTGGTCT CAAACTCCTG ACCTCAAGCA ATGTGCCCAC 180 CTCAGCCTCC CAAAGTGCTG GGATTACAGG CATAAGCCAC CATGCCCAGT CCATNTTTAA 240 TCTTTTCCTAC CACATTCTTA CCACACTTTC TTTTATGTTT AGATACATAA ATGCTTACCA 300 TTATGATACA ATTGCCCACA GTATTAAGAC AGTAACATGC TGCACAGGTT TGTAGCCTAG_360_GAACAGTAGG CAATACCACA TAGCTTAGGT GTGTGGTAGA CTATACCATC TAGGTTTGTG 420 TAAGTTACAC TTTATGCTGT TTACACAATG ACAAAACCAT CTAATGATGC ATTTCTCAGA 480 ATGTATCCTT GTCAGTAAGC TATGATGTAC AGGGAACACT GCCCAAGGAC ACAGATATTG 540 TACCTGT 547 (2) IN FORMAC TION FOR SEQ ID NO: 1 59: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 203 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple ( D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 159: GCTCCTCTTG CCTTACCAAC TCACCCAGTA TGTCAGCAAT TTTATCRGCT TTACCTACGA 60 AACAGCCTGT ATCCAAACAC TTAACACACT CACCTGAAAA GTTCAGGCAA CAATCGCCTT 120 CTCATGGGTC TCTCTGCTCC AGTTCTGAAC CTTTCTCTTT TCCTAGAACA TGCATTTARG 180 TCGATAGAAG TTCCTCTCAG TGC 203 (2) I NFORMATION FOR SEQ ID NO: 160: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 402 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 1 60: TGTAAGTCGA GCAGTGTGAT GGGTGGAACA GGGTTGTAAG CAGTAATTGC AAACTGTATT 60 TAAACAATAA TAATAATATT TAGCATTTAT AGAGCACTTT ATATCTTCAA AGTACTTGCA 120 AACATTAYCT AATTAAATAC CCTCTCTGAT TATAATCTGG ATACAAATGC ACTTAAACTC 180 AGGACAGGGT CATGAGARAA GTATGCATTT GAAAGTTGGT GCTAGCTATG CTTTAAAAAC 240 CTATACAATG ATGGGRAAGT TAGAGTTCAG ATTCTGTTGG ACTGTTTTTG TGCATTTCAG 300 TTCAGCCTGA TGGCAGAATT AGATCATATC TGCACTCGAT GACTYTGCTT GATAACTTAT 360 CACTGAAATC TGAGTGTTGA TCATCACACT GCTCGACTTA CA 402 (2) I NFORMATION FOR SEQ ID NO: 161: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 1 93 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 61: AGCATGTTGA GCCCAGACAC TGACCAGGAG AAAAACCAAC CAATAGAAAC ACGCCCAGAC 60 ACTGACCAGG AGAAAAACCA ACCAATAAAA ACAGGCCCGG ACATAAGACA AATAATAAAA 120 TTAGCGGACA AGGACATGAA AACAGCTATT GTAAGAGCGG ATATAGTGGT GTGTGTCTGG 180 GCTCAACATG CTA. 193 (2) INFORMATION FOR SEQ ID NO: 162: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 147 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 162: TGTTGAGCCC AGACACTGAC CAGGAGAAAA ACCAACCAAT AAAAACAGGC CCGGACATAA 60AAAATTAGCG GACAAGGACA TGAAAACAGC TATTGTAAGA GCGGATATAG_120_TGGTGTGTGT CTGGGCTCAA CATGCTA 147 (2) INFORMATION FOR SEQ ID NO: 163: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 294 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163: TAGCATGTTG AGCCCAGACA CAAATCTTTC CTTAAGCAAT AAATCATTTC TGCATATGTT 60 TTTAAAACCA CAGCTAAGCC ATGATTATTC AAAAGGACTA TTGTATTGGG TATTTTGATT 120 TGGGTTCTTA TCTCCCTCAC ATTATCTTCA TTTCTATCAT TGACCTCTTA TCCCAGAGAC 180 TCTCAAACTT TTATGTTATA CAAATCACAT TCTGTCTCAA AAAATATCTC ACCCACTTCT 240 CTTCTGTTTC TGCGTGTGTA TGTGTGTGTG TGTGTGTCTG GGCTCAACAT GCTA 294 (2) INFORMATION FOR SEQ ID NO: 164: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 412 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164: CGGGATTGGC TTTGAGCTGC AGATGCTGCC TGTGACCGCA CCCGGCGTGG AACAGAAAGC 60 CACCTGGCTG CAAGTGCGCC AGAGCCGCCC TGACTACGTG CTGCTGTGGG GCTGGGGCGT 120 GATGAACTCC ACCGCCCTGA AGGAAGCCCA GGCCACCGGA TACCCCCGCG ACAAGATGTA 180 CGGCGTGTGG TGGGCCGGTG CGGAGCCCGA TGTGCGTGAC GTGGGCGAAG GCGCCAAGGG 240 CTACAACGCG CTGGCTCTGA ACGGCTACGG CACGCAGTCC AAGGTGATCC ANGACATCCT 300 GAAACACGTG CACGACAAGG GCCAGGGCAC GGGGCCCAAA GACGAAGTGG GCTCGGTGCT 360 GTACACCCGC GGCGTGATCA TCCAGATGCT GGACAAGGTG TCAATCACTA AT 412 (2) IN FORMATION FOR SEQ ID NO: 165: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 361 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) descri PTION OF SEQUENCE: SEQ ID NO: 165: TTGACACCTT GTCCAGCATC TGCATCTGAT GAGAGCCTCA GATGGCTACC ACTAATGGCA 60 GAAGGCAAAG GAGAACAGGC ATTGTATGGC AAGAAAGGAA GAAAGAGAGA GGGGAGAAAG 12 GTGCTAGGTT CTTTTCAACA ACCAGTTCTT GATGGAACTG AGAGTAAGAG CTCAAGGCCA 180 GGTGTGGTGA CTCCAACCAG TAATCCCAAC ATTTTAGGAG GCTGAGGCAG GCAGATGTCT 24 TGACCCCATG AGTTTGTGAC CAGCCTGAAC AACATCATGA GACTCCATCT CTACAATAAT 300 TACAAAAATT AATCAGGCAT TGTGGTATGC CCTGTAGTCC CAGATGCTGG ACAAGGTGTC 36 A 36 (2) I NFORMATION FOR S EQ ID NO: 1 66: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 427 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 166: TWGACTGACT CATGTCCCCT ACACCCAACT ATCTTCTCCA GGTGGCCAGG CATGATAGAA 6 TCTGATCCTG ACTTAGGGGA ATATTTTCTT TTTACTTCCC ATCTTGATTC CCTGCCGGTG 12 AGTTTCCTGG TTCAGGGTAA GAAAGGAGCT CAGGCCAAAG TAATGAACAA ATCCATCCTC 18 ACAGACGTAC AGAATAAGAG AACWTGGACW TAGCCAGCAG AACMCAA-CTG AAAMCAGAAC 24 MCTTAMCTAG GATRACAAMC MCRRARATAR KTGCYCMCMC WTATAATAGA AACCAAACTT 30 GTATCTAATT AAATATTTAT CCACYGTCAG GGCATTAGTG GTTTTGATAA ATACGCTTTG 36 GCTAGGATTC CTGAGGTTAG AATGGAARAA CAATTGCAMC GAGGGTAGGG GACATGAGTC 42 AKTCTAA 42 (2) IN TRAINING FOR S EQ ID NO: 167: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 500 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SECU ENCE: SEQ ID NO: 167: AACGTCGCAT GCTCCCGGCC GCCATGGCCG CGGGATAGAC TGACTCATGT CCCCTAAGAT 60 AGAGGAGACA CCTGCTAGGT GTAAGGAGAA GATGGTTAGG TCTACGGAGG CTCCAGGGTG 120 GGAGTAGTTC CCTGCTAAGG GAGGGTAGAC TGTTCAACCT GTTCCTGCTC CGGCCTCCAC 180 TATAGCAGAT GCGAGCAGGA GTAGGAGAGA GGGAGGTAAG AGTCAGAAGC TTATGTTGTT 240 TATGCGGGGA AACGCCRTAT CGGGGGCAGC CRAGTTATTA GGGGACANTR TAGWYARTCW 300 AGNTAGCATC CAAAGCGNGG GAGTTNTCCC ATATGGTTGG ACCTGCAGGC GGCCGCATTA 360 GTGATTAGCA TGTGAGCCCC AGACACGCAT AGCAACAAGG ACCTAAACTC AGATCCTGTG 420 CTGATTACTT AACATGAATT ATTGTATTTA TTTAACAACT TTGAGTTATG AGGCATATTA 480 TTAGGTCCAT ATTACCTGGA 500 (2) INFORMATION FOR SEQ ID NO: 168: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 358 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168: TTCATCGCTC GGTGACTCAA GCCTGTAATC CCAGAACTTT GGGAGGCCGA GGGGAGCAGA 60 TCACCTGAGG TTGGGAGTTT GAGACCAGCC TGGCCAACAT GGTGACAACC CGTCTCTGCT 120AAATTAGCCA AGCATGGTGG CATGCACTTG TAATCCCAGC TACTCGGGAG 180 GCTGAGGCAG GAGAATCACT TGAGGCCAGG AGGCAGAGGT TGCAGTGAGG CAGAGGTTGA 240 GATCATGCCA CTGCACTCCA GCCTGGGCAA CAGAGTAAGA CTCCATCTCA AAAAAAAAAA 300 AAAAAAAGAA TGATCAGAGC CACAAATACA GAAAACCTTG AGTCACCGAG CGATGAAA 358 (2) INFORMATION FOR SEQ ID NO: 169: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 1265 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRI SECU Y ACCEPTANCE PC: S EQ ID NO: 1 69: TTCTGTCCAC ACCAATCTTA GAGCTCTGAA AGAATTTGTC TTTAAATATC TTTTAATAGT 60 AACATGTATT TTATGGACCA AATTGACATT TTCGACTATT TTTTCCCAAA AAAAGTCAGG 120 TGAATTTCAG CACACTGAGT TGGGAATTTC TTATCCCAGA AGWCGGCACG AGCAATTTCA 180 TATTTATTTA AGATTGATTC CATACTCCGT TTTCAAGGAG AATCCCTGCA GTCTCCTTAA 240 AGGTAGAACA AATACTTTCT ATTTTTTTTTT CACCATTGTG GGATTGGACT TTAAGAGGTG 300 ACTCTAAAAA AACAGAGAAC AAATATGTCT CAGTTGTATT AAGCACGGAC CCATATTATC 360 ATATTCACTT AAAAAAATGA TTTCCTGTGC ACCTTTTGGC AACTTCTCTT TTCAATGTAG_420_ssAAAAAACTT AGTCACCCTG AAAACCCACA AAATAAATAA AACTTGTAGA TGTGGGCAGA 480 ARGTTTGGGG GTGGACATTG TATGTGTTTA AATTAAACCC TGTATCACTG AGAAGCTGTT 540 GTATGGGTCA GAGAAAATGA ATGCTTAGAA GCTGTTCACA TCTTCAAGAG CAGAAGCAAA 600 CCACATGTCT CAGCTATATT ATTATTTATT TTTTATGCAT AAAGTGAATC ATTTCTTCTG .660 TATTAATTTC CAAAGGGTTT TACCCTCTAT TTAAATGCTT TGAAAAACAG TGCATTGACA 72 ATGGGTTGAT ATTTTTCTTT AAAAGAAAAA TATAATTATG AAAGCCAAGA TAATCTGAAG 78 CCTGTTTTAT TTTAAAACTT TTTATGTTCT GTGGTTGATG TTGTTTGTTT GTTTGTTTCT 840 ATTTTTTTTGG TTTTTTACTT TGTTTTTTTT TTTGTTTTT TTTGTTTTDG CATACTACAT 900 GCAGTTTCTT TAACCAATGT CTGTTTGGCT AATGTAATTA AAGTTGTTAA TTTATATGAG 960 TGCATTTCAA CTATGTCAAT GGTTTCTTAA TATTTATTGT GTAGAAGTAC TGGTAATTTT 1020 TTTATTTACA A.TATGTTTAA AGAGATAACA GTTTGATATG TTTTCATGTG TTTATAGCAG 108 AAGTTATTTA TTTCTATGGC ATTCCAGCGG ATATTTTGGT GTTTGCGAGG CATGCAGTCA 114 ATATTTTGTA CAGTTAGTGG ACAGTATTCA GCAACGCCTG ATAGCTTCTT TGGCCTTATG 120 TTAAATAAAA AGACCTGTTT GGGATGTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAAA 126 AAAAA 1265 (2) I NFORMATION FOR SEQ ID NO: 170: (i) CHARACTERISTICS OF THE SEQUENCE: (A) ITU D LONG: 383 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) DESCRI PTION OF SECU ENCE: SEQ ID NO: 170: TGTAAGTCGA GCAGTGTGAT GACGATATTC TTCTTATTAA TGTGGTAATT GAACAAATGA 6 TCTGTGATAC TGATCCTGAG CTAGGAGGCG CTGTTCAGTT AATGGGACTT CTTCGTACTC 12 TAATTGATCC AGAGAACATG CTGGCTACAA CTAATAAAAC CGAAAAAAGT GAATTTCTAA 18 ATTTTTTTCTA CAACCATTGT ATGCATGTTC TCACAGCACC ACTTTTGACC AATACTTCAG 24 AAGACAAATG TGAAAAGGAT AATATAGTTG GATCAAACAA AAACAACACA ATTTGTCCCG 30 ATAATTATCA AACAGCACAG CTACTTGCCT TAATTTTAGA GTTACTCACA TTTTGTGTGG 36 AACATCACAC TGCTCGACTT ACA 38 (2) IN TRAINING FOR S EQ ID NO: 1 71: (i) SEQUENCE CHARACTERISTICS: (A) ITU D LONG: 383 base pairs (B) TI PO: nucleic acid (C) FI LAM E NTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 171: TGGGCACCTT CAATATCGCA AGTTAAAAAT AATGTTGAGT TTATTATACT TTTGACCTGT 60 TTAGCTCAAC AGGGTGAAGG CATGTAAAGA ATGTGGACTT CTGAGGAATT TTCTTTTAAA 120 AAGAACATAA TGAAGTAACA TTTTAATTAC TCAAGGACTA CTTTTGGTTG AAGTTTATAA 180 TCTAGATACC TCTACTTTTT GTTTTTGCTG TTCGACAGTT CACAAAGACC TTCAGCAATT 240 TACAGGGTAA AATCGTTGAA GTAGTGGAGG TGAAACTGAA ATTTAAAATT ATTCTGTAAA 300 TACTATAGGG AAAGAGGCTG AGCTTAGAAT CTTTTGGTTG TTCATGTGTT CTGTGCTCTT 360 ATCATCACAC TGCTCGACTT ACA 383 (2) I NFORMATION FOR SEQ ID NO: 172: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 699 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 172: TCGGGTGATG CCTCCTCAGG CTTGTCGTTA GTGTACACAG AGCTGCTCAT GAAGCGACAG 60 CGGCTGCCCC TGGCACTTCA GAACCTCTTC CTCTACACTT TTGGTGCGCT TCTGAATCTA 120 GGTCTGCATG CTGGCGGCGG CTCTGGCCCA GGCCTCCTGG AAAGTTTCTC AGGATGGGCA 180 GCACTCGTGG TGCTGAGCCA GGCACTAAAT GGACTGCTCA TGTCTGCTGT CATGGAGCAT 240 GGCAGCAGCA TCACACGCCT CTTTGTGGTG TCCTGCTCGC TGGTGGTCAA CGCCGTGCTC 300 TCAGCAGTCC TGCTACGGCT GCAGCTCACA GCCGCCTTCT TCCTGGCCAC ATTGCTCATT 360 GGCCTGGCCA TGCGCCTGTA CTATGGCAGC CGCTAGTCCC TGACAACTTC CACCCTGATT 420 CCGGACCCTG TAGATTGGGC GCCACCACCA GATCCCCCTC CCAGGCCTTC CTCCCTCTCC 480 CATCAGCGGC CCTGTAACAA GTGCCTTGTG AGAAAAGCTG GAGAAGTGAG GGCAGCCAGG 540 TTATTCTCTG GAGsTTGGTG GATGAAGGGG TACCCCTAGG AGATGTGAAG TGTGGGTTTG 600 GTTAAGGAAA TGCTTACCAT CCCCCACCCC CAACCAAGTT NTTCCAGACT AAAGAATTAA 660 GGTAACATCA ATACCTAGGC CTGAGGAGGC ATCACCCGA 699 (2) INFORMATION FOR SEQ ID NO: 173: (i) CHARACTERISTICS OF THE! SEQUENCE: (A) LONG ITUD: 701 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRI PTION OF SEC U IN C IA: S EQ ID NO: 173: TCGGGTGATG CCTCCTCAGG CCAGATCAAA CTTGGGGTTG AAAACTGTGC AAAGAAATCA 60 ATGTCGGAGA AAGAATTTTG CAAAAGAAAA ATGCCTAATC AGTACTAATT TAATAGGTCA 120 CATTAGCAGT GGAAGAAGAA ATGTTGATAT TTTATGTCAG CTATTTTATA ATCACCAGAG 180 TGCTTAGCTT CATGTAAGCC ATCTCGTATT CATTAGAAAT AAGAACAATT TTATTCGTCG 240 GAAAGAACTT TTCAATTTAT AGCATCTTAA TTGCTCAGGA TTTTAAATTT TGATAAAGAA 300 AGCTCCACTT TTGGCAGGAG TAGGGGGCAG GGAGAGAGGA GGCTCCATCC ACAAGGACAG 360 AGACACCAGG GCCAGTAGGG TAGCTGGTGG CTGGATCAGT CACAACGGAC TGACTTATGC 420 CATGAGAAGA AACAACCTCC AAATCTCAGT TGCTTAATAC AACACAAGCT CATTTCTTGC 480 TCACGTTACA TGTCCTATGT AGATCAACAG CAGGTGACTC AGGGACCCAG GCTCCATCTC 540 CATATGAGCT TCCATAGTCA CCAGGACACG GGCTCTGAAA GTGTCCTCCA TGCAGGGACA 600 CATGCCTCTT CCTTTCATTG GGCAGAGCAA GTCACTTATG GCCAGAAGTC ACACTGCAGG 660 GCAGTGCCAT CCTGCTGTAT GCCTGAGGAG GCATCACCCG A 701 (2) IN TRAINING FOR SEQ ID NO: 174: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 700 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY ÍA: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 174: TCGGGTGATG CCTCCTCANG CCCCTAAATC AGAGTCCAGG GTCAGAGCCA CAGGAGACAG 60 GGAAAGACAT AGATTTTAAC CGGCCCCCTT CAGGAGATTC TGAGGCTCAG TTCACTTTGT 120 TGCAGTTTGA ACAGAGGCAG CAAGGCTAGT GGTTAGGGGC ACGGTCTCTA AAGCTGCACT 180 GCCTGGATCT GCCTCCCAGC TCTGCCAGGA ACCAGCTGCG TGGCCTTGAG CTGCTGACAC 240 GCAGAAAGCC CCCTGTGGAC CCAGTCTCCT CGTCTGTAAG ATGAGGACAG GACTCTAGGA 300 ACCCTTTCCC TTGGTTTGGC CTCACTTTCA CAGGCTCCCA TCTTGAACTC TATCTACTCT 360 TTTCCTGAAA CCTTGTAAAA GAAAAAAGTG CTAGCCTGGG CAACATGGCA AAACCCTGTC 420 TCTACAAAAA ATACAAAAAT TAGTTGGGTG TGGTGGCATG TGCCTGTAGT CCCAGCCACT 480 TGGGAGGTGC TGAGGTGGGA GGATCACTTG AGCCCGGGAG GTGGAGGTTG CAGTGAGCCA 540 AGATCATGCC ACTGCACTCC AGCCTGAGTA ATAGAGTAAG ACTCTGTCTC AAAAACAACA 600 ACAACAACAG TGAGTGTGCC TCTGTTTCCG GGTTGGATGG GGCACCACAT TTATGCATCT 660 CTCAGATTTG GACGCTGCAG CCTGAGGAGG CATCACCCGA 700 (2) I NFORMATION FOR SEQ ID NO: 175: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 484 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESC RI PTION OF SEQUENCE: SEQ ID NO: 175: TATAGGGCGA ATTGGGCCCG AGTTGCATGN TCCCGGCCGC CATGGCCGCG GGATTCGGGT 60 GATGCCTCCT CAGGCTTGTC TGCCACAAGC TACTTCTCTG AGCTCAGAAA GTGCCCCTTG 120 ATGAGGGAAA ATGTCCTACT GCACTGCGAA TTTCTCAGTT CCATTTTACC TCCCAGTCCT 180 CCTTCTAAAC CAGTTAATAA ATTCATTCCA CAAGTATTTA CTGATTACCT GCTTGTGCCA 240 GGGACTATTC TCAGGCTGAA GAAGGTGGGA GGGGAsssCG GAACCTGAGG AGCCACCTGA 300 GCCAGCTTTA TATTTCAACC ATGGCTGGCC CATCTGAGAG CATCTCCCCA CTCTCGCCAA 360 CCTATCGGGG CATAGCCCAG GGATGCCCCC AGGCGGCCCA GGTTAGATGC GTCCCTTTGG 420 CTTGTCAGTG ATGACATACA CCTTAGCTGC TTAGCTGGTG CTGGCCTGAG GAGGCATCAC 480 CCGA 484 (2) INFORMATION FOR SEQ ID NO: 176: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 432 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) descri PTION OF SEQUENCE: SEQ ID NO: 176: TCGGGTGATG CCTCCTCAGG GCTCAAGGGA TGAGAAGTGA CTTCTTTCTG GAGGGACCGT 60 TCATGCCACC CAGGATGAAA ATGGATAGGG ACCCACTTGG AGGACTTGCT GATATGTTTG 120 GACAAATGCC AGGTAGCGGA ATTGGTACTG GTCCAGGAGT TATCCAGGAT AGATTTTCAC 180 CCACCATGGG ACGTCATCGT TCAAATCAAC TCTTCAATGG CCATGGGGGA CACATCATGC 240 CTCCCACACA ATCGCAGTTT GGAGAGATGG GAGGCAAGTT TATGAAAAGC CAGGGGCTAA 300 GCCAGCTCTA CCATAACCAG AGTCAGGGAC TCTTATCCCA GCTGCAAGGA CAGTCGAAGG 360 ATATGCCACC TCGGTTTTCT J.AGAAAGGAC AGCTTAATGC AGATGAGATT AGCCTGAGGA 420 GGCATCACCC GA 432 (2) I NFORMATION FOR SEQ ID NO: 177: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 788 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) descri PTION Secu GUM: SEQ ID NO: 177: TAGCATGTTG AGCCCAGACA CAGTAGCATT TGTGCCAATT TCTGGTTGGA ATGGTGACAA 60 CATGCTGGAG CCAAGTGCTA ACATGCCTTG GTTCAAGGGA TGGAAAGTCA CCCGTAAGGA 120 TGGCAATGCC AGTGGAACCA CGCTGCTTGA GGCTCTGGAC TGCATCCTAC CACCAACTCG 180 CCCAACTGAC AAGCCCTTGC GCCTGCCTCT CCAGGATGTC TACAAAATTG GTGGTATTGG 240 TACTGTTCCT GTTGGCCGAG TGGAGACTGG TGTTCTCAAA CCCGGTATGG TGGTCACCTT 300 TGCTCCAGTC AACGTTACAA CGGAAGTAAA ATCTGTCGAA ATGCACCATG AAGCTTTGAG 360 TGAAGCTCTT CCTGGGGACA ATGTGGGCTT CAATGTCAAG AATGTGTCTG TCAAGGATGT 420 TCGTCGTGGC AACGTTGCTG GTGACAGCAA AAATGACCCA CCAATGGAAG CAGCTGGCTT 480 CACTGCTCAG GTGATTATCC TGAACCATCC AGGCCAAATA AGTGCCGGCT ATGCCCCTGT 540 ATTGGATTGC CACACGGCTC ACATTGCATG CAAGTTTGCT GAGCTGAAGG AAAAGATTGA 600 TCGCCGTTCT GGTAAAAAGC TGGAAGATGG CCCTAAATTC TTGAAGTCTG GTGATGCTGC 660 CATTGTTGAT ATGGTTCCTG GCAAGCCCAT GTGTGTTGAG AGCTTCTCAG ACTATCCACC 720 TTTGGGTCGC TTTGCTGTTC GTGATATGAG ACAGACAGTT GCGGTGGGTG TCTGGGCTCA 780 ACATGCTA 788 (2) I NFORMATION FOR SEQ ID NO: 178: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 786 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) descri PTION Secu GUM: SEQ ID NO: 178: TAGCATGTTG AGCCCAGACA CCTGTGTTTC TGGGAGCTCT GGCAGTGGCG GATTCATAGG 6 CACTTGGGCT GCACTTTGAA TGACACACTT GGCTTTATTA GATTCACTAG TTTTTAAAAA 12 ATTGTTGTTC GTTTCTTTTC ATTAAAGGTT TAATCAGACA GATCAGACAG CATAATTTTG 18 TATTTAATGA CAGAAACGTT GGTACATTTC TTCATGAATG AGCTTGCATT CTGAAGCAAG 24 AGCCTACAAA AGGCACTTGT TATAAATGAA AGTTCTGGCT CTAGAGGCCA GTACTCTGGA 30 GTTTCAGAGC AGCCAGTGAT TGTTCCAGTC AGTGATGCCT AGTTATATAG AGGAGGAGTA 36 CACTGTGCAC TCTTCTAGGT GTAAGGGTAT GCAACTTTGG ATCTTAAAAT TCTGTACACA 42 TACACACTTT ATATATATGT ATGTATGTAT GAAAACATGA AATTAGTTTG TCAAATATGT 48 GTGTGTTTAG TATTTTAGCT TAGTGCAACT ATTTCCACAT TATTTATTAA ATTGATCTAA 54 GACACTTTCT TGTTGACACC TTGAATATTA ATGTTCAAGG GTGCAATGTG TATTCCTTTA 60 GATTGTTAAA GCTTAATTAC TATGATTTGT AGTAAATTAA CTTTTAAAAT GTATTTGAGC 66 CCTTCTGTAG TGTCGTAGGG CTCTTACAGG GTGGGAAAGA TTTTAATTTT CCAGTTGCTA 72 ATTGAACAGT ATGGCCTCAT TATATATTTT GATTTATAGG AGTTTGTGTC TGGGCTCAAC 78 ATGCTA 78 (2) IN TRAINING FOR SEQ ID NO: 179: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 796 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 79: TAGCATGTTG AGCCCAGACA CTGGTTACAA GACCAGACCT GCTTCCTCCA TATGTAAACA 60 GCTTTTAAAA AGCCAGTGAA CCTTTTTAAT ACTTTGGCAA CCTTCTTTCA CAGGCAAAGA 120 ACACCCCCAT CCGCCCCTTG TTTGGAGTGC AGAGTTTGGC TTTGGTTCTT TGCCTTGCCT 180 GGAGTATACT TCTAATTCCT GTTGTCCTGC ACAAGCTGAA TACCGAGCTA CCCACCGCCA 240 CCCAGGCCAG GTTTCCACTC ATTTATTACT TTATGTTTCT GTTCCATTGC TGGTCCACAG 300 AAATAAGTTT TCCTTTGGAG GAATGTGATT ATACCCCTTT AATTTCCTCC TTTTGCTTTT 360 TTTTAATATC ATTGGTATGT GTTTGGCCCA GAGGAAACTG AAATTCACCA TCATCTTGAC 420 TGGCAATCCC ATTACCATGC TTTTTTTTAAA AAACGTAATT TTTCTTGCCT TACATTGGCA 480 GAGTAGCCCT TCCTGGCTAC TGGCTTAATG TAGTCACTCA GTTTCTAGGT GGCATTAGGC 540 ATGAGACCTG AAGCACAGAC TGTCTTACCA CAAAAGGTGA CAAGATCTCA AACCTTAGCC 600 AAAGGGCTAT GTCAGGTTTC AATGCTATCT GCTTCTGTTC CTGCTCACTG TTCTGGATTT 660 TGTCCTTCTT CATCCCTAGC ACCAGAATTT CCCAGTCTCC CTCCCTACCT TCCCTTGTTT 720 TAATTCTAAT CTATCAGCAA AATAACTTTT CAAATGTTTT AACCGGTATC TCCATGTGTC 780 TGGGCTCAAC ATGCTA 796 (2) I NFORMATION FOR SEQ ID NO: 1 80: (i) SEQUENCE CHARACTERISTICS: (A) ITU D LONG: 488 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 180: GGATGTGCTG CAAGGCGATT AAGTTGGGTA ACGCCAGGGT TTTCCCAGTC ACGACGTTGT 6 AAAACGACGG CCAGTGAATT GTAATACGAC TCACTATAGG GCGAATTGGG CCCGACGTCG 12 CATGCTCCCG GCCGCCATGG CCGCGGGATA GCATGTTGAG CCCAGACACC TGCAGGTCAT 18 TTGGAGAGAT TTTTCACGTT ACCAGCTTGA TGGTCTTTTT CAGGAGGAGA GACACTGAGC 24TGAGGTTGAA GATTTCCTCT AGATAGCCGG ATAAGAAGAC TAGGAGGGAT 30 GCCTAGAAAA TGATTAGCAT GCAAATTTCT ACCTGCCATT TCAGAACTGT GTGTCAGCCC 36 ACATTCAGCT GCTTCTTGTG AACTGAAAAG AGAGAGGTAT TGAGACTTTT CTGATGGCCG 42 CTCTAACATT GTAACACAGT AATCTGTGTG TGTGTGGGTG TGTGTGTGTG TCTGGGCTCT 48 ACATGCTA 48 (2) INFORMATION FOR SEQ ID NO.181: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 81 TAGCATGTTG AGCCCAGACA CGGCGACGGT ACCTGATGAG TGGGGTGATG GCACCTGTGA 6 AAAGGAGGAA CGTCATCCCC CATGATATTG GGGACCCAGA TGATGAACCA TGGCTCCGCG 12 TCAATGCATA TTTAATCCAT GATACTGCTG ATTGGAAGGA CCTGAACCTG AAGTTTGTGC 18 TGCAGGTTTA TCGGGACTAT TACCTCACGG GTGATCAAAA CTTCCTGAAG GACATGTGGC 24 CTGTGTGTCT AGTAAGGGAT GCACATGCAG TGGCCAGTGT GCCAGGGGTA TGGTTGGTGT 30 CTGGGCTCCA CATGCTA 31 (2) INFORMATION FOR SEQ ID NO: 182: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 507 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRI SEQUENCE POINT: SEQ ID NO: 1 82: TAGCATGTTG AGCCCAGACA CTGGCTGTTA GCCAAATCCT CTCTCAGCTG CTCCCTGTGG 6 TTTGGTGACT CAGGATTACA GAGGCATCCT GTTTCAGGGA ACAAAAAGAT TTTAsctscc 12 AGCAGAGAGC ACCACATACA TTAGAATGGT AAGGACTGCC ACCTCCTTCA AGAACAGGAG 18 TGAGGGTGGT GGTGAATGGs AATGGAAGCC TGCATTCCCT GATGCATTTG TGCTCTCTCA 24 AATCCTGTCT TAGTCTTAGG AAAGGAAGTA AAGTTTCAAG GACGGTTCCG AACTGCTTTT 30 TGTGTCTGGG CTCAACATGC TATCCCGCGG CCATGGCGGC CGGGAGCATG CGACGTCGGG 36 CCCAATTCGC CCTATAGTGA GTCGTATTAC AATTCACTGG CCGTCGTTTT ACAACGTCGT 42 GACTGGGAAA ACCCTGGCGT TACCCAACTT AATCGCCTTG CA.GCACATCC CCCTTTCCCA 48 GCTGGCGTAA TANCGAAAAG GCCCGCA 50 (2) I NFORMATION FOR SEQ ID NO: 1 83: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 227 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 183: GATTTACGCT GCAACACTGT GGAGGTAGCC CTGGAGCAAG GCAGGCATGG ATGCTTCTGC 6 AATCCCCAAA TGGAGCCTGG TATTTCAGCC AGGAATCTGA GCAGAGCCCC CTCTAATTGT 12 AGCAATGATA AGTTATTCTC TTTGTTCTTC AACCTTCCAA TAGCCTTGAG CTTCCAGGGG 18 AGTGTCGTTA ATCATTACAG CCTGGTCTCC ACAGTGTTGC AGCGTAA 22 (2) I NFORMATION FOR SEQ ID NO: 1 84: (i) CHARACTERISTICS OF THE S ECU ENCE: (A) LONG ITUD: 225 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 84: TTACGCTGCA ACACTGTGGA GCAGATTAAC ATCAGACTTT TCTATCAACA TGACTGGGGT 6 TACTAAAAAG ACAACAAATC AATGGCTTCA AAAGTCTAAG GAATAATTTC GATACTTCAA 12 CTTTATAAAA CCTGACAAAA CTATCAATCA AGCATAAAGA CAGATGAAGA ACATTTCCAG 18 ATTTTGGCCA ATCAGATATT TTACCTCCAC AGTGTTGCAG CGTAA 22 (2) I NFORMATION FOR SEQ ID NO: 185: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 597 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 1 85: GGCCCGACGT CGCATGCTCC CGGCCGCCAT GGCCGCGGGA TTCGTTAGGG TCTCTATCCA 6 CTGGGACCCA TAGGCTAGTC AGAGTATTTA GAGTTCAGTT CCTTTCTGCT TCCCAGAATT 12 TGAAAGAAAA GGAGTGAGGT GATAGAGCTG AGAGATCAGA TTTGCCTCTG AAGCCTGTTC 18 AAGATGTATG TGCTCAGACC CCACCACTGG GGCCTGTGGG TGAGGTCCTG GGCATCTATT 24 TGAATGAATT GCTGAAGGGG AGCACTATGC CAAGGAAGGG GAACCCATCC TGGCACTGGC 30 ACAGGGGTCA CCTTATCCAG TGCTCAGTGC TTCTTTGCTG CTACCTGGTT TTCTCTCATA 36 TGTGAGGGGC AGGTAAGAAG AAGTGCCCRG TGTTGTGCGA GTTTTAGAAC ATCTACCAGT 42 AAGTGGGGAA GTTTCACAAA GCAGCAGCTT TGTTTTGTGT ATTTTCACCT TCAGTTAGAA 48 GAGGAAGGCT GTGAGATGAA TGTTAGTTGA GTGGAAAAGA CGGGTAAGCT TAGTGGATAG_54_AGACCCTAAC GAATCACTAG TGCGGCCGCC TTGCAGGTCG ACCATATGGG AGAGCTC 59 (2) INFORMATION FOR SEQ ID NO: 186: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 597 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESC RITION: SEQ ID NO: 1 86: GGCCCGAAGT TGCATGTTCC CGGCCGCCAT GGCCGCGGGA TTCGTTAGGG TCTCTATCCA 6 CTACCTAAAA AATCCCAAAC ATATAACTGA ACTCCTCACA CCCAATTGGA CCAATCCATC 12 ACCCCAGAGG CCTACAGATC CTCCTTTGAT ACATAAGAAA ATTTCCCCAA ACTACCTAAC 18 TATATCATTT TGCAAGATTT GTTTTACCAA ATTTTGATGG CCTTTCTGAG CTTGTCAGTG 24 TGAACCACTA TTACGAACGA TCGGATATTA ACTGCCCCTC ACCGTCCAGG TGTAGCTGGC 30 AACATCAAGT GCAGTAAATA TTCATTAAGT TTTCACCTAC TAAGGTGCTT AAACACCCTA 36 GGGTGCCATG TCGGTAGCAG ATCTTTTGAT TTGTTTTTAT TTCCCATAAG GGTCCTGTTC 42 AAGGTCAATC ATACATGTAG TGTGAGCAGC TAGTCACTAT CGCATGACTT GGAGGGTGAT 48 AATAGAGGCC TCCTTTGCTG TTAAAGAACT CTTGTCCCAG CCTGTCAAAG TGGATAGAGA 54 CCCTAACGAA TCACTAGTGC GGCCGCCTGC AGGTCGACCA TATGGGAGAG CTCCCAA 59 (2) INFORMATION FOR SEQ ID NO: 187: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 324 pairs of bases (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 187: TCGTTAGGGT CTCTATCCAC TTGCAGGTAA AATCCAATCC TGTGTATATC TTATAGTCTT 6 CCATATGTAG TGGTTCAAGA GACTGCAGTT CCAGAAAGAC TAGCCGAGCC CATCCATGTC 12 TTCCACTTAA CCCTGCTTTG GGTTACACAT CTTAACTTTT CTGTTCAAGT TTCTCTGTGT 18 AGTTTATAGC ATGAGTATTG GGAWAATGCC CTGAAACCTG 'ACATGAGATC TGGGAAACAC 24 AAACTTACTC AATAAGAATT TCTCCCATAT TTTTATGATG GAAAAATTTC ACATGCACAG 30 AGGAGTGGAT AGAGACCCTA ACGA 32 (2) I NFORMATION FOR SEQ ID NO: 1 88: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 78 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 88: GCGCGGGGAT TCGGGGTGAT ACCTCCTCAT GCCAAAATAC AACGTNTAAT TTCACAACTT 6 GCCTTCCAAT TTACGCATTT TCAATTTGCT CTCCCCATTT GTTGAGTCAC AACAAACACC 12 ATTGCCCAGA AACATGTATT CCTAACATG CACATACTCT TAAAACTACT CATCCCTT 17 (2) I NFORMATION FOR SEQ ID NO: 1 89: (i) CHARACTERISTICS OF THE S ECU ENC IA: (A) LONG ITUD: 367 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple ( D) TOPOLOGY: linear (xi) descri PTION OF SEQUENCE: SEQ ID NO: 1 89: TGACACCTTG TCCAGCATCT GACACAGTCT TGGCTCTTGG AAAATATTGG ATAAATGAAA 6 ATGAATTTCT TTAGCAAGTG GTATAAGCTG AGAATATACG TATCACATAT CCTCATTCTA 12 AGACACATTC AGTGTCCCTG AAATTAGAAT AGGACTTACA ATAAGTGTGT TCACTTTCTC 18 AATAGCTGTT ATTCAATTGA TGGTAGGCCT TAAAAGTCAA AGAAATGAGA GGGCATGTGA 24 AAAAAAGCTC AACATCACTG ATCATTAGAA AACTTCCATT CAAACCCCCA ATGAGATACC 30 ATCTCATACC AGTCAGAATG GCTATTATTA AAAAGTCAAA AAATAACAGA TGCTGGACAA 36 GGTGTCA 36 (2) I NFORMATION FOR SEQ ID NO: 1 90: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 369 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) descri PTION OF SEQUENCE: SEQ ID NO: 190: GACACCTTGT CCAGCATCTG ACAACGCTAA CAGCCTGAGG AGATCTTTAT TTATTTATTT 6 AGTTTTTACT CTGGCTAGGC AGATGGTGGC TAAAACATTC ATTTACCCAT TTATTCATTT 12 AATTGTTCCT GCAAGGCCTA TGGATAGAGT ATTGTCCAGC ACTGCTCTGG AAGCTAGGAG 18 CATGGGGATG AACAAGATAG GCTACATCCT GTTCCCACAG AACTTCCACT TTAGTCTGGG 24 AAACAGATGA TATATACAAA TATATAAATG AATTCAGGTA GTTTTAAGTA CGAAAAGAAT 30 AAGAAAGCAG AGTCATGATT TAN ATGCTG GAAACAGGGG CTATTGCTTG AGATATTGAA 36 GGTGCCCAA 36 (2) I NFORMATION FOR SEQ ID NO: 1 91: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 369 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) descri PTION Secu GUM: SEQ ID NO: January 91 TGACACCTTG TCCAGCATCT GCACAGGGAA AAGAAACTAT TATCAGAGTG AACAGGCAAC 60 CTACAGAATG GGAGAAAATT TTTGCAATCT ATCCATCTGA CAAAGGGCTA ATATCCAGAA 120 TCTACAAAGA ACTTATACAA ATTTACAAGA AACAAACAAA CAAACAACTC CTCAAAAAGT 180 GGGTGAAGGA TGTGAACAGA CACTTCTCAA AAGAAGACAT TTATGGGGCC AACAAACATA 240 TGAAAAAAAG CTCATCATCA CTGGTCACTA GATAAATGCA AATCAAAACC ACAATGAGAT 300 ACCATCTCAT TCCAGTTAGA ATGGCAATCA TTAAAAAGTC AGGAAACAAC AGATGCTGGA 360 CAAGGTGTC 36 (2) IN TRAINING FOR SEQ ID NO: 1 92: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 449 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) descri PTION Secu GUM: SEQ ID NO: 1 92: TGACGCTTGG CCACTTGACA CTTCATCTTT GCACAGAAAA ACTTCTTTAC AGATTTAATT 6 CAAGACTGGT CTAGTGACAG TCCTCCAGAC ATTTTTTCAT TTGTTCCATA TACGTGGAAT 12 TTTAAAATCA TGTTTCATCA GTTTGAAATG ATTTGGGCTG CTAATCAACA CAATTGGATC 18 GACTGTTCTA CTAAACAACA GGAAAATGTG TATCTGGCAG CCTGTGGAGA AACACTAAAC 24 ATTGATTTTT CTTTGCCTTT TACGGACTTT GTTCCAGCTA CATGTAATAC CAAGTTCTCT 30 TTAAGAGGAG AAGATGTTGA TCTTCATTTG TTTCTACCAG ACTGCCACCC TAGTAAATAT 36 TCTTTATTTA TGCTGGTAAA AAATTGCCAT CCAAATAAGA TGATTCATGA TACTGGTATT 42 CCTGCTGAGT GTCAAGTGGC CAAGCGTCA 44 (2) IN TRAINING FOR SEQ ID NO: 193: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 372 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( xi) DESCRITION OF SEQUENCE: SEQ ID NO: 193: TGACGCTTGG CCACTTGACA CCAGGGATGT AKCAGTTGAA TATAATCCTG CAATTGTACA 60 TATTGGCAAT TTCCCATCAA ACATTCTAGA AAGAGACAAC CAGGATTGCT AGGCCATAAA 120 AGCTGCAATA AATAACTGGT AATTGCAGTA ATCATTTCAG GCCAATTCAA TCCAGTTTGG 180 CTCAGAGGTG CCTTTGGCTG AGAGAAGAGG TGAGATATAA TGTGTTTTCT TGCAACTTCT 240 TGGAAGAATA ACTCCACAAT AGTCTGAGGA CTAGATACAA ACCTATTTGC CATTAAAGCA 300 CCAGAGTCTG TTAATTCCAG TACTGATAAG TGTTGGAGAT TAGACTCCAG TGTGTCAAGT 360 GGCCAAGCGT CA 372 (2) IN TRAINING FOR SEQ ID NO: 194: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 309 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 94: TGACGCTTGG CCACTTGACA CTTATGTAGA ATCCATCGTG GGCTGATGCA AGCCCTTTAT 60 TTAGGCTTAG TGTTGTGGGC ACCTTCAATA TCACACTAGA GACAAACGCC ACAAGATCTG 120 CAGAAACATT CAGTTCTGAN CACTCGAATG GCAGGATAAC TTTTTG.TGTT GTAATCCTTC 180 ACATATACAA AAACAAACTC TGCANTCTCA CGTTACAAAA AAACGTACTG CTGTAAAATA 240 TTAAGAAGGG GTAAAGGATA CCATCTATAA CAAAGTAACT TACAACTAGT GTCAAGTGGC 300 CAAGCGTCA 309 (2) I NFORMATION FOR SEQ ID NO: 1 95: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 312 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) descri PTION Secu GUM: SEQ ID NO: 1 95: TGACGCTTGG CCACTTGACA CCCAATCTCG CACTTCATCC TCCCAGCACC TGATGAAGTA 60 GGACTGCAAC TATCCCCACT TCCCAGATGA GGGGACCAAN GTACACATTA GGACCCGGAT 120 GGGAGCACAG ATTTGTCCGA TCCCAGACTC CAAGCACTCA GCGTCACTCC AGGACAGCGG 180 CTTTCAGATA AGGTCACAAA CATGAATGGC TCCGACAACC GGAGTCAGTC CGTGCTGAGT 240 TAAGGCAATG GTGACACGGA TGCACGTGTN ACCTGTAATG GTTCATCGTA AGTGTCAAGT 300 GGCCAAGCGT CA 312 (2) I NFORMATION FOR SEQ ID NO: 196: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 288 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 96: TGTATCGACG TAGTGGTCTC CTCAGCCATG CAGAACTGTG ACTCAATTAA ACCTCTTTCC 6 TTTATGAATT ACCCAATCTC GGGTAGTGTC TTTATAGTAG TGTGAGAATG GACTAATACA 12 AGTACATTTT ACTTAGTAAT AATAATAAAC AAATATATTA CATTTTTGTG TATTTACTAC 18 ACCATATTTT TTATTGTTAT TGTAGTGTAC ACCTTCTACT TATTAAAAGA AATAGGCCCG 24 AGGCGGGCAG ATCACGAGGT CAGGAGATGG AGACCACTAC GTCGATAC 28 (2) I NFORMATION FOR S EQ ID NO: 1 97: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 289 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) ) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 197: TTGGGCACCT TCAATATCAT GACAGGTGAT GTGATAACCA AGAAGGCTAC TAAGTGATTA 6 ATGGGTGGGT AATGTATACA GAGTAGGTAC ACTGGACAGA GGGGTAATTC ATAGCCAAGG 12 CAGGAGAAGC AGAATGGCAA AACATTTCAT CACACTACTC AGGATAGCAT GCAGTTTAAA 18 ACCTATAAGT AGTTTATTTT TGGAATTTTC CACTTAATAT TTTCAGACTG CAGGTAACTA 24 AACTGTGGAA CACAAGAACA TAGATAAGGG GAGACCACTA CGTCGATAC 28 (2) IN TRAINING FOR SEQ ID NO: 198: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 288 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 1 98: GTATCGACGT AGTGGTCTCC CAAGCAGTGG GAAGAAAACG TGAACCAATT AAAATGTATC 60 AGATACCCCA AAGAAAGGCG CTTGAGTAAA GATTCCAAGT GGGTCACAAT CTCAGATCTT 120 AAAATTCAGG CTGTCAAAGA GATTTGCTAT GAGGTTGCTC TCAATGACTT CAGGCACAGT 180 CGGCAGGAGA TTGAAGCCCT GGCCATTGTC AAGATGAAGG AGCTTTGTGC CATGTATGGC 240 AAGAAAGACC CCAATGAGCG GGACTCCTGG AGACCACTAC GTCGATAC 288 (2) I NFORMATION FOR SEQ ID NO: 199: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 1 027 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) ) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199: GCTTTTTGGG AAAAACNCAA NTGGGGGAAA GGGGGNTTNN TNGCAAGGGG ATAAAGGGGG 6 AANCCCAGGG TTTCCCCATT CAGGGAGGTG TAAAAAGNCG GCCAGGGGAT TGTAANAGGA 12 TTCAATAATA GGGGGAATGG GCCCNGAAGT TGCAAGGTTC CNGCCCGCCA TGNCCGCGGG 18 ATTTAGTGAC ATTACGACGS TGGTAATAAA GTGGGSCCAA WAAATATTTG TGATGTGATT 24 TTTSGACCAG TGAACCCATT GWACAGGACC TCATTTCCTY TGAGATGRTA GCCATAATCA 30 GATAAAAGRT TAGAAGTYTT TCTGCACGTT AACAGCATCA TTAAATGGAG TGGCATCACC 36 AATTTCACCC TTTGTTAGCC GATACCTTCC CCTTGAAGGC ATTCAATTAA GTGACCAATC 42 GTCATACGAG AGGGGATGGC ATGGGGATTG ATGATGATAT CAGGGGTGAT ACCTTCACAG 48 GTGAAAGGCA TATCCTCTTG TCTATACTGA ATACCACAAG TACCCTTTTG ACCATGTCGA 54 CTAGCAAATT TGTCTCCAAT CTGTGTWATC CCTAACAGAG CGTACCCTTA TTTTACAAAA 60 TTTATATCCT TCCTGATTGA GAGTTACCAT AACCTGATCC ACAATGCCCG TCTCGCTWGT 66 TCTGAGAAAA GTGCTACAGT CTCTCTTGGT ATAGCGTCTA TTGGTGCTCT CCAATTCATC 72 TTCATTTTTC AGGCAAGGTG AACTGTTTTG CCTATAATAA CMTCATCTCC TGATACMCGA 78 AACCCCKGGA RCTATCAAAC CATCATCATC CAGCGTTCKT WATGTYMCTA AATCCCTATT 84 GCGGCCGCCT GCAGGTCAAC ATATNGGAAA ACCCCCCACC CCTTNGGAGC NTACCTTGAA 90 TTTTCCATAT GTCCCNTAAA TTANCTNGNC TTANCCTGGC CNTAACCTNT TCCGGTTTAA 96 ATTGTTTCCG CCCCCNTTCC CCNCCTTNNA ACCGGAAACC TTAATTTTNA ACCNGGGGTT 102 CCTATCC 102 (2) INFORMATION FOR SEQ ID NO: 200: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 207 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY:: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 200: AGTGACATTA CGACGCTGGC CATCTTGAAT CCTAGGGCAT GAAGTTGCCC CAAAGTTCAG 6 CACTTGGTTA AGCCTGATCC CTCTGGTTTA TCACAAAGAA TAGGATGGGA TAAAGAAAGT 12 GGACACTTAA ATAAGCTATA AATTATATGG TCCTTGTCTA GCAGGAGACA ACTGCACAGG 18 TATACTACCA GCGTCGTAAT GTCACTA 20 (2) I NFORMATION FOR SEQ ID NO: 201: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 209 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY ÍA: linear (xi) DESCRI PC ION OF SECU EN C IA: SEQ ID NO: 201 TGGGCACCTT CAATATCTAT TAAAAGCACA AATACTGAAG AACACACCAA GACTATCAAT 60 GAGGTTACAT CTGGAGTCCT CGATATATCA GGAAAAAATG AAGTGAACAT TCACAGAGTT 120 TTACTTCTTT GGGAACTCAA ATGCTAGAAA AGAAAAGGGT GCCCTCTTTC TCTGGCTTCC 180 TGGTCCTATC CAGCGTCGTA ATGTCACTA 209 (2) INFORMATION FOR SEQ ID NO: 202: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 349 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 202: NTACGCTGCA ACACTGTGGA GCCACTGGTT TTTATTCCCG GCAGGTTATC CAGCAAACAG 60 TCACTGAACA CACCGAAGAC CGTGGTATGG TAACCGTTCA CAGTAATCGT TCCAGTCGTC 120 TGCGGGACCC CGACGAGCGT CACTGGOTAC AGACCAGATT CAGCCGGAAG AGAAAGCGCC 180 GCAGGGAGAG ACTCGAACTC CACTCCGCTG GTGAGCAGCC CCATGTTTTC AACTCGAAGT 240 TCAAACGGCA TTGGGTTATA TACCATCAGC TGAACTTCAC ACACATCTCC TTGAACCCAC 300 TGGAAATCTA TTTTCTTGTT CCGCTCTTCT CCACAGTGTT GCAGCGTAA 349 (2) I NFORMATION FOR SEQ ID NO: 203: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 241 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203: TGCTCCTCTT GCCTTACCAA CCCAAAGCCC ACTGTGAAAT ATGAAGTGAA TGACAAAATT 60 CAGTTTTCAA CGCAATATAG TATAGTTTAT CTGATTCTTT TGATCTCCAG GACACTTTAA 120 ACAACTGCTA CCACCACCAC CAACCTAGGG ATTTAGGATT CTCCACAGAC CAGAAATTAT 180 TTCTCCTTTG AGTTTCAGGC TCCTCTGGGA CTCCTGTTCA TCAATGGGTG GTAAATGGCT 240 A • 241 (2) I NFORMATION FOR SEQ ID NO: 204: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 248 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 204: TAGCCATTTA CCACCCATCT GCAAACCSWG ACMWWCARGR CYWGWACKYA GGCGATTTGA 60 AGTACTGGTA ATGCTCTGAT CATGTTAGTT ACATAAGTGT GGTCAGTTTA CAAAAATTCA 120 CAGAACTAAA TACTCAATGC TATGTGTTCA TGTCTGTGTT TATGTGTGTG TAATGTTTCA 180 ATTAAGTTTT TTTAAAAAAA AGAGATGATT TCCAAATAAG AAAGCCGTGT TGGTAAGGCA 240 AGAGGAGC 248 (2) I NFORMATION FOR SEQ ID NO: 205: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 505 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 205: TACGCTGCAA CACTGTGGAG CCATTCATAC AGGTCCCTAA TTAAGGAACA AGTGATTATG 60 CTACCTTTGC ACGGTTAGGG TACCGCGGCC GTTAAACATG TGTCACTGGG CAGGCGGTGC 120 CTCTAATACT GGTGATGCTA GAGGTGATGT TTTTGGTAAA CAGGCGGGGT AAGATTTGCC 180 GAGTTCCTTT TACTTTTTTT AACCTTTCCT TATGAGCATG CCTGTGTTGG GTTGACAGTG 240 GGGGTAATAA TGACTTGTTG GTTGATTGTA GATATTGGGC TGTTAATTGT CAGTTCAGTG 300 TTTTAATCTG ACGCAGGCTT ATGCGGAGGA GAATGTTTTC ATGTTACTTA TACTAACATT 360 AGTTCTTCTA TAGGGTGATA GATTGGTCCA ATTGGGTGTG AGGAGTTCAG TTATATGTTT 420 GGGATTTTTT AGGTAGTGGG TGTTGANCTT GAACGCTTTC TTAATTGGTG GCTGCTTTTA 480 RGCCTACTAT GGGTGGTAAA TGGCT 505 (2) INFORMATION FOR SEQ ID NO: 206: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 79 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 206: TAGACTGACT CATGTCCCCT ACCAAAGCCC ATGTAAGGAG CTGAGTTCTT AAAGACTGAA 60 GACAGACTAT TCTCTGGAGA AAAATAAAAT GGAAATTGTA CTTTAAAAAA AAAAAAAAATC 120 GGCCGGGCAT GGTAGCACAC ACCTGTAATC CCAGCTACTA GGGGACATGA GTCAGTCTA 179 (2) IN TRAINING FOR SEQ ID NO: 207: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 176 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 207: AGACTGACTC ATGTCCCCTA CCCCACCTTC TGCTGTGCTG CCGTGTTCCT AACAGGTCAC 60 AGACTGGTAC TGGTCAGTGG CCTGGGGGTT GGGGACCTCT ATTATATGGG ATACAAATTT 120 AGGAGTTGGA ATTGACACGA TTTAGTGACT GATGGGATAT GGGTGGTAAA TGGCTA 176 (2) I NFORMATION FOR SEQ ID NO: 208: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 196 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear 5 (xi) SEQUENCE DESCRITION: SEQ ID NO: 208: AGACTGACTC ATGTCCCCTA TTTAACAGGG TCTCTAGTGC TGTGAAAAAA AAAAATGCTG 60 AACATTGCAT ATAACTTATA TTGTAAGAAA TACTGTACAA TGACTTTATT GCATCTGGGT 120 AGCTGTAAGG CATGAAGGAT GCCAAGAAGT TTAAGGAATA TGGGTGGTAA ATGGCTAGGG 180 GACATGAGTC AGTCTA 196 (2) I NFORMATION FOR SEQ ID NO: 209: (i) CHARACTERISTICS OF THE SEQUENCE: 0 (A) LENGTH: 345 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 209: GACGCTTGGC CACTTGACAC CTTTTATTTT TTAAGGATTC TTAAGTCATT TANGTNACTT 60 TGTAAGTTTT TCCTGTGCCC CCATAAGAAT GATAGCTTTA AAAATTATGC TGGGGTAGCA 120 AAGAAGATAC TTCTAGCTTT AGAATGTGTA GGTATAGCCA GGATTCTTGT GAGGAGGGGT 180 GATTTAGAGC AAATTTCTTA TTCTCCTTGC CTCATCTGTA ACATGGGGAT AATAATAGAA 240 CTGGCTTGAC AAGGTTGGAA TTAGTATTAC ATGGTAAATA CATGTAAAAT GTTTAGAATG 300 GTGCCAAGTA TCTAGGAAGT ACTTGGGCAT GGGTGGTAAA TGGCT 345 Z > (2) IN TRAINING FOR S EQ ID NO: 21 0: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 1 78 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) ) TOPOLOGY: linear (xi) SEQUENCE descri PTION: SEQ ID NO: 21 0: GACGCTTGGC CACTTGACAC TAGAGTAGGG TTTGGCCAAC TTTTTCTATA AAGGACCAGA 60 GAGTAAATAT TTCAGGCTTT GTGGGTTGTG CAGTCTCTCT TGCAACTACT CAGCTCTGCC 120 ATTGTAGCAT AGAAATCAGC CATAGACAGG ACAGAAATGA ATGGGTGGTA AATGGCTA 178 (2) INFORMATION FOR SEQ ID NO: 21 1: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 454 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21 1: TGGGCACCTT CAATATCTAT CCAGCGCATC TAAATTCGCT TTTTTCTTGA TTAAAAATTT 60 CACCACTTGC TGTTTTTGCT CATGTATACC AAGTAGCAGT GGTGTGAGGC CATGCTTGTT 120 TTTTGATTCG ATATCAGCAC CGTATAAGAG CAGTGCTTTG GCCATTAATT TATCTTCATT 180 GTAGACAGCA TAGTGTAGAG TGGTATCTCC ATACTCATCT GGAATATTTG GATCAGTGCC 240 ATGTTCCAGC AACATTAACG CACATTCATC TTCCTGGCAT TGTACGGCCT TTGTCAGAGC 300 TGTCCTCTTT TTGTTGTCAA GGACATTAAG TTGACATCGT CTGTCCAGCA CGAGTTTTAC 360 TACTTCTGAA TTCCCATTGG CAGAGGCCAG ATGTAGAGCA GTCCTCTTTT GCTTGTCCCT 420 CTTGTTCACA TCAGTGTCCC TGAGCATAAC GGAA 454 (2) INFORMATION FOR SEQ ID NO: 212: (i) CHARACTERISTICS OF THE SEQUENCE .. (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRITION: SEQ ID NO: 21 2: TCCGTTATGC CACCCAGAAA ACCTACTGGA GTTACTTATT AACATCAAGG CTGGAACCTA 60 TTTGCCTCAG TCCTATCTGA TTCATGAGCA CATGGTTATT ACTGATCGCA TTGAAAACAT 120 TGATCACCTG GGTTTCTTTA TTTATCGACT GTGTCATGAC AAGGAAACTT ACAAACTGCA 180 ACGCAGAGAA ACTATTAAAG GTATTCAGAA ACGTGAAGCC AGCAATTGTT TCGCAATTCG 240 GCATTTTGAA AACAAATTTG CCGTGGAAAC TTTAATTTGT TCTTGAACAG TCAAGAAAAA 300 CATTATTGAG GAAAATTAAT ATCACAGCAT AACGGAA 337 (2) INFORMATION FOR SEQ ID NO: 213: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 71 5 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) ) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 21 3: TCGGGTGATG CCTCCTCAGG CATCTTCCAT CCATCTCTTC AAGATTAGCT GTCCCAAATG 60 TTTTTCCTTC TCTTCTTTAC TGATAAATTT GGACTCCTTC TTGACACTGA TGACAGCTTT 12 AGTATCCTTC TTGTCACCTT GCAGACTTTA AACATAAAAA TACTCATTGG TTTTAAAAGG 18 AAAAAAGTAT ACATTAGCAC TATTAAGCTT GGCCTTGAAA CATTTTCTAT CTTTTATTAA 24 ATGTCGGTTA GCTGAACAGA ATTCATTTTA CAATGCAGAG TGAGAAAAGA AGGGAGCTAT 30 ATGCATTTGA GAATGCAAGC ATTGTCAAAT AAACATTTTA AATGCTTTCT TAAAGTGAGC 36 ACATACAGAA ATACATTAAG ATATTAGAAA GTGTTTTTGC TTGTGTACTA CTAATTAGGG 42 AAGCACCTTG TATAGTTCCT CTTCTAAAAT TGAAGTAGAT TTTAAAAACC CATGTAATTT 48 AATTGAGCTC TCAGTTCAGA TTTTAGGAGA ATTTTAACAG GGATTTGGTT TTGTCTAAAT 54 TTTGTCAATT TNTTTAGTTA ATCTGTATAA TTTTATAAAT GTCAAACTGT ATTTAGTCCG 60 TTTTCATGCT GCTATGAAAG AAATACCCAN GACAGGGTTA TTTATAAANG GAAAGANGTT 660 AATTTGACTC CCAGTTCACA GGCCTGAGGA NGNATCNCCC GAAATCCTTA TTGCG 715 (2) I NFORMATION FOR SEQ ID NO: 214: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 214: GGTAANGNGC ATACNTCGGT GCTCCGGCCG CCGGAGTCGG GGGATTCGGG TGATGCCTCC 60 TCAGGCCCAC TTGGGCCTGC TTTTCCCAAA TGGCAGCTCC TCTGGACATG CCATTCCTTC 120 TCCCACCTGC CTGATTCTTC ATATGTTGGG TGTCCCTGTT TTTCTGGTGC TATTTCCTGA 180 CTGCTGTTCA GCTGCCACTG TCCTGCAAAG CCTGCCTTTT TAAATGCCTC ACCATTCCTT 240 CATTTGTTTC TTAAATATGG GAAGTGAAAG TGCCACCTGA GGCCGGGCAC AGTGGCTCAC 300 GCCTGTAATC CCAGCACTTT GGGAGCCTGA GGAGGCATCA CCCGA 345 (2) INFORMATION FOR SEQ ID NO: 215: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 429 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 215: GGTGATGCCT CCTCAGGCGA AGCTCAGGGA GGACAGAAAC CTCCCGTGGA GCAGAAGGGC 60 AAAAGCTCGC TTGATCTTGA TTTTCAGTAC GAATACAGAC CGTGAAAGCG GGGCCTCACG 120 ATCCTTCTGA CCTTTTGGGT TTTAAGCAGG AGGTGTCAGA AAAGTTACCA CAGGGATAAC 180 TGGCTTGTGG CGGCCAAGCG TTCATAGCGA CGTCGCTTTT TGATCCTTCG ATGTCGGCTC 240 TTCCTATCAT TGTGAAGCAG AATTCACCAA GCGTTGGATT GTTCACCCAC TAATAGGGAA 300 CGTGAGCTGG GTTTAGACCG TCGTGAGACA GGTTAGTTTT ACCCTACTGA TGATGTGTKG 360 TTGCCATGGT AATCCTGCTC AGTACGAGAG GAACCGCAGG TTCA3ACATT TGGTGTATGT 420 GCTTGCCTT 429 (2) INFORMATION FOR SEQ ID NO: 216: (i) CHARACTERISTICS OF THE SEQUENCE _. (A) LENGTH: 593 base pairs (B) TYPE: nucleic acid (C) FILAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 216: TGACACCTAT GTCCNGCATC TGTTCACAGT TTCCACAAAT AGCCAGCCTT TGGCCACCTC 6 TCTGTCCTGA GGTATACAAG TATATCAGGA GGTGTATACC TCTCTTCTC TTCCCCACCA 12 AAGAGAACAT GCAGGCTCTG GAAGCTGTCT TAGGAGCCTT TGGGCTCAGA ATTTCAGAGT 18 CTTGGGTACC TTGOATGTGG TCTGGAAGGA GAAACATTGG CTCTGGATAA GGAGTACAGC 24 CGGAGGAGGG TCACAGAGCC CTCAGCTCAA GCCCCTGTGC CTTAGTCTAA AAGCAGCTTT 30 GGATGAGGAA GCAGGTTAAG TAACATACGT AAGCGTACAC AGGTAGAAAG TGCTGGGAGT 36 CAGAATTGCA CAGTGTGTAG GAGTAGTACC TCAATCAATG AGGGCAAATC AACTGAAAGA 42 AGAAGACCNA TTAATGAATT GCTTANGGGG AAGGATCAAG GCTATCATGG AGATCTTTCT 48 AGGAAGATTA TTGTTTANAA TTATGAAAGG ANTAGGGCAG GGACAGGGCC AGAAGTANAA 54 GANAACATTG CCTATANCCC TTGTCTTGCA CCCAGATGCT GOACAAGGTG TCA 59 (2) INFORMATION FOR SEQ ID NO: 217: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESC R ECTION OF S ECUENCY: SEQ ID NO: 21 7: TGACACCTTG TCCAGCATCT GACGTGAAGA TGAGCAGCTC AGAGGAGGTG TCCTGGATTT 60TG TGGGCTCCGT GGCAATGAAT TCTTCTGTGA AGTGGATGAA GACTACATCC 120 AGGACAAATT TAATCTTACT GGACTCAATG AGCAGGTCCC TCACTATCGA CAAGCTCTAG_180_ACATGATCTT GGACCTGGAG CCTGATGAAG AACTGGAAGA CAACCCCAAC CAGAGTGACC 240 TGATTGAGCA GGCAGCCGAG ATGCTTTATG GATTGATCCA CGCCCGCTAC ATCCTTACCA 300 ACCGTGGCAT CGCCCAGATG CTGGACAAGG TGTCA 335 (2) INFORMATION FOR SEQ ID NO: 218: (i) CHARAISTICS OF THE SEQUENCE: (A) LENGTH: 248 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 21 8: TACGTACTGG TCTTGAAGGT CTTAGGTAGA GAAAAAATGT GAATATTTAA TCAAAGACTA 60 TGTATGAAAT GGGACTGTAA GTACAGAGGG AAGGGTGGCC CTTATCGCCA GAAGTTGGTA 120 GATGCGTCCC CGTCATGAAA TGTTGTGTCA CTGCCCGACA TTTGCCGAAT TACTGAAATT 180 CCGTAGAATT AGTGCAAATT CTAACGTTGT TCATCTAAGA TTATGGTTCC ATGTTTCTAG TACTTTTA 240 248 (2) I NFORMATION FOR SEQ ID NO: 21 9: (i) CHARAISTICS OF THE SEQUENCE: (A) LENGTH: 530 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 21 9: TGACGCTTGG CCACTTGACA CAAGTAGGGG ATAAGGACAA AGACCCATNA GGTGGCCTGT 60 CAGCCTTTTG TTACTGTTGC TTCCCTGTCA CCACGGCCCC CTCTGTAGGG GTGTGCTGTG 120 CTCTGTGGAC ATTGGTGCAT TTTCACACAT ACCATTCTCT TTCTGCTTCA CAGCAGTCCT 180 GAGGCGGGAG CACACAGGAC TACCTTGTCA GATGANGATA ATGATGTCTG GCCAACTCAC 240 CCCCCAACCT TCTCACTAGT TATANGAAGA GCCANGCCTA NAACCTTCTA TCCTGNCCCC 300 TTGCCCTATG ACCTCATCCC TGTTCCATGC CCTATTCTGA TTTCTGGTGA ACTTTGGAGC 360 AGCCTGGTTT NTCCTCCTCA CTCCAGCCTC TCTCCATACC ATGGTANGGG GGTGCTGTTC 420 CACNCAAANG GTCAGGTGTG TCTGGGGAAT CCTNANANCT GCCNGGAGTT TCCNANGCAT 480 TCTTAAAAAC CTTCTTGCCT AATCANATNG TGTCCAGTGG CCAACCNTCN 530 (2) IN TRAINING FOR S EQ ID NO: 220: (i) CHARAISTICS OF THE SECU ENCIA: (A) LONG ITUD: 531 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) ) TOPOLOGY: linear (xi) descri PTION Secu GUM: SEQ ID NO: 220: TGACGCTTGG CCACTTGACA CTAAATAGCA TCTTCTAAAG GCCTGATTCA GAGTTGTGGA 60 AAATTCTCCC AGTGTCAGGG ATTGTCAGGA ACAGGGCTGC TCCTGTGCTC ACTTTACCTG 120 CTGTGTTTCT GCTGGAAAAG GAGGGAAGAG GAATGGCTGA TTTTTACCTA ATGTCTCCCA 180 GTTTTTCATA TTCTTCTTGG ATCCTCTTCT CTGACAACTG TTCCCTTTTG GTCTTCTTCT 240 TCTTGCTCAG AGAGCAGGTC TCTTTAAAAC TGAGAAGGGA GAATGAGCAA ATGAT AAAG 300 AAAACACACT TCTGAGGCCC AGAGATCAAA TATTAGGTAA ATACTAAACC GCTTGCC OC 360 TGTGGTCACT TTTCTCCTCT TTCACATGCT CTATCCCTCT ATCCCCCACC TATTCA AG 420 GCTTTTATCT GCCAAGTTAT CCGGCCTCTC ATCAACCTTC TCCCCTAGCC TACTGGsGGA 480 TATCCATCTG GGTCTGTCTC TGGTGTATTG GTGTCAAGTG GCCAAGCGTC A 531 (2) I NFORMATION FOR S EQ ID NO: 221: (i) CHARAISTICS OF THE SEQUENCE: (A) LENGTH: 530 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 221: ATTGACGCTT GGCCACTTGA CACCCGCCTG CCTGCAATAC TGGGGCAAGG GCCTTCACTG 60 CTTTCCTGCC ACCAGCTGCC ACTGCACACA GAGATCAGAA ATGCTACCAA CCAAGACTGT 120 TGGTCCTCAG CCTCTCTGAG GAGAAAGAGC AGAAGCCTGG AAGTCAGAAG AGAAGCTAGA 180 TCGGCTACGG CCTTGGCAGC CAGCTTCCCC ACCTGTGGCA ATAAAGTCGT GCATGGCTTA 240 ACAATGGGGG CACCTCCTGA GAAACACATT GTTAGGCAAT TCGGCGTGTG TTCATCAGAG 300 CATATTTACA CAAACCTCGA TAGTGCAGCC TACTATCCAC TATTGCTCCT ACGCTGCAAA 36 CCTGAACAGC ATGGGACTGT ACTGAATACT GGAAGCAGCT GGTGATGGTA CTTATTTGTG 42 TATCTAAACA CAGAGAAGGT ACAGTAAGAA TATGGTATCA TAAACTTACA GGGACCGCCA 48 TCCTATATGC AGTCTGTTGT GACCAAAATG TGTCAAGTGG CCAAGCGTCA 53 (2) INFORMATION FOR SEQ ID NO: 222: (i) CHARAISTICS OF THE SEQUENCE: (A) LENGTH: 578 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRI PCI SECTION: SEQ ID NO: 222: TGTATCGACG TAGTGGTCTC CGGGCTACTA GGCCGTTGTG TGCTGGTAGT ACCTGGTTCA 60 CTGAAAGGCG CATCTCCCTC CCCGCGTCGC CCTGAAGCAG GGGGAGGACT TCGCCCAGCC 120 AAGGCAGTTG TATGAGTTTT AGCTGCGGCA CTTCGAGACC TCTGAGCCCA CCTCCTTCAG 180 GAGCCTTCCC CGATTAAGGA AGCCAGGGTA AGGATTCCTT CCTCCCCCAG ACACCACGAA 240 CAAACCACCA CCCCCCCTAT TCTGGCAGCC CATATACATC AGAACGAAAC AAAAATAACA 300 AATAAACNAA AACCAAAAAA AAAAGAGAAG GGGAAATGTA TATGTCTGTC CATCCTGTTG 360 CTTTAGCCTG TCAGCTCCTA NAGGGCAGGG ACCGTGTCTT CCOAATGGTC TGTGCAGCGC 420 CGACTGCGGG AAGTATCGGA GGAGGAAGCA GAGTCAGCAG AAGTTGAACG GTGGGCCCGG 480 CGGCTCTTGG GGGCTGGTGT TGTACTTCGA GACCGCTTTC GCTTTTTGTC TTAGATTTAC 540 GTTTGCTCTT TGGAGTGGGA NACCACTACN TCNATACA 578 (2) INFORMATION FOR SEQ ID NO: 223: (i) CHARACTERISTICS OF THE SEQUENCE .. (A) LENGTH: 578 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRITION: SEQ ID NO: 223: TGTATCGACG TAGTGGTCTC CTCTTGCAAA GGACTGGCTG GTGAATGGTT TCCCTGAATT 60 ATGGACTTAC CCTAAACATA TCTTATCATC ATTACCAGTT GCAAAATATT AGAATGTGTT 120 GTCACTGTTT CATTTGATTC CTAGAAGGTT AGTCTTAGAT ATGTTACTTT AACCTGTATG 180 CTGTAGTGCT TTGAATGCAT TTTTTGTTTG CATTTTTGTT TGCCCAACCT GTCAATTATA 240 GCTGCTTAGG TCTGGACTGT CCTGGATAAA GCTGTTAAAA TATTCACCAG TCCAGCCATC 300 TTACAAGCTA ATTAAGTCAA CTAAATGCTT CCTTGTTTTG CCAGACTTGT TATGTCAATC 360 CTCAATTTCT GGGTTCATTT TGGGTGCCCT AAATCTTAGG GTGTGACTTT CTTAGCATCC 420 TGTAACATCC ATTCCCAAGC AAGCACAACT TCACATAATA CTTTCCAGAA GTTCATTGCT 480 GAAGCCTTTC CTTCACCCAG CGGAGCAACT TGATTTTCTA CAACTTCCCT CATCAGAGCC 540 ACAAGAGTAT GGGATATGGA GACCACTACG TCGATACA 578 (2) I NFORMATION FOR SEQ ID NO: 224: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 345 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) descri PTION Secu GUM: SEQ ID NO: 224: TGTATCGACG TANTGGTCTC CCAAGGTGCT GGGATTGCAG GCATGAGCCA CCACTCCCAG 6 GTGGATCTTT TTCTTTATAC TTACTTCATT AGGTTTCTGT TATTCAAGAA GTGTAGTGGT 12 AAAAGTCTTT TCAATCTACA TGGTTAAATA ATGATAGCCT GGGAAATAAA TAGAAATTTT 18 TTCTTTCATC TTTAGGTTGA ATAAAGAAAC AGAAAAAATA GAACATACTG AAAATAATCT 24 AAGTTCCAAC CATAGAAGAA CTGCAGAAGA AATGAAGAAA GTGATGATGA TTTAGATTTT 30 GATATTGATT TAGAAGACAC AGGAGGAGAC CACTACGTCG ATTACK 34 (2) I NFORMATION FOR SEQ ID NO: 225: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 347 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple ( D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 225: TGTATCGACG TAGTGGTCTC CAAACTGAGG TATGTGTGCC ACTAGCACAC AAAGCCTTCC 6 AACAGGGACG CAGGCACAGG CAGTTTAAAG GGAATCTGTT TCTAAATTAA TTTCCACCTT 12 CTCTAAGTAT TCTTTCCTAA AACTGATCAA GGTGTGAAGC CTGTGCTCTT TCCCAACTCC 18 CCTTTGACAA CAGCCTTCAA CTAACACAAG AAAAGGCATG TCTGACACTC TTCCTGAGTC 24 TGACTCTGAT ACGTTGTTCT GATGTCTAAA GAGCTCCAGA ACACCAAA.GG GACAATTCAC- 30 AATGCTGGTG TATAACAGAC TCCAATGGAG ACCACTACGT CGATACA 34 (2) I NFORMATION FOR SEQ ID NO: 226: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 281 base pairs (B) TYPE: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 226: AGGNGNGGGA NTGTATCGAC GTAGTGGTCT CCCAACAGTC TGTCATTCAG TCTGCAGGTG 6 TCAGTGTTTT GGACAATGAG GCACCATTGT CACTTATTGA CTCCTCAGCT CTAAATGCTG 12 AAATTAAATC TTGTCATGAC AAGTCTGGAA TTCCTGATGA GGTTTTACAA AGTATTTTGG 18 ATCAATACTC CAACAAATCA GAAAGCCAGA AAGAGGATCC TTTCAATATT GCAGAACCAC 24 GAGTGGATTT ACACACCTCA GGAGACCACT ACGTCGATAC A 28 (2) I NFORMATION FOR SEQ ID NO: 227: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 3646 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRI PTION OF S ECU ENCE: SEQ ID NO: 227: GGGAAACACT TCCTCCCAGC CTTGTAAGGG TTGGAGCCCT CTCCAGTATA TGCTGCAGAA 60 TTTTTCTCTC GGTTTCTCAG AGGATTATGG AGTCCGCCTT AAAAAAGGCA AGCTCTGGAC 120 ACTCTGCAAA GTAGAATGGC CAAAGTTTGG AGTTGAGTGG CCCCTTGAAG GGTCACTGAA 180 CCTCACAATT GTTCAAGCTG TGTGGCGGGT TGTTACTGAA ACTCCCGGCC TCCCTGATCA 2 GTTTCCCTAC ATTGATCAAT GGCTGAGTTT GGTCAGGAGC ACCCCTTCCG TGGCTCCACT 3 CATGCACCAT TCATAATTTT ACCTCCAAGG TCCTCCTGAG CCAGACCGTG TTTTCGCCTC 3 GACCCTCAGC CGGTTCGGCT CGCCCTGTAC TGCCTCTCTC TGAAGAAGAG GAGAGTCTCC 4 CTCACCCAGT CCCACCGCCT TAAAACCAGC CTACTCCCTT AGGGTCATCC CATGTCTCCT 4 CGGCTATGTC CCCTGTAGGC TCATCACCCA TTGCCTCTTG GTTGCAACCG TGGTGGGAGG 5 AAGTAGCCCC TCTACTACCA CTGAGAGAGG CACAAGTCCC TCTGGGTGAT GAGTGCTCCA 6GGTTTATGTC CCTTCTTTCT ACTTCTGACT TGTATAATTG GAAAACCCAT 6 AATCCTCCCT TCTCTGAAAA GCCCCAGGCT TTGACCTCAC TGATGGAGTC TGTACTCTGG 7 ACACATTGGC CCACCTGGGA TGACTGTCAA CAGCTCCTTT TGACCCTTTT CACCTCTGAA 7 GAGAGGGAAA GTATCCAAAG AGAGGCCAAA AAGTACAACC TCACATCAAC CAATAGGCCG 8 GAGGAGGAAG CTAGAGGAAT AGTGATTAGA GACCCAATTG GGACCTAATT GGGACCCAAA 9 TTTCTCAAGT GGAGGGAGAA CTTTTGACGA TTTCCACCGG TATCTCCTCG TGGGTATTCA 9 GGGAGCTGCT CAGAAACCTA TAAACTTGTC TAAGGCGACT GAAGTCGTCC AGGGGCATGA 10 TGAGTCACCA GGAGTGTTTT TAGAGCACCT CCAGGAGGCT TATCAGATTT ACACCCCTTT 10 TGACCTGGCA GCCCCCGAAA ATAGCCATGC TCTTAATTTG GCATTTGTGG CTCAGGCAGC 11 CCCAGATAGT AAAAGGAAAC TCCAAAAACT AGAGGGATTT TGCTGGAATG AATACCAGTC 12 AGCTTTTAGA GATAGCCTAA AAGGTTTTTG ACAGTCAAGA GGTTGAAAAA CAAAAACAAG 12 CAGCTCAGGC AC-CTGAAAAA AGCCACTGAT AAAGCATCCT GGAGTATCAG AGTTTACTGT 13 TAGATCAGCC TCATTTGACT TCCCCTCCCA CATGGTGTTT AAATCCAGCT ACACTACTTC 13 CTGACTCAAA CTCCACTATT CCTGTTCATG ACTGTCAGGA ACTGTTGGAA ACTACTGAAA 14 CTGGCCGACC TC-ATCTTCAA AATGTGCCCC TAGGAAAGGT GGATGCCACC ATGTTCACAG 15 ACAGTAGCAG CT CCTCGAG AAGGGACTAC GAAAGGCCGG TGCAGCTGTT ACCATGGAGA 15 CAGATGTGTT GTGGGCTCAG GCTTTACCAG CAAACACCTC AGCACAAAAG GCTGAATTGA 16 TCGCCCTCAC TCAGGCTCTC CGATGGGGTA AGGATATTAA CGTTAACACT GACAGCAGGT 16 ACGCCTTTGC TA TGTGCAT GTACGTGGAG CCATCTACCA GGAGCGTGGG CTACTCACCT 17 CAGCAGGTGG CTGTAATCCA CTGTAAAGGA CATCAAAAGG AAAACACGGC TGTTGCCCGT 18 GGTAACCAGA AAGCTGATTC AGCAGCTCAA GATGCAGTGT GACTTTCAGT CACGCCTCTA 18 AACTTGCTGC CCACAGTCTC CTTTCCACAG CCAGATCTGC CTGACAATCC CGCATACTCA 19 ACAGAAGAAG AAAACTGGCC TCAGAACTCA GAGCCAATAA AAATCAGGAA GGTTGGTGGA 19 TTCTTCCTGA CTCTAGAATC TTCATACCCC GAACTCTTGG GAAAACTTTA ATCAGTCACC 20 TACAGTCTAC CACCCATTTA GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTTTTA 21 AGATCCCCCA T TTCAAAGC CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC 21 AGGTAAATGC CAAAAAAGGT CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC 22 CAGGAGAAAA GTGGGAAATT GACTTTACAG AAGTAAAACC ACACCGGGCT GGGTACAAAT 22 ACCTTCTAGT ACTGGTAGAC ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG 23 AAACTGTCAA TATGGTAGTT AAGTTTTTAC TCAATGAAAT CATCCCTCGA CATGGGCTGC 24 CTGTTTGCCA TAGGGTCTGA TAATGGACCG GCCTTCGCCT TGTCTATAGT .TTAGTCAGTC 24 AGTAAGGCGT TAAACATTCA ATGGAAGCTC CATTGTGCCT ATCGACCCCA GAGCTCTGGG 25 CAAGTAGAAC GCATGAACTG CACCCTAAAA AACACTCTTA CAAAATTAAT CTTAGAAACC 25 GGTGTAAATT GTGTAAGTCT CCTTCCTTTA GCCCTACTTA GAGTAAGGTG CACCCCTTAC 26 TGGGCTGGGT TCTTACCTTT TGAAATCATG TATGGGAGGG TGCTGCCTAT CTTGCCTAAG 27 CTAAGAGATG CCCAATTGGC AAAAATATCA CAAACTAATT TATTACAGTA CCTACAGTCT 27 CCCCAACAGG TACAAGATAT CATCCTGCCA CTTGTTCGAG GAACCCATCC CAATCCAATT 28 CCTGAACAGA CAGGGCCCTG CCATTCATTC CCGCCAGGTG ACCTGTTGTT TGTTAAAAAG 288 TTCCAGAGAG AAGGACTCCC TCCTGCTTGG AAGAGACCTC ACACCGTCAT CACGATGCCA 294 ACGGCTCTGA AGGTGGATGG CATTCCTGCG TGGATTCATC ACTCCCGCAT CAAAAAGGCC 300 AACAGAGCCC AACTAGAAAC ATGGGTCCCC AGGGCTGGGT CAGGCCCCTT AAAACTGCAC 306 CTAAGTTGGG TGAAGCCATT AGATTAATTC TTTTTCTTAA TTTTGTAAAA CAATGCATAG_312_CTTCTGTCAA ACTTATGTAT CTTAAGACTC AATATAACCC CCTTGTTATA ACTGAGGAAT 318 CAATGATTTG ATTCCCCCAA AAACACAAGT GGGGAATGTA GTGTCCAACC TGGTTTTTAC 324 TAACCCTGTT TTrAGACTCT CCCTTTCCTT TAATCACTCA GCTTGTTTCC ACCTGAATTG 330 ACTCTCCCTT AGCTAAGAGC GCCAGATGGA CTCCATCTTG GCTCTTTCAC TGGCAGCCGC 336 TTCCTCAAGG ACTTAACTTG TGCAAGCTGA CTCCCAGCAC ATCCAAGAAT GCAATTAACT 342 GATAAGATAC TG GGCAAGC TATATCCGCA GTTCCCAGGA ATTCGTCCAA TTGATCACAG 348 CCCCTCTACC CTTCAGCAAC CACCACCCTG ATCAGTCAGC AGCCATCAGC ACCGAGGCAA 3540 GGCCCTCCAC CAGCAAAAAG ATTCTGACTC ACTGAAGACT TGGATGATCA TTAGTATTTT 360 TAGCAGTAAA GTTTTTTT TT CTTTTTTTTT CTTTTTTTTCT CGTGCC 364 (2) I NFORMATION FOR SEQ ID NO: 228: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 41 9 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: cDNA (vi) ORIGINAL ORIGINAL ENERGY: (A) ORGAN ISMO: Homo sapiens (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 228: TAAGAGGGTA CAAGATCTAA GCACAGCCGT CAATGCAGAA CACAGAACGT AGCCTGGTAA 60 GTGTGTTAAG AGTGGGAATT TTTGGAGTAC AGAGTAAGGC ACCTAACCCT AGCTGGGGTT 120 TGGTGACGGT CCCAGATGGC TTACAGAAGA AAGTGTCCTG AGATGAGTTT TTAAGAATGA 180 ATAAGGATAG ACACAAGTGA GGACTGACTT GGCAGTGGTG AATGGTGGGT GGCAAAAAAC 240 TTCGCATGTA TGGAAACTGC ACGTACAGGA ATGAAGAATG AGACTGTGTG GTGTTTAATG 300 AGCTGCAAAT ACTAATTTTA TCCTGAAAGT TTTGAAGAGT TAACTAAAAA GTATTTTTTA 360 GTAAGGAAAT AACCCTACAT TTCAGGGTTA TTGTTTGTTT ANATATTGAA GGTGCCCAA 419 (2) I NFORMATION FOR SEQ ID NO: 229: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 148 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (I) TI PO OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 229: AAGAGGGTAC CTGTATGTAG CCATGGTGGC AATGAGAGAC TGATTACTAC CTGCTGGAGA 60 TTGTTTAAGT GAGTTAATAT ATTAAGGATA AAGGGAGCCA GGTTTTTTTGA CTGTTGGAGA 120 AGGAAATTAC AGATATTGAA GGTCCCAA 148 (2) INFORMATION FOR SEQ ID NO: 230: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 257 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 230: TAAGAGGGTA CMAAAAAAAA AAAATAGAAC GAATGAGTAA GACCTACTAT TTGATAGTAC 60 AACAGGGTGA CTATAGTCAA TGATAACTTA ATTATACATT TAACATAGAG TGTAATTGGA 120 TTGTTTGTAA CTCGAAGGAT AAATGCTTGA GAGGATGGAT ACCCCATTCT CCATGATGTA 180 CTTATTTCAC ATTACATGCC TGTATCAAAG CATCTCATAT ACCCTATAAA TATGTACACC 240 TACTATGTAC CCTCTTA 257 (2) INFORMATION FOR SEQ ID NO: 231: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 231 Í44 TAAGAGGGTA CGGGTATTTG CTGATGGGAT TTTTTTTTTCT TTCTTTTTCT TTGGAAAACA 60 AAATGAAAGC CAGAACAAAA TTATTGAACA AAAGACAGGG ACTAAATCTG GAGAAATGAA 120 GTCCCCTCAC CTGACTGCCA TTTCATTCTA TCTGACCTTC CAGTCTAGGT TAGGAGAATA 180 GGGssTGGAG GGGATTAATC TGATACAGGT ATATTTAAAG CAACTCTGCA TGTGTGCCAG 240 AAGTCCATGG TACCCTCTTA 260 (2) INFORMATION FOR SEQ ID NO: 232: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 596 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 232: TGCTCCTCTT GCCTTACCAA CCACAAATTA GAACCATAAT GAGATGTCAC CTCATACCTG 60 GTGGGATTAA CATTATTTAA AAAATCAGAA GTATTGACAA GGATGTGAAG AAATTAGAAC 120 ATCTGTGCAC TGTTGGTGGG AATGTAAAAA AGGTGTGGCC ACTATGGGTA ACAGCATGAA 180 GGTTCCTCAA AAAAAATTTT TTTTAATCTA CTCTATGATC GATCTTGAGO TTGTTTATGC 240 AAAAGAACTG AAATCAGGAT TTTGAGGAAA TATTCACATT CCCACATCCA TTTCTGCTTT 300 ATTCATAATA CTCAAGAGAT GGAAACAACC TAAATGTCCA TCCCGGGATG AATGGATAAA 360 CACAGTGTGG TATATGCATA CAATGGAATA TTATTTAGTC TTTAAAAAGA AAAATTCTAT 420 CATATACTAC AACTTANATN AACCTTGAGG ACACAATGCT NAGTGAAATA AGCCACGGAA 48 GGACGAATAC TGCATTATTC CCTTATATGA AGTATCTAAA GTGGTCAAAC TCTTANAGCA 54 NAAAGTAAAA ATGGGTGGTT GCCANACAGT TGGTTAGGCN AGAAGANAAN CCTANT 59 (2) INFORMATION FOR SEQ ID NO: 233: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 96 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 233: TCTTCTGAAG ACCTTTCGCG ACTCTTAAGC TCGTGGTTGG TAAGGCAAGA GGAGCGTTGG 60 TAAGGCAAGA GGAGCGTTGG TAAGGCAAGA GGAGCA 96 (2) I NFORMATION FOR SEQ ID NO: 234: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 313 base pairs (B) TYPE: nucleic acid (C) FILAM ENTO: simple (D) TOPOLOGY: linear ( ii) TI PO OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGAN ISMO: Homo sapiens (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 234: TGTAAGTCGA GCAGTGTGAT GATAAAACTT GAATGGATCA ATAGTTGCTT CTTATGGATG 60 AGCAAAGAAA GTAGTTTCTT GTGATGGAAT CTGCTCCTGG CAAAAATGCT GTGAACGTTG 120AACAAAGAGT TTAGAGTAGT ACATAAATTT AGAATAGTAC ATAAACTTAG_180_AATAGTACAT AAACTTAGTA CATAAATAAT GCACOAAGCA GGGGCAGGGC TTGAGAGAAT 240 TGACTTCAAT TTGGAAAGAG TATCTACTGT AGGTTAGATG CTCTCAAACA GCATCACACT 300 GCTCGACTTA CAA 313 (2) I NFORMATION FOR SEQ ID NO: 235: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 550 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (ii) TI PO OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGAN ISMO: Homo sapiens (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 235: AACGAGGACA GATCCTTAAA AAGAATGTTG AGTGAAAAAA GTAGAAAATA AGATAATCTC 6 CAAAGTCCAG TAGCATTATT TAAACATTTT TAAAAAATAC ACTGATAAAA ATTTTGTACA 12 TTTCCACAAA ATACATATGG AAGCACAGCA GCATGAATGC CTATGGGRTT GAGGATAGGG 18 GTTGGGAGTA GGGATGGGGA TAAAGGGGGA AAATAAAACC AGAGAGGAGT CTTACACATT 24 TCATGAACCA AGGAGTATAA TTATTTCAAC TATTTGTACC WGAAGTCCAG AAAGAGTGGA 30 GGCAGAAGGG GGAGAAGAGG GCGAAGAAAC GTTTTTGGGA GAGGGGTTC ASAAGAGAGA 36 TTTTCGCGAT GTGGCGCTAC ATACGTTTTT CCAGGATGCC TTAAGCTCTG CACCCTATTT 42 TTCTCATCAC TAATATTAGA TTAAACCCTT TGAAGACAGC GTCTGTGGTT TCTCTACTTC 48 AGCTTTCCCT CCGTGTCTTG CACACAGTAG CTGTTTTACA AGGGTTGAAC TGACTGAAGT 54 GAGATTATTC 55 (2) I NFORMATION FOR SEQ ID NO: 236: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONGITU D: 325 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (ii) TI PO OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGAN ISMO: Homo sapiens (xi) DESCRI PTION OF SEQUENCE: SEQ ID NO: 236: TAGACTGACT CATGTCCCCT ACCAGAGTAG CTAGAATTAA TAGCACAAGC CTCTACACCC 6 AGGAACTCAC TATTGAATAC ATAAATGGAA TTTATTCAGC CTTAAAAAGT TTGGAAGGAA 12 ATTCTGACAT ATGCTAAAAC ATGGATGAAC CTTGAAGACT TTATGATAAG TAAAAGAAGC 18 CAGTCATAAA AGGAAAAATA TTGCATGATT CCACTTATAT GAGGTACCTA GAGTAGTCAA .24 TTTCATAGAA ACACAAAATA GAATGGTGTT TGCCAGGGCT TTTGAGGAAA AGGGAATGAC 30 AAGTTAGGGG ACATGAGTCA GTCTA 32 (2) I NFORMATION FOR SEQ ID NO: 237: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 373 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (ii) TI PO DE MOLÉCU LA: cDNA (vi) ORIGINAL ORIGINAL ENERGY: (A) ORGAN IS MO: Homo sapie ns (xi) DESC RI PTION OF SEQUENCE: SEQ ID NO: 237: TAGACTGACT CATGTCCCCT ATCTACTCAA CATTTCCACT TGAAGTCTGA TAGGCATCTC 6 AGACTTATCT TGTCCCAAAG CAAACTCTTT ATTTCTTTTC ATCCTAGTCT TTATTTCTTG 12 TGCTGTCTTA CCCATCTCAA AAGAGTGCCA AAATCCACCA AGTTGCTGAA ACAGAAATCT 18 AAGAAATATC CTTGATTCTT CTTTTTCCCA TCTACTTCAC TTCTAATTCA TTAGTAAATA 24 ATCTGTTTCA GAAAACCAAA CACCTCATGT TCTCACTCAT AAGGGGGGT TGAACAATGA 30 GAACACACAG ACACAGGGAG GGGAACATCA CACACCACGG CCCGTCAGGG AGTANGGGAC 36 ATGAGTCAGT CTA 373 (2) IN TRAINING FOR SEQ ID NO: 238: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 492 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (ii) TI PO DE MOLÉCU LA: cDNA (vi) ORIGINAL SOURCE: (A) ORGAN ISMO: Homo sapiens (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 238: TAGACTGACT CATGTCCCCT ATAATGCTCC CAGGCATCAG AAAGCATCTC AAACTGGAGC 60 TGACACCATG GCAGAGGTTT CAGGTAAGTC ACAAAAGGGG TCCTAAAGAA TTTGCCCTCA 120 ATATCAGAGT GATTAGAAGA AGTGGACAGA GCTACCCAAG TTAAACATAT GCGAGATAAA 180 AAAAATATGG CACTTGTGAA CACACACTAC AGGAGGAAAA TAAGGAACAT AATAGCATAT 240 TGTGCTATTA TGATGATGAA GAACCTCTCT ANAAGAAAAC ATAACCAAAG AAACAAAGAA 300 AATTCCTGCN AATGTTTAAT GCTATAGAAG AAATTAACAA AAACATATAT TCAATGAATT 360 CAGAAAAGTT AGCAGGTCAN AAGAAAACAA ATCAAAGACC AGAATAATCC CATTTTAGAT 420 TGTCGAGTAA ACTANAACAG AAAGAATACC ACTGGAAATT GAATTCCTAC GTANGGGACA 480 TGANTCANTC TA 492 (2) I NFORMATION FOR SEQ ID NO: 239: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 482 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (ü) TI PO DE MOLÉCU LA: cDNA (vi) WAS NTE ORIGINAL: (A) ORGAN I SMO: Hom o sapiens (xi) SECURITY DESCRITION: SEQ ID NO: 239: TGGAAAGTAT TTAATGATGG GCAACTTGCT GTTTACTTCC TACATATCCC ATCATCTTCT 60 GTATTTTTTT AAATAACTTT TTTTTGGATT TTTAAAGTAA CCTTATTCTG AGAGGTAACA 120 TGGATTACAT ACTTCTAAGC CATTAGGAGA CTCTATGTTA AACCAAAAGG AAATGTTACT 180 AGATCTTCAT TTGATCAATA GGATGTGATA ATCATCATCT TTCTGCTCTA ATGGAAAAGT 240 ACTANAAACA TGGAACCATA ATCTTAGATG AACAACGTTA GAATTTGCAC TAATTCTACG 300 GAATTTCAGT AATTCGGCAA ATGTCGGGCA GTGACACAAC ATTTCATGAC GGGGACGCAT 360 CTACCAACTT CTGGCGATAA GGGCCACCCT TCCCTCTGTA CTTACAGTCC CATTTCATAC 420 ACAGTCTTTG ATTAAATATT CACATTTTTT CTCTACCTAA AGACCTTCAA GACCAGTACG 480 TA 482 (2) INFORMATION FOR SEQ ID NO: 240: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 519 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( ii) TI PO OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGAN ISMO: Homo sapiens (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 240: TGTATCGACG TAGTGGTCTC CCCATGTGAT AGTCTGAAAT ATAGCCTCAT GGGATGAGAG 6 GCTGTGCCCC AGCCCGACAC CCGTAAAGGG TCTGTGCTGA GGTGGATTAG TAAAAGAGGA 12 AAGCCTTGCA GTTGAGATAG AGGAAGGGCA CTGTCTCCTG CCTGCCCCTG GGAACTGAAT 18 GTCTCGGTAT AAAACCCGAT TGTACATTTG TTCAATTCTG AGATAGGAGA AAAACCACCC 24 TATGGCGGGA GGCGAGACAT GTTGGCAGCA ATGCTGCCTT GTTATGCTTT ACTCCACAGA 30 TGTTTGGGCG GAGGGAAACA TAAATCTGGC CTACGTGCAC ATCCAGGCAT AGTACCTCCC 36 TTTGAACTTA ATTATGACAC AGATTCCTTT GCTCACATGT TTTTTTGCTG ACCTTCTCCT 42 TATTATCACC CTGCTCTCCT ACCGCATTCC TTGTGCTGAG ATAATGAAAA TAATATCAAT 48 AAAAACTTGA NGGAACTCGG AGACCACTAC GTCGATACA 51 (2) I NFORMATION FOR SEQ ID NO: 241 (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 771 base pairs (B) TYPE: nucleic acid (C) FILAM ENTO: simple (D) TOPOLOGY: linear (ii) MOLECULE TI PO: cDNA (vi) ORIGINAL ORGANISM: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRITION: SEQ ID NO: 241: TGTATCGACG TAGTGGTCTC CACTCCCGCC TTGACGGGGC TGCTATCTGC CTTCCAGGCC 60 ACTGTCACGG CTCCCGGGTA GAAGTCACTT ATGAGACACA CCAGTGTGGC CTTGTTGGCT 120 TGAAGCTCCT CAGAGGAGGG TGOGAACAGA GTGACCGAGG GGGCAGCCTT GGGCTGACCT 180 AGGACGGTCA GCTTGGTCCC TCCGCCAAAC ACGAGAGTGC TGCTGCTTGT ATATGAGCTG 240 CAGTAATAAT CAGCCTCGTC CTCAGCCTGG AGCCCAGAGA TGGTCAGGGA GGCCGTGTTG 300 CCANACTTGG AGCCAGAGAA GCGATTAGAA ACCCCTGAGG GCCGATTACC GACCTCATAA 360 ATCATGAATT TGGGGGCTTT GCCTGGGTGC TGTTGGTACC ANGAGACATT ATTATAACCA 420 CCAACGTCAC TGCTGGTTCC ANTGCAGGGA AAATGGTTGA TCNAACTGTC CAAGAAAACC 480 ACTACGTCCA TACCAATCCA CTAATTGCCN GCCGCCTGCA GGTTCAACCA TATTGGGGAA 540 NAACTCCCCN CCGCCGTTTG GGATTGNCAT NAACCTTTGA AATTTTTTCC TATTANTTGT 60 CCCCCTAAAA TAAACCNTTG GGCNTTAATC CATTGGGTCC ATANCTTNTT TNCCCGGTTT 660 TTAAAANTTG TTTATCCCGC CNCCCNATTT CCCCCCCAAC TTTCCAAAAC CCGAAACCNT 720 TNAAATTTNT TNAAACCCTG GGGGGTTCCC NNAATTNNAN TTNAANCTNC C 771 (2) I NFORMATION FOR SEQ ID NO: 242: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 167 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( ii) TYPE OF MOLECULA: cDNA (vi) ORIGINAL SOURCE: (A) ORGAN ISMO: Homo sapiens (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 242: TGGGCACCTT CAATATCGGG CTCATCGATA ACATCACGCT GCTGATGCTG CTGTTGCTGG 6 TCCTCTCTAG GAACCTCTGG ATTTTCAAAT TCTTTGAGGA ATTCATCCAA ATTATCTGCC 12 TCTCCTCCTT TCCTCCTTTT TCTAAGGTCT TCTGGTACAA GCGGTCA 16 (2) I NFORMATION FOR SEQ ID NO: 243: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 338 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TO POLOGY : linear (¡i) MOLÉCU LA TI: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRITION: SEQ ID NO: 243: TTGGGCACCT TCAATATCTA CTGATCTAAA TAGTGTGGTT TGAGGCCTCT TGTTCCTGGC 6 TAAAAATCCT TGGCAAGAGT CAATCTCCAC TTTACAATAG AGGTAAAAAT CTTACAATGG 12 ATATTCTTGA CAAAGCTAGC ATAGAGACAG CAATTTTACA CAAGGTATTT TTCACCTGTT 18 TAATAACAGT GGTTTTTCCTA CACCCATAGG GTGCCACCAA GGGAGGAGTG CACAGTTGCA 24 GAAACAAATT AAGATACTGA AGACAACACT ACTTACCATT TCCCGTATAG CTAACCACCA 30 GTTCAACTGT ACATGTATGT TCTTATGGGC AATCAAGA 33 (2) I NFORMATION FOR SEQ ID NO: 244: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 346 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linearF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) DESCRIPTION OF SEQUENCE: SEQ I D NO: 244: TTTTTGGCTC CCATACAGCA CACTCTCATG GGAAATGTCT GTTCTAAGGT CAACCCATAA 6 TGCAAAAATC ATCAATATAC TTGAAGATCC CCGTGTAAGG TACAATGTAT TTAATATTAT 12 CACTGATACA ATTGATCCAA TACCAGTTTT AGTCTGGCAT TGAATCAAAT CACTGTTTTT 18 GTTGTATAAA AAGAGAAATA TTTAGCTTAT ATTTAAGTAC CATATTGTAA GAAAAAAGAT 24 GCTTATCTTT ACATGCTAAA ATCATGATCT GTACATTGGT GCAGTGAATA TTACTGTAAA 30 AGGGAAGAAG GAATGAAGAC GAGCTAAGGA TATTGAAGGT GCCCAA 34 (2) I NFORMATION FOR SEQ ID NO: 245: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 521 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (ii) TI MOLECULE PO: cDNA (vi) ORIGINAL ENTITY: (A) ORGANI SMO: Homo sapiens (xi) SECTION DECLARATION: SEQ ID NO: 245: ACCAATCCCA CACGGATACT GAGGGACAAG TATATCATCC CATTTCATCC CTACAGCAGC 60 AACTTCATGA GGCAGGAGTT ATTAGTCCCA TTTTACAGAA GAGGAAACTG AGACTTAGGG 12 AGATCAAGTA ATTTGCCCAG GTCGCACAAT TAGTGATAGA GCCAGOGCTT GAAGCGACGT 180 CTGTCTTAAG CCAATGACCC CTGCAGATTA TTAGAGCAAC TGTTCTCCAC AACAGTGTAA 240 GCCTCTTGCT ANAAGCTCAG GTCCACAAGG GCAGAGATTT TTGTCTGTTT TGCTCATTGC 300 TCCTTCCCCA TTGCTTAGAG CAGGGTCTGC CACGAANCAG GTTCTCAATG CATAGTTATT 36 AAATGTATAT AAGAGCAAAC ATATGTTACA GAGAACTTTC TGTATGCTTG TCACTTACAT 420 GAATCACCTG TGANATGGGT ATGCTTGTTC CCCANTGTTG CAGATNAAGA TATTGAANGT 480 GCCCAAATCA CTANTTGCGG GCGCCTGCAN GTCCANCATA T 521 (2) INFORMATION FOR SEQ ID NO: 246: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 482 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 246: TGGAACCAAT CCAAATACCC ATCAATGATA GACTGGATAA AGAAAATTTG GCACATGTTC 60 ACCATGAAAT ACTATGCAGC CATAAAAAAG GATGAGTTCA TATCCTTTGC AGGGACATGG 120 ATGAAGCTGG AGACCATCAT TCTCAGCAAA CTAACAAGGG AACAGAAAAC CAAACACTGC 180 ATGTTCTCAC TCTTAAGTGG GAGCTGAACA ATGAGAACAC ATGGACACAG GGAGGGGAAC 240 ATCACACAGT GGGGCCTGCT GGTGGGTAGG GGTCTAGGGG AGGGATAGCA TTAGGAGAAA 300 TACCTAATGT AGATOACGGG TTGATGGGTG CAGCAAACCA CCATGACACG TGTATACCTA 360 TGTAACAAAC CTGCATGTTC TGCACATGTA CCCCAGAACT TAAAGTGTTA ATAAAAAAAT 420 TAAGAAAAAA GTTAAGTATG TCATAGATAC ATAAAATATT GTANATATTG AAGGTGCCCA 480 AA 48 (2) I NFORMATION FOR S EQ ID NO: 247: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 474 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (ü) TI PO DE MOLÉCU LA: cD NA (vi) ORIGINAL ORIGINAL ENERGY: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRITION: SEQ ID NO: 247: TTCGATACAG GCACAGAGTA AGCAGAAAAA TGGCTGTGGT TTAACCAAGT GAGTACAGTT 6 AAGTGAGAGA GGGGCAGAGA AGACAAGGGC ATATGCAGGG GGTGATTATA ACAGGTGGTT 12 GTGCTGGGAA GTGAGGGTAC TCGGGGATGA GGAACAGTGA AAAAGTGGCA AAAAGTGGTA 18 AGATCAGTGA ATTGTACTTC TCCAGAATTT GATTTCTGGN GGAGTCAAAT AACTATCCAG 24 TTTGGGGTAT CATANGGCAA CAGTTGAGGT ATAGGAGGTA GAAGTCNCAG TGGGATAATT 30 GAGGTTATGA ANGGTTTGGT ACTGACTGGT ACTGACAANG TCTGGGTTAT GACCATGGGA 36 ATGAATGACT GTANAAGCGT ANAGGATGAA ACTATTCCAC GANAAAGGGG TCCNAAAACT 42 AAAAANNNAA GNNNNNGGGG AATATTATTT ATGTGGATAT TGAANGTGCC CAAA 47 (2) INFORMATION FOR SEQ ID NO: 248: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 355 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 248: TTCGATACAG GCAAACATGA ACTGCAGGAG GGTGGTGACG ATCATGATGT TCCCGATGGT 6 CCGGATGGNC ACGAAGACGC ACTGGANCAC GTGCTTACGT CCTTTTGCTC TGTTGATGGC 12 CCTGAGGGGA CGCAGGACCC TTATGACCCT CAGAATCTTC ACAACGGGAG ATGGCACTGG 18 ATTGANTCCC ANTGACACCA GAGACACCCC AACCACCAGN ÁTATCANTAT ATTGATGTAG_24_TTCCTGTAGA NGGCCCCCTT GTGGAGGAAA GCTCCATNAG TTGGTCATCT TCAACAGGAT 30 CTCAACAGTT TCCGATGGCT GTGATGGGCA TAGTCATANT TAACCNTGTN TCGAA 35 (2) IN TRAINING FOR SEQ ID NO: 249: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 434 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 249: TTGGATTGGT CCTCCAGGAG AACAAGGGGA AAAAGGTGAC CGAGGGCTCC CTGGAACTCA 6 AGGATCTCCA GGAGCAAAAG GGGATGGGGG AATTCCTGGT CCTGCTGGTC CCTTAGGTCC 12 ACCTGGTCCT CCAGGCTTAC CAGGTCCTCA AGGCCCAAAG GGTAACAAAG GCTCTACTGG 18 ACCCGCTGGC CAGAAAGGTG ACAGTGGTCT TCCAGGGCCT CCTGGGCCTC CAGGTCCACC 24 TGGTGAAGTC ATTCAGCCTT TACCAATCTT GTCCTCCAAA AAAACGAGAA GACATACTGA 30 AGGCATGCAA GCAGATGCAG ATGATAATAT TCTTGATTAC TCGGATGGAA TGGAAGAAAT 36 ATTTGGTTCC CTCAATTCCC TGAAACAAGA CATCGAGCAT ATGAAATTTC CAATGGGTAC TCAGACCAAT 42 CCAA 43 (2) I NFORMATION FOR SEQ ID NO: 250: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONGITU D: 430 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 250: TGGATTGGTC ACATGGCAGA GACAGGATTC CAAGGCAGTG AGAGGAGGAT ACAATGCTTC 6 TCACTAGTTA TTATTATTTA TTTTATTTTT GAGATGAAGT CTCGCTTTGT CTCCCAGGCT 12 GGAGAGCGGT GGTGCGATCT TGGCTCTCTG CAACCCCCGC CTCAAGCAAT TCTCCTGTCT 18 TAGCCTCGCG GGTAGATGGA ATTACAGGCG CCCACCGCCA TGCCCAACTA ATTTTTTTTT 24 GTCTTCAGTA GAGACAOGGT TTCGCCATGT TGGGCAGGCT GGTCTTGAAC TCCTGACCTC 30 NAGTGATCTG CCCTCCTCGG CCTCACAAAG TGCTGGAATT ACAGGCATGG GCTGCTGCAC 36 CCAGTCAACT TCTCACTAGT TATGGCCTTA TCATTTTCAC CACATTCTAT TGGCCCAAAA 42 AAAAAAAAAN 43 (2) I NFORMATION FOR S EQ ID NO: 251: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 329 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) descri PTION Secu GUM: SEQ ID NO: 251: TGGTACTCCA CCATYATGGG GTCAACCGCC ATCCTCGCCC TCCTCCTGGC TGTTCTCCAA 6 GGAGTCTGTG CCGAGGTGCA GCTGRTGCAG TCTGGAGCAG AGGTGAAAAA GTCCGGGGAG 12 TCTCTGAAGA TCTCCTGTAA GGGTTCTGGA TACACCTTTA AGATCTACTG GATCGCCTGG 18 GTGCGCCAGT TGCCCGGGAA AGGCCTGGAG TGGATGGGGC TCATCTTTCC TGATGACTCT 24 GATACCAGAT ACAGCCCGTC CTTCCAAGGC CAGGTCACCA TCTCAGTCGA TAAGTCCATC 30 AGCACCGCCT ATCTGCAGTG GAGTACCAA 32 (2) IN TRAINING FOR S EQ ID NO: 252: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 536 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) ) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 252: TGGTACTCCA CTCAGCCCAA CCTTAATTAA GAATTAAGAG GGAACCTATT ACTATTCTCC 60 CAGGCTCCTC TGCTCTAACC AGGCTTCTGG GACAGTATTA GAAAAGGATG TCTCAACAAG 120 TATGTAGATC CTGTACTGGC CTAAGAAGTT AAACTGAGAA TAGCATAAAT CAGACCAAAC 180 TTAATGGTCG TTGAGACTTG TGTCCTGGAG CAGCTGGGAT AGGAAAACTT TTGGGCAGCA 240 AGAGGAAGAA CTGCCTGGAA GGGGGCATCA TGTTAAAAAT TACAAGGGGA ACCCACACCA 300 GGCCCCCTTC CCAGCTCTCA GCCTAGAGTA TTAGCATTTC TCAGCTAGAG ACTCACAACT 360 TCCTTGCTTA GAATGTGCCA CCGGGGGGAG TCCCTGTGGG TGATGAGGCT CTCAAGAGTG 420 AGAGTGGCAT CCTATCTTCT GTGTGCCCAC AGGAGCCTGG CCCGAGACTT AGCAGGTGAA 480 GTTTCTGGTC CAGGCTTTGC CCTTGACTCA CTATGTGACC TCTGGTGGAG TACCAA 536 (2) I NFORMATION FOR SEQ ID NO: 253: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 507 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 253: NTGTTGCGAT CCCAGTAACT CGGGAAGCTG AGGCGGGAGG ATCACCTGAG CTCAGGAGGT 60 TGAGGCCGCA GTGAGCCGGG ACCACGCCAC TACACTCCAG CCTGGGGCAT AGAGTGAGAC 120 CCTCCAAGAC AGAAAAGAAA AGAAAGGAAG GGAAAGGGAA AGGGAAAAGG AAAAGGAAAA 180 GGAAAAGGAA AAGGAAAAGA CAAGACAAAA CAAGACTTGA ATTTGGATCT CCTGACTTCA 240 ATTTTATGTT CTTTCTACAC CACAATTCCT CTGCTTACTA AGATGATAAT TTAGAAACCC 300 CTCGTTCCAT TCTTTACAGC AAGCTGGAAG TTTGGTCAAG TAATTACAAT AATAGTAACA 360 AATTTGAATA TTATATGCCA GGTGTTTTTC ATTCCTGCTC TCACTTAATT CTCACCACTC 420 TGATATAAAT ACAATTGCTG CCGGGTGTGG TGGCTCATGC CTGTAATCCC GGCACTTTGG 480 GAGACCGAGG TGGGCGGATS GCAACAA 507 (2) INFORMATION FOR SEQ ID NO: 254: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 222 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRI SEQUENCE PION: SEQ ID NO: 254: TTGGATTGGT CACTGTGAGG AAGCCAAATC GGATCCGAGA GTCTTTTTCT AAAGGCCA.GT 6 ACTGGCCACA CTTTCTCCTG CCGCCTTCCT CAAAGCTGAA GACACACAGA GCAAGGCGCT 12 TCTGTTTTAC TCCCCAATGG TAACTCCAAA CCATAGATGG TTAGCTNCCC TGCTCATCTT 18TGCTATTCAG TATAGTCCGT GGACCAATCC AA 22 (2) INFORMATION FOR SEQ ID NO: 255: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 463 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear 10 (x) ) SEQUENCE DESCRIPTION: SEQ ID NO: 255: TGTTGCGATC CATAAATGCT GAAATGGAAA TAAACAACAT GATGAGGGAG GATTAAGTTG 6 GGGAGGGAGC ACATTAAGGT GGCCATGAAG TTTGTTGGAA GAAGTGACTT TTGAACAAGG 12 CCTTGGTGTT AAGAGCTGAT GAGAGTGTCC CAGACAGAGG GGCCACTGGT ACAATAGACG 18 AGATGGGAGA GGGCTTGGAA GGTGTGCGAA ATAGGAAGGA GTTTGTTCTG GTATGAGTCT 24 AGTGAACACA GAGGCGAGAG GCCCTGGTGG GTGCAGCTGG AGAGTTATGC AGAATAACAT 30 TAGGCCCTGT GGGGGACTGT AGACTGTCAG CAATAATCCA CAGTTTGGAT TTTATTCTAA 36 GAGTGATGGG AAGCCGTGGA AAGGGGGTTA AGCAAGGAGT GAAATTATCA GATTTACAGT 42 GATAAAAATA AATTGGTCTG GCTACTGGGG AAAAAAAAAA AAA 46 (2) I NFORMATION FOR SEQ ID NO: 256: 15 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 262 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear 20 (xi) SEQUENCE DESCRITION: SEQ ID NO: 256: TTGGATTGGT CAACCTGCTC AACTCTACYT TTCCTCCTTC TTCCTAAAAA ATT ATGAAT 6 CCAATACATT AATGCCAAAA CCCTTGGGTT TTATCAATAT TTCTGTTAAA AAGTATTATC 12 CAGAACTGGA CATAATACTA CATAATAATA CATAACAACC CCTTCATCTG GATGCAAACA 18 TCTATTAATA TAGCTTAAGA TCACTTTCAC TTTACAGAAG CAACATCCTG TTGATGTTAT 24 TTTGATGTTT GGACCAATCC AA 26 (2) INFORMATION FOR SEQ ID NO: 257: (i) CHARACTERISTICS OF THE SECU ENCIA: z > (A) LENGTH: 461 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 257: GNGGNNNNNN NNNCAATTCG ACTCNGTTCC CNTGGTANCC GGTCGACATG GCCGCGGGAT 60 TACCGCTTGT NNCTGGGGGT GTATGGGGGA CTATGACCGC TTGTAGCTGG GGGTGTATGG 120 GGGACTATGA CCGCTTGTAG MTGGKGGTGT ATGGGGGACT ATGACCGCTT GTCGsGTGGT 180 CGGATAAACC GACGCAAGGG ACGTGATCGA AGCTGCGTTC CCGCTCTTTC GCATCGGTAG_24_GGATCATGGA CAGCAATATC CGCATTCGYC TGAAGGCGTT CGACCATCGC GTGCTCGATC 30 AGGCGACCGG CGACATCGCC GACACCGCAC GCCGTACCGG cscscTCATC CGCGGTCCGA 36 TCCCGCTTCC CACGCGCATC GAGAAGTTCA CGGTCAACCG TGGCCCGCAC GTCGACAAGA 42 AGTCGCGCGA GCAGTTCGAG GTGCGTACCT ACAAGCGGTC A 46 (2) INFORMATION FOR SEQ ID NO: 258: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 332 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRI SECTION: SEQ ID NO: 258: TGACCGCTTG TAGCTGGGGG TGTATGGGGG ACTACGACCG CTTGTAGCTG GGGGTGTATG 60 GGGGACTATG ACCGCTTGTA GCTGGGGGTG TATGGGGGAC TATGACCGCT TGTAGCTGGG 120 GGTGTATGGG GGACTAGGAC CGCTTGTAGC TGGGGGTGTA TGGGGGACTA TGACCGCTTG 180 TAGCTGGGGG TGTATGGGGG ACTACGACCG CTTGTAGCTG GGGGTGTATG GGGGACTATG 24 ACCGCTTGTA NCTGGGGGTG TATGGGGGAC TATGACCGCT TGTGCTGCCT GGGGGATGGG 30 AGGAGAGTTG TGGTTGGGGA AAAAAAAAAA AA 33 (2) I NFORMATION FOR SEQ ID NO: 259: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 291 base pairs (B) TYPE: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) DESCRI SEQUENCE PC: SEQ ID NO: 259: TACCGCTTGT GACCGCTTGT GACCGCTTG GACCGCTTGT GACCGCTTGT GACCGCTTGT 60 GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT 120 GACCGCTTGT GACCGCTTGT NACNGGGGGT GTCTGGGGGA CTATGANNGA NTGTNACTGG 180 GGGTGTCTGG GGGNCTATGA NNGANTGTNA CNGGGGGTGT CTGGGGGACT ATGANNGACT 240 GTGCNNCCTG GGGGATCNGA GGAGANTNGN GGNTAGNGAT GC-TTNGGGAN A 291 (2) I NFORMATION FOR S EQ ID NO: 260: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 238 base pairs (B) TI PO: nucleic acid (C) ) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 260: TAAGAGGGTA CTGGTTAAAA TACAGGAAAT CTGGGGTAAT GAGGCAGAGA ACCAGGATAC 6 TTTGAGGTCA GsGATGAAAA CTAGAATTTT TTTCTTTTTT TTTGCCTGAG AAACTTGCTG 12 CTCTGAAGAG GCCCATGTAT TAATTGCTTT GATCTTCCTT TTCTTACAGC CCTTTCAAGG 18 GCAGAGCCCT CCTTATCCTG AAGGAATCTT ATCCTTAGCT ATAGTATGTA CCCTCTTA 23 (2) INFORMATION FOR SEQ ID NO.261: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 746 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 261: TTGGGCACCT TCAATATCAA TAGCTAACAT TTATTGAGTG TTTATCGTAT CATAAAACAC 6CTTTAAACGT ACTAATTCAT TTAATGCTCA TAATCACTTT AGAAGGTGGG 12 TACTAGTATT AGTCTCATTT ACAGATGCAA CATGCAGGCA CAGAGAGGTT AATTAACTTG 18 CCCAAGGTAA CACAGCTAAG AAATAGAAAA AATATTGAAT CTGGAAAGTT GGGCTTCTGG 24 GTAACCCACA GAGTCTTCAA TGAGCCTGGG GCCTCACTCA GTTTGCTTTT ACAAAGCGAA 30 TGAGTAACAT CACTTAATTC AGTGAGTAGG CCAAATGGAG GTCAGCTACG AGTTTCTGCT 36 GTTCTTGCAG TGGACTGACA GATGTTTACA ACGTCTGGCC ATCAGTWAAT GsACTGATTA 42 TCATTGGGAW GTGGGTGGGC TGAATGTTGG CCAGTGAAGT TTATTCAWGC CATATTTTTA 48 TGTTTAGGAT GACTTTTGGC TGGTCCTAGG GCAAGCTCTG TCTGSCACGG AACACAGAAT 54 WACACAGGGA CCCCCTCAAT TTCTGGTGTG GCTAGAACCA TGAACCACTG GTTGGGGGAA 60 CAAGCGGTCA AAACCTAAGT GCGGCCGGCT GGCAGGGTCC ACCCATATGG GGAAAACTCC 66 CNACGCGTTT GGAATGCCTN AGCTNGAATT ATTCTAANAG TTGTCCNCNT AAAATTAGCC 72 TGGGCGTTAA TCANGGGTCN NAAGCC 74 (2) INFORMATION FOR SEQ ID NO: 262: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 588 base pairs (B) TI PO, nucleic acid (C) FI LAM E NTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 262: TGACCGCTTG TCATCTCACA TGGGGTCCTG CACGCTTTTG CCTTTGTAGG AAACCTGACA 6 TTTGTCTGTT TCTTCTTTCT CTTTTCCTTC CCATATCCTC CTAATTTACG TTTGACTTGT 12 TTGCTGAGGA GGCAGGAGCT AGAGACTGCT GTGAGCTCAT AGGGGTGGGA AGTTTATCCT 18 TCAAGTCCCG CCCACTCATC ACTGCTTCTC ACCTTCCCCT GACCAGGCTT ACAAGTGGGT 24 TCTTGCCTGC TTTCCCTTTG GACCCAACAA 7CCCCTGTAA TGAGTGTGCA TGACTCTGAC 30 AGCTsTGGAC TCAGGGTCCT TGGCTACAGC TGCCATGTAA AATATCTCAT CCAGTTCTCG 36 CAAATTGTTA AAATAACCAC ATTTCTTAGA TTCCAGTACC CAAATCATGT CTTTACGAAC 42 TGCTCCTCAC ACCCAGAAGT GGCACAATAA TTCTTGGGGA ATTATTACTT TTTTTTTTCT 48 CTCTNTTNNC GNNNGNNNNG GNNNGNCCAG GAATTACCAC NTTGGAAGAC CTGGCCNGAA 54 TTTATTATAN AGGGGAGCCG ATTNTTTTTC CTAACACAAA GCGGGTCA 58 (2) INFORMATION FOR SEQ ID NO: 263: (i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 730 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESC RIPTION DI = SEQUENCE: SEQ ID NO: 263: '["i' '! * T ** m *" i'T TTTGGCCTGA GCAACTGAAA TTATGAAATT TCCATATACT CAAAAGAGTA 6 AGACTGCAAA AAGATTAAAT GTAAAAGTTG TCTTGTATAC AGTAATGTTT AAGATACCTA 12 TTANATTTAT AAATGGAAAA TTAGGGCATT TGGATATACA AGTTGAAAAT TCAGGAGTGA 18 GGTTGGGCTG GCTGGGTATA TACTGAAAAC TGTCAGTACA CAGATGACAT CTAAAACCAC 24 AAATCTGGTT TTATTTTAGC AGTGATATGT GTCACTCCCA CAAAAGCCTT CCCAATTGGC 30 CTCAGCATAC ACAACAAGTC ACCTCCCCAC AGCCCTCTAC ACATAAACAA ATTCCTTAGT 36 TTAGTTCAGG AGGAAATGCG CCCTTTTCCT TCCGCTCTAG GTGACCGCAA GGCCCAGTTC 42 TCGTCACCAA GATGTTAAGG GAAGTCTGCC AAAGAGGCAT CTGAAAGGAA ATAAGGGGAA 48 TGGGAGTGAC CACAAAGGAA AGCCAAGGAN AAACTTTGGA GACCGTTTCT AGANCCCTGG 54 CATTTCACAA CAAAACTCNG GAACAAACCT TGTCTCATCA ATCATTTAAG CCCTTCGTTT 60 GGANNAGACT TTCTGAACTG GGCGCTGAAC ATAANCCTCA TTGAATGTCT TCACAGTCTC 66 CCAGCTGAAG GCACACCTTG GGCCAGAAGG GGAATCTTCC AGGTCCTCAA NACAGGGCTC 72 GCCCTTTGNC 73 (2) INFORMATION FOR SEQ ID NO: 264: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 715 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) DESCRI PCI SECTION: SEQ ID NO: 264: TTTTTTTTTT TTTGGCCAGT ATGATAGTCT CTACCACTAT ATTGAAGCTC TTAGGTCATT 6 TACACTTAAT GTGGTTATAG ATGCTGTTGA GCTTACTTCT ACCACCTTGC TATTTCTCCC 12 GTCTCTTTTT TGTTCCTTTT CTCTTCTTTT CCTCCCTTAT TTTATAATTG AATTTTTTAG_18_GATTCTATTT TATATAGATT TATCAGCTAT AACACTTTGT ATTCTTTTGT TTTGTGGTTC 24 TTCTGTCATT TCAATGTGCA TCTTAAACTC ATCACAATCT ATTTTCAAAT AATATCATAT 30 AACCTTACAT ATAATGTAAG AATCTACCAC CATATATTTC CATTTCTCCC TTCCATCCTA 36 TGTNTGTCAT ATTTTTTTCCT TTATATATGT TTTAAAGACA TAATAGTATA TGGGAGGTTT 42 TTGCTTAAAA TGTGATCAAT ATTCCTTCAA NGAAACGTAA AAATTCAAAA TAAATNTCTG 48 TTTATTCTCA AATNNACCTA ATATTTCCTA CCATNTCTNA TACNTTTCAA GAATCTGAAG 54 GCATTGGTTT TTTCCGGCTT AAGAACCTCC TCTAAAGCAC TCTAAGCAGA ATTAAGTCTT 60 CTGGGAGAGG AATTCTCCCA AGCTTGGGCC TTNANNTGTA CTCCNTNANG GTTAAANTTT 66 GGCCGGGAAA TAGAAATTCC AAGTTAACAG G TANTTTTT NTTTTTNTTN TCNCC 71 (2) I NFORMATION FOR SEQ ID NO: 265: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 1 52 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) DESCRI PTION OF SECU ENCIA: SEQ ID NO: 265: TTTTTTTTTTT TTTCCCAACA CAAAGCACCA TTATCTTTCC TCACAATTTT CAACATAGTT 6 TGATTCCCAT GAAGAGGTTA TGATTTCTAA AGAAAACATG GCTACTATAC TATCAATCAG 12 GGTTAAATCT TTTTTTTTTTG AGACGGAGTT TA 15 (2) I NFORMATION FOR SEQ ID NO: 266: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 93 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQ ID NO: 266: TAAACTCCGT CCCCTTCTTA ATCAATATGG AGGCTACCCA CTCCACATTA CCTTCTTTTC 6 AAGGGACTGT TTCCGTAACT GTTGTGGGTA TTCACGACCA GGCTTCTAAA CCTCTTAAAA 12 CTCCCCAATT CTGGTGCCAA CTTGGACAAC ATGCTTTTTT TTTTTTTTTT TTTTTTTTTN 18 GAGACGGAGT TTA 19 (2) IN FORMAC Y FOR S EQ ID NO: 267: (i) SEQUENCE CHARACTERISTICS: (A) LONGITU D: 460 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) ) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 267: TGTTGCGATC CCTTAAGCAT GGGTGCTATT AAAAAAATGG TGGAGAAGAA AATACCTGGA 60 ATTTACGTCT TATCTTTAGA GATTGGGAAG ACCCTGATGG AGGACGTGGA GAACAGCTTC 120 TTCTTGAATG TCAATTCCCA AGTAACAACA GTGTGTCAGO CACTTGCTAA GGATCCTAAA 180 TTGCAGCAAG GCTACAATGC TATGGGATTC TCCCAGGGAG GCCAATTTCT GAGGGCAGTG 240 GCTCAGAGAT GCCCTTCACC TCCCATGATC AATCTGATCT CGGTTGGGGG ACAACATCAA 300 GGTGTTTTTG GACTCCCTCG ATGCCCAGGA GAGAGCTCTC ACATCTGTGA CTTCATCCGA 360 AAAACACTGA ATGCTGGGGC GTACTCCAAA GTTGTTCAGG AACGCCTCGT GCAAGCCGAA 420 TACTGGCATG ACCCATAAAA GGAGGATGTG GATCGCAACA 460 (2) I NFORMATION FOR SEQ ID NO: 268: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 533 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 268: TGTTGCGATC CGTTGATAGA ATAGCGACGT GGTAATGAGT GCATGGCACG CCTCCGACTT 60 ACCTTCGCCC GTGGGGACCC CGAGTACGTC TACGGCGTCG TCACTTAGAG TACCCTCTGG 120 ACGCCCGGGC GCGTTCGATT TACCGGAAGC GCGAGCTGCA GTGGGCTCTGC GCCCCCGGCC 180 AAATTCTTTGGGGGGTTTAA GGCCGCGGGG AATTTGAGGT ATCTCTATCA GTATGTAGCC 240 AAGTTGGAAC AGTCGCCATT CCCGAAATCG CTTTCTTTGA ATCCGCACCG CCTCCAGCAT 300 TGCCTCATTC ATCAACCTGA AGGCACGCAT AAGTGACGGT TGTGTCTTCA GCAGCTCCAC 360 TCCATAACTA GCGCGCTCGA CCTCGTCTTC GTACGCGCCA GGTCCGTGCG TGCGAATTCC 420 CAACTCCGGT GAGTTGCGCA TTTCAAGTTN CGAAACTGTT CGCCTCCACN ATTTGGCATG 480 TTCACGCATG ACACGGAATA AACTCGTCCA GTACCGGGAA TGGGATCGCA ACA 533 (2) I NFO RMATION FOR SEQ ID NO: 269: (i) CHARACTERISTICS OF THE SEQUENCE: (A) ITU D LONG: 50 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) ) TOPOLOGY: linear (xi) DESCRI SEQUENCE CIA PC: SEQ ID NO: 269: TTTTTTTTTTT TTCGCCTGAA TTAGCTACAG ATCCTCCTCA CAAGCGGTCA 50 (2) I NFORMATION FOR S EQ ID NO: 270: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 519 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGIA : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 270: TGTTGCGATC CAAATAACCC ACCAGCTTCT TGCACACTTC GCAGAAGCCA CCGTCCTTTG 60 GCTGAGTCAC GTGAACGGTC AGTGCAAGCA GCCGCGTGCC AGAGCAGAGG TGCAGCATGC 120 TGCACACCAG CTCAGGGCTG ACCTCCTCCA GCAGGATGGA CAGGATGGAG CTGCCGTACG 180 TGTCCACCAC CTCCTGGCAC TCTTCCGACA GGGACTTCGG CAGCTTCGAG CACATTTTGT 24 CAAAAGCGTC GAGTATTTCT TTCTCAGTCT TGTTGTTGTC AATCAGCTTG GTCACCTCCT 30 TCACCAGGAA TTCACACACC TCACAGTAAA CATCAGACTT TGCTGGGACC TCGTGCTTCT 36 TAATGGGCTC CACCAGTTCC AGGGCAGGGA TGACATTCTT GGAGGCCACT TTGGCGGGGA 42 CCAGAGTCTG CATGGGCATC TCTTTCACCT CATCACAGAA CCCAACCAGC GCACAGATCT 48 CCTTGGGTTG CATGTGCATC ATCATCTGGG ATCGCAACA 51 (2) I NFORMATION FOR SEQ ID NO: 271: (i) SEQUENCE CHARACTERISTICS: (A) ITU D LONG: 457 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 271: TTCGGGCGGC GACCGGACGT GCACTCCTCC AGTAGCGGCT GCACGTCGTG 6 CCAATGGCCC GCTATGAGGA GGTGAGCGTG TCCGGCTTCG AGGAGTTCCA CCGGGCCGTG 12 GAACAGCACA ATGGCAAGAC CATTTTCGCC TACTTTACGG GTTCTAAGGA CGCCGGGGGG 18 AAAAGCTGGT GCCCCGACTG CGTGCAGGCT GAACCAGTCG TACGAGAGGG GCTGAAGCAC 24 ATTAGTGAAG GATGTGTGTT CATCTACTGC CAAGTAGGAG AAGAGCCTTA TTGGAAAGAT 30 CCAAATAATG ACTTCAGAAA AAACTTGAAA GTAACAGCAG TGCCTACACT ACTTAAGTAT 36 GGAACACCTC AAAAACTGGT AGAATCTGAG TGTCTTCAGG CCAACCTGGT GGAAATGTTG 42 TTCTCTGAAG ATTAAGATTT 'TAGGATGGCA ATCAAGA 45 (2) IN TRAINING FOR S EQ ID NO: 272: (i) CHARACTERI STI CASE OF THE SECU ENCIA: (A) LENGTH: 102 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) ) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 272: TTTTTTTTTTT TTGGGCAACA ACCTGAATAC CTTTTCAAGG CTCTGGCTTG GGCTCAAGCC 6 CGCAGGGGAA ATGCAACTGG CCAGGTCACA GGGCAATCAA GA 10 (2) I NFORMATION FOR SEQ ID NO: 273: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 455 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION Dí E: SEQ ID NO: 273: TTTTTTTTTT TTGGCAATCA ACAGGTTTAA GTCTTCGGCC GAAGTTAATC TCGTGTTTTT 6 GGCAATCAAC AGGTTTAAGT CTTCGGCCGA AGTTAATCTC GTGTTTTTGG CAATCAACAG 12 GTTTAAGTCT TCGGCCGAAG TTAATCTCGT GTTTTTGGCA ATCAACAGGT TTAAGTCTTC 18 .GGCCGAAGTT AATCTCGTGT TTTTGGCAAT CAACAGGTTT AAGTCTTCGG CCGAAGTTAA 24 TCTCGTGTTT TTGGCAATCA ACAGGTTTAA GTCTTCGGCC GAAGTTAATC TCGTGTTTTT 30 ssCAATCAAG AGGtTTAAGT CTTCGGCCGA AGTTAATCTC GTGTTTTTGG CAATCAACAG 36 GTTTAAGTCT TCGGCCGAAN TTAATCTCGT GTTTTTGGCA ATCAACAGGT TTAANTCTTC 42 GGCCGAAGTT AATCTCGTGT TTTTGGCAAT CAANA 45 (2) I NFORMATION FOR SEQ ID NO: 274: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 461 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 274: TTTTTTTTTTT TTGGCCAATA CCCTTGATGA ACATCAATGT GAAAATCCTC GGTAAAATAC 6 TGGCAAACCA AATCCAGCAG CACATCAAAA AGCTTATCCA CCATGATCAA GTGGGCTTCA 12 TCCCTGGGAT GCAAGGCTGG TTCAACATAA GAAAATCAAT AAATGTAATC CATCACATAA 18 ACAGAACCAA AGACAAAAAC CACATGATTA TCTCAATAGA TGCAGAAAAG GCCTTGGACA 24 AATTCAACAG CCCTTCATGC TAAACACTCT TAATAAACTA GATATTGATG GAATGTATCT 30 CAAAATAATA AGAGCTATTT ATGACAAACC CACAGCCAAT ATCATACTGA ATGGGCAAAG 36 ACTGGAAGCA TTCCCTTTOA AAACTGGCAC AAGACAAGGA TGCCCTCTCT CACCGCTCCT 42 ATTCAACATA GTATTGGAAG TTCTGGCCAG GGCAATCAAG A 46 (2) INFORMATION FOR SEQ ID NO: 275: (i) CHARACTERISTICS OF THE SECU ENC IA: (A) LENGTH: 729 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 275: TTGGCCAACA CCAAGTCTTC CACGTGGGAG GTTTTATTAT GTTTTACAAC 6 CATGAAAACA TAGGAAGGTG GCTGTTACAG CAAACATTTC AGATAGACGA ATCGGCCAAG 12 CTCCCCAAAC CCCACCTTCA CAGCCTCTTC CACACGTCTC CCANAGATTG TTGTCCTTCA 18 CTTGCAAATT CANGGATGTT GGAAGTNGAC ATTTNNAGTN GCNGGAACCC CATCAGTGAA 24 NCANTAAGCA GAANTACGAT GACTTTGANA NACANCTGAT GAAGAACACN CTACNGANAA 30 CCCTTTCTNT CGTGTTANGA TCTCNNGTCC NTCACTAATG CGGCCCCCTG CNGGTCCACC 36 ATTTGGGAGA ACTCCCCCCN CGTTGGATCC CCCCTTGAGT NTCCCATTCT NGTCCCCCAN 42 ACCNGNCTTG NGNGNCANTN CNNCCTCNCA CCNTGTTTCC CTGNNGTNAA AATNNGTTTT 48 NCCGCCNCCC NAATTCCCAC CCNAATCACA GCGAANCCNG AAGGCCTTCN NAAGTGTTTA 54 ANGCCCNGNG GTTTCCTCNT NTANTTGCAG CCTACCCTCC CNCTTNNNNT TNCGNGTTGG 60 TCGCGCCCTG GNCNCGCCTN GTTCCTCTTT NNGGNNACAA CCTNGNTCNN NGGCNCNTCN 66 NNNCTNTTCC TNNNACTAGC TNGCCTNTCC NCNCCGNGGN NCANNGCACA TTNCNCNNAC 72 TNTGTNNCC 72 (2) I NFORMATION FOR SEQ ID NO: 276: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 339 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 276: TGACCTGACA TGTAGTAGAT ACTTAATAAA TATTTGTGGA ATGAATGGAT GAAGTGGAGT 60 TACAGAGAAA AATAGAAAAG TACAAATTGT TGTCAGTGTT TTGAAGGAAA ATTATGATCT 120 TTCCCAAAGT TCTGACTTCA TTCTAAGACA GGGTTAGTAT CTCCATACAT AATTTTACTT 180 GCTTTTGAAA ATCAAATGAG ATAATCTATT TAGATTGATA ATTTATTTAG ACTGGCTATA 240 AACTATTAAG TGCTAGCAAA TATACATTTT AATCTCATTT TCCACCTCTT GTGATATAGC 300 TATGTAGGTG TTGACTTTAA TGaATGTCAG GTCAATCCC 339 (2) IN TRAINING FOR SEQ ID NO: 277: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) ITU D LONG: 664 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) ) TOPOLOGY: linear (xi) DESCRITION OF SEQUENCE: SEQ ID NO: 277: TGACCTGACA AATCTTTCTC CATTATATTC TTCTAGGGGA ATTTCTTGAA 60 AAGCATCCAA AGGAAACAAA TGATGGTAAG ACCGTGCCAA GTGGGGAGCA GACACCAAAG 120 TAAGACCACA GATTTTACAT TCAACAGGTA GCTCACAGTA CTTTGCCCGA CACTGTGGGC 180 AGAAATAGCC TCCTAATGTA AGCCCTGGCT CAGTATTGCC ATCCAAATGC GCCATGCTGA 240 AAGAGGGTTT TGCATCCTGG TCAGATNAAG AAGCAATGGT GTGCTGAGGA AATCCCATAC 300 GAATAAGTGA GCATTCAGAA CTTGAGCTAG CAGGAGGAGG ACTAAGATGA TGTGTGAGCA 360 ACTCTTTGTA ATGGCTTTCA TCTAAAATAA CATGGTACGT GCCACCAGTT TCACGAGCAA 420 GTACAGTGCA AACGCGAACT TCTGCAGACA ATCCAATAAC AGATACTCTA ATTTTAGCTG 480 CCTTTAGGGT CTTGATTAAA TCATAAATAT TAGATGGATC GCAAGTTGTA AGGNTGCTAA 540 AAGATGATTA GTACTTCTCG ACTTGTATGT CCAGGCATGT TGTTTTAAAN TCTGCCTTAG_600_NCCCTGCTTA GGGGAATTTT TAAAGAAGAT GGCTCTCCAT GTTCANGGTC AATCACNAAT CCGT 660 664 (2) I NFORMATION FOR SEQ ID NO: 278: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 452 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 278: TGACCTGACA TTGAGGAAGA GCACACACCT CTGAAATTCC TTAGGTTCAG AAGGGCATTT 60 GACACAGAGT GGGCCTCTGA TAATTCATGA AATGCATTCT GAAGTCATCC AGAATGGAGG 120 CTGCAATCTG CTGTGCTTTG GGGGTTGCCT CACTGTGCTC CTGGATATCA CACAAAAGCT 180 GCAATCCTTC TTCTTCAACT AACATTTTGC AGTATTTGCT GGGATTTTTA CTGCAGACAT 240 GATACATAGC CCATAGTGCC CAGAGCTGAA CCTCTGGTTG AGAGAAGTTG CCAAGGAGCG 300 GGAAAAATGT CTTGAAAGAT CTATAGGTCA CCAATGCTGT CATCTTACAA CTTGAACTTG 360 GCCAATTCTG TATGGTTGCA TGCAGATCTT GGAGAAGAGT ACGCCTCTGG AAGTCACGGG 420 ATATCCAAAN CTGTCTGTCA GATGTCAGGT CA 452 (2) IN TRAINING FOR SEQ ID NO: 279: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 274 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) DESC RI S ECU ENCE PC: SEQ ID NO: 279: TTTTTTTTTTT TTCGGCAAGG CAAATTTACT TCTGCAAAAG GGTGCTGCTT GCACTTTTGG 60 CCACTGCGAG AGCACACCAA ACAAAGTAGG GAAGGGGTTT TTATCCCTAA CGCGGTTATT 120 CCCTGGTTCT GTGTCGTGTC CCCATTGGCT GGAGTCAGAC TGCACAATCT ACACTGACCC 180 AACTGGCTAC TGTTTAAAAT TGAATATGAA TAATTAGGTA GGAAGGGGGA GGCTGTTTGT 240 TACGGTACAA GACGTGTTTG GGCATGTCAG GTCA 274 (2) IN TRAINING FOR SEQ ID NO: 280: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 272 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 280: TACCTGACAT GGAGAAATAA CTTGTAGTAT TTTGCGTGCA ATGGAATACT ATATGAGGGT 60 GAAAATGAAT GAACTAGCAA TGCGTGTATC AACATGAATA AATCCCCAAA ACATAATAAT 120 GTTGAATGGA AAAGGTGAGT TTCAGAAGGA TATATATGCC CTCTAAATCC ATTTATGTAA 180 ACCTTTAAAA AACTACATTA TTTATGGTCA TAAGTCCATC CAGAAAATAT TTAAAAACCT 240 ACATGGGATT GATAACTACT GATGTCAGGT CA 272 (2) I NFORMATION FOR SEQ ID NO: 281: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LONG ITUD: 431 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY : linear (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 281 TTTTTTTTTTT TTGGCCAATA GCATGATTTA AACATTGGAA AAAGTCAAAT GAGCAATGCG 60 AArrri ATG TTCTCTTGAA TAATCAAAAG AGTAGGCAAC ATTGGTTCCT CATTCTTGAA 120 TAGCATTAAT CAGAAAATAT TGCATAGCCT CTAGCCTCCT TAGAGTAGGT GTGCTCTCTC 180 AAATATATCA TAGTCCCACA GTTTATTTCA TGTATATTTT CTGCCTGAAT CACATAGACA 240 TTTGAATTTG CAACGCCTGA TGTAAATATA TAAATTCTTA CCAATCAGAA ACATAGCAAG 300 AAATTCAGGG ACTTGGTCAT YATCAGGGTA TGACAGCANA TCCCTGTARA AACACTGATA 360 CACACTCACA CACGTATGCA ACGTGGAGAT GTCGCYTTWW KKKTWYWCWM RMRYCRWCGN 420 AATCACTTAN N 431 (2) I NFORMATION FOR SEQ ID NO: 282: (i) SEQUENCE CHARACTERISTICS: (A) LONG I TU D: 98 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple ( D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 282: ATTCGATTCG ATGCTTGAGC CCAGGAGTTC AAGACTGCAG TGAGCCACTG CACTTCAGGC 60 TGGACAACAG AGCGAGTCCC TGTGCCAAAA AAAAAAAA 98 (2) I NFORMATION FOR S EQ ID NO: 283: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 764 base pairs (B) TYPE: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 283: TTTTTTTTTTT TTCGCAAGCA CGTGCACTTT ATTGAATGAC ACTGTAGACA GGTGTGTGGG 60 TATAAACTGC TGTATCTAGG GGCAGGACCA AGGGGGCAGG GGCAACAGCC CCAGCGTGCA 120 GGGCCASCAT TGCACAGTGG ASTGCAAAGG TTGCAGGCTA TGGGCGGCTA CTAVTAACCC 180 CGTTTTTTCCT GTATTATCTG TAACATAATA TGGTAGACTG TCACAGAGCC GAATWCCART 240 HACASGATGA ATCCAAWGGT CAYGAGGATG CCCASAATCA GGGCCCASAT STTCAGGCAC 300 TTGGCGGTGG GGGCATASGC CTGKGCCCCG GTCACGTCSC CAACCWTCTY CCTGTCCCTA 360 CMCTTGAWTC CNCNCCTTNN N TNCCNTNA TNTGCCCGCC CNCCTCCTNG NGTCAACCNG 420 NATCTGCACT ANCTCCCTCN CCCCTTNTGG ANTCTCNTCC TTCAANTAAN NTTATCCTTN 480 ACNCCCCCCT CNCCTTTCCC CTNCCNCCCN TNATCCCNGN NCCNCTATCA NTCNTNCCCT 540 CNCTNTNCTN CNNATCGTTC CNCCTNNTAA CTACNCTTTN NACNANNCCT CACTNATNCC 600 NGNNANTTCT TTCCTTCCCT CCCNACGCNN TGCGTGCGCC CGTCTNGCCT NNNCTNCGNA 660 CCCNNACTTT ATTTACCTTT NCACCCTAGC NCTCTACTTN ACCCANCCNC TCCTACCTCC 720 NGGNCCACCC NNCCCTNATC NCTNNCTCTN TCNNCTCNTT CCCC 764 (2) I NFORMATION FOR SEQ ID NO: 284: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LONG ITUD: 1 57 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY : linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 284: CAAGTGTAGG CACAGTGATG AAAGCCTGGA GCAAACACAA TCTGTGGGTA ATTAACGTTT 60 ATTTCTCCCC TTCCAGGAAC GTCTTGCATG GATGATCAAA GATCAGCTCC TGGTCAACAT 120 AAATAAGCTA GTTTAAGATA CGTTCCCCTA CACTTGA 157 (2) INFORMATION FOR SEQ ID NO: 285: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 150 base pairs (B) TYPE: nucleic acid (C) FILAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185: ATTCGATTGT ACTCAGACAA CAATATGCTA AGTGGAAGAA GTCAGTCACA AAAGACCACA 60 TACTGTATGA CTTCATTTAC ATTAAGTGTC CAGAATAGGC AAATCCGTAG AGACAGAAAG 120 TAGATGAGCA GCTGCCTAGG TCTGAGTACA 150 (2) INFORMATION FOR SEQ ID NO: 286: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 286: ATTCGATTTT TTTTTTTTTTG GCCATGATGA AATTCTTACT CCCTCAGATT TTTTGTCTGG 60 ATAAATGCAA GTCTCACCAC CAOATGTGAA ATTACAGTAA ACTTTGAAGG AATCTCCTGA 120 GCAACCTTGG TTAGGATCAA TCCAATATTC ACCATCTGGG AAGTCAGGAT GGCTGAGTTG 180 CAGGTCTTTA CAAGTTCGGG CTGGATTGGT CTGAGTACA 219 (2) INFORMATION FOR SEQ ID NO: 287: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 196 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 287: ATTCGATTCT TGAGGCTACC AGGAGCTAGG AGAAGAGGCA TGGAACAAAT TTTCCCTCAT 60 ATCCATACTC AGAAGGAACC AACCCTGCTG ACACCTTAAT TTCAGCTTCT GGCCTCTAGA 120 ACTGTGAGAG AGTACATTTC TCTTGGTTTA AGCCAAGAGA ATCTGTCTTT TGGTACTTTA 180 TATCATAGCC TCAAGA 196 (2) INFORMATION FOR SEQ ID NO: 288: (i) CHARACTERISTICS OF THE SECU ENCIA: (A) LENGTH: 1 99 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 288: ATTCGATTTC AGTCCAGTCC CAGAACCCAC ATTsTCAATT ACTACTCTGT ARAAGATTCA 60 TTTGTTsAAA TTCATTGAGT AAAACATTTA TGATCCCTTA ATATATGCCA ATTACCATGC 120 TAGGTACTGA AGATTCAAGT GACCGAGATG CTAGCCCTTG GGTTCAAGTG ATCCCTCTCC 180 CAGAGTGCAC TGGACTGAA 199 (2) I NFORMATION FOR SEQ ID NO: 289: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 182 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 289: ATTCGATTCT TGAGGCTACA AACCTGTACA GTATGTTACT CTACTGAATA CTGTAGGCAA 60 TAGTAATACA GAAGCAAGTA TCTGTATATG TAAACATTAA AAAGGTACAG TGAAACTTCA 120 GTATTATAAT CTTAGGGACC ACCATTATAT ATGTGGTCCA TCATTGGCCA AAAAAAAAAA 180 AA 182 (2) IN TRAINING FOR SEQ ID NO: 290: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1646 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 290: GGCACGAGGA GAAATGT AT TCCATATTTT ATTTGAAACT TATTCCATAT TTTAATTGGA 60 TATTGAGTGA TTGGGTTATC AAACACCCAC AAACTTTAAT TTTGTTAAAT TTATATGGCT 120 TTGAAATAGA AGTATAAGTT GCTACCATTT TTTGATAACA TTGAAAGATA GTATTTTACC 180 ATCTTTAATC ATCTTGGAAA ATACAAGTCC TGTGAACAAC CACTCTTTCA CCTAGCAGCA 240 TGAGGCCAAA AGTAAAGGCT TTAAATTATA ACATATGGGA TTCTTAGTAG TATGTTTTTT 300 TCTTGAAACT CAGTGGCTCT ATCTAACCTT ACTATCTCCT CACTCTTTCT CTAAGACTAA 360 ACTCTAGGCT CT AAAAATC TGCCCACACC AATCTTAGAA GCTCTGAAAA GAATTTGTCT 420 TTAAATATCT TTTAATAGTA ACATGTATTT TATGGACCAA ATTGACATTT TCGACTATTT 480 TTTCCAAAAA AGTCAGGTGA ATTTCAGCAC ACTGAGTTGG GAATTTCTTA TCCCAGAAGA 540 CCAACCAATT TCATATTTAT TTAAGATTGA TTCCATACTC CGTTTTCAAG GAGAATCCCT 600 GCAGTCTCCT TAAAGGTAGA ACAAATACTT TCTATTTTTT TTTCACCATT sTGGGATTGG 660 ACTTTAAGAG GTGACTCTAA AAAAACAGAG AACAAATATG TCTCAGTTGT ATTAAGCACG 720 GACCCATATT ATCATATTCA CTTAAAAAAA TGATTTCCTG TGCACCTTTT GGCAACTTCT 780 CTTTTCAATG TAGGGAAAAA CTTAGTCACC CTGAAAACCC ACAAAATAAA TAAAACTTGT 840 AGATGTGGGC AGAAGGTTTG GGGGTGGACA TTGTATGTGT TTAAAT AAA CCCTGTATCA 900 CTGAGAAGCT GTTGTATGGG TCAGAGAAAA TGAATGCTTA GAAGCTGTTC ACATCTTCAA 960 GAGCAGAAGC AAACCACATG TCTCAGCTAT ATTATTATTT ATTTTTTTATG CATAAAGTGA 1020 ATCATTTCTT CTGTATTAAT TTCCAAAGGG TTTTACCCTC TATTTAAATG CTTTGAAAAA 1080 CAGTGCATTG ACAATGGGTT GATATTTTTC TTTAAAAGAA AAATATAATT ATGAAAGCCA 1140 AGATAATCTG AAGCCTGTTT TATTTTAAAA CTTTTTATGT TCTGTGGTTG ATGTTGTTTG 1200 TTTGTTTGTT TCTATTTTGT TGGTTTTTTA CTTTGTTTTT TGTTTTGTTT TGTTTTGTTT 1260 KGCATACTAC ATGCAGTTCT TTAACCAATG TCTGTTTGGC TAATGTAATT AAAGTTGTTA 1320 ATTTATATGA GTGCATTTCA ACTATGTCAA TGGTTTCTTA ATATTTATTG TGTAGAAGTA 1380 CTGGTAATTT TTTTATTTAC AATATGTTTA AAGAGATAAC AGTTTGATAT GTTTTCATGT 1440 GTTTATAGCA GAAGTTATTT ATTTCTATGG CATTCCAGCG OATATTTTGG TGTTTGCGAs 1500 GCATGCAGTC AATATTTTGT ACAGTTAGTG GACAGTATTC AGCAACGCCT GATAGCTTCT 1560 TTGGCCTTAT GTTAAATAAA AAGACCTGTT TGGGATGTAT TTTTTATTTT TAAAAAAAAA 1620 AAAAAAAAAA AAAAAAAAAA AAAAAA 1646 (2) INFORMATION FOR SEQ ID NO: 291: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1851 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 291: TCATCACCAT TGCCAGCAGC GGCACCGTTA GTCAGGTTTT CTGGGAATCC CACATGAGTA 6 CTTCCGTGTT CTTCATTCTT CTTCAATAGC CATAAATCTT CTAGCTCTOG CTGGCTGTTT 12 TCACTTCCTT TAAGCCTTTG TGACTCTTCC TCTGATGTCA GCTTTAAGTC TTGTTCTGGA 18 TTGCTGTTTT CAGAAGAGAT TTTTAACATC TGTTTTTCTT TGTAGTCAGA AAGTAACTGG 24 CAAATTACAT GATGATGACT AGAAACAGCA TACTCTCTGG CCGTCTTTCC AGATCTTGAG 30 AAGATACATC AACATTTTGC TCAAGTAGAG GGCTGACTAT ACTTGCTGAT CCACAACATA 36 CAGCAAGTAT GAGAGCAGTT CTTCCATATC TATCCAGCGC ATTTAAATTC GCTTTTTTCT 42 TGATTAAAAA TTTCACCACT TGCTGTTTTT GCTCATGTAT ACCAAGTAGC AGTGGTGTGA 48 GGCCATGCTT GTTTTTTGAT TCGATATCAG CACCGTATAA GAGCAGTGCT TTGGCCATTA 54 ATTTATCTTC ATTGTAGACA GCATAGTGTA GAGTGGTATT TCCATACTCA TCTGGAATAT 60 TTGGATCAGT GCCATGTTCC AGCAACATTA ACGCACATTC ATCTTCCTGG CATTGTACGG 66 CCTTTGTCAG AGCTGTCCTC TTTTTGTTGT CAAGGACATT AAGTTGACAT CGTCTGTCCA 72 GCACGAGTTT TACTACTTCT GAATTCCCAT TGGCAGAGGC CAGATGTAGA GCAGTCCTCT 78 TTTGCTTGTC CCTCTTGTTC ACATCCGTGT CCCTGAGCAT GACGATGAGA TCCTTTCTGG 84 GGACTTTACC CCACCAGGCA GCTCTGTGGA GCTTGTCCAG ATCTTCTCCA TGGACGTGGT 90 ACCTGGGATC CATGAAGGCG CTGTCATCGT AGTCTCCCCA AGCGACCACG TTGCTCTTGC 96 CGCTCCCCTG CAGCAGGGGA AGCAGTGGCA GCACCACTTG CACCTCTTGC TCCCAAGCGT 102 CTTCACAGAG GAGTCGTTGT GGTCTCCAGA AGTGCCCACG TTGCTCTTGC CGCTCCCCCT 108 GTCCATCCAG OGACGAAGAA ATGCAGGAAA TGAAAGATGC ATGCACGATG GTATACTCCT 114 CAGCCATCAA ACTTCTGGAC AGCAGGTCAC TTCCAGCAAG GTGGAGAAAG CTGTCCACCC 120 ACAGAGGATG AGATCCAGAA ACCACAATAT CCATTCACAA ACAAACACTT TTCAGCCAGA 126 CACAGGTACT GAAATCATGT CATCTGCGGC AACATGGTGG AACCTACCCA ATCACACATC 132 AAGAGATGAA GACACTGCAG TATATCTGCA CAACGTAATA CTCTTCATCC ATAACAAAAT 138 AATATAATTT TCCTCTGGAG CCATATGGAT GAACTATGAA GGAAGAACTC CCCGAAGAAG 144 CCAGTCGCAG AGAAGCCACA CTGAAGCTCT GTCCTCAGCC ATCAGCGCCA CGGACAGGAR 150 TGTGTTTCTT CCCCAGTGAT GCAGCCTCAA GTTATCCCGA AGCTGCCGCA GCACACGGTG 156 GCTCCTGAGA AACACCCCAG CTCTTCCGGT CTAACACAGG CAAGTCAATA AATGTGATAA 162 TCACATAAAC AGAATTAAAA GCAAAGTCAC ATAAGCATCT CAACAGACAC AGAAAAGGCA 168 TTTGACAAAA TCCAGCATCC TTGTATTTAT TGTTGCAGTT CTCAGAGGAA ATGCTTCTAA 174 CTTTTCCCCA TTTAGTATTA TGTTGGCTGT GGGCTTGTCA TAGGTGGTTT TTATTACTTT 180 AAGGTATGTC CCTTCTATGC CTGTTTTGCT GAGGGTTTTA ATTCTCGTGC C 185 (2) I NFORMATION FOR SEQ ID NO: 292: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1851 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) ) SEQUENCE DESCRIPTION: SEQ ID NO: 292: TCATCACCAT TGCCAGCAGC GGCACCGTTA GTCAGGTTTT CTGGGAATCC CACATGAGTA 6 CTTCCGTGTT CTTCATTCTT CTTCAATAGC CATAAATCTT CTAGCTCTGG CTGGCTGTTT 12 TCACTTCCTT TAAGCCTTTG TGACTCTTCC TCTGATGTCA GCTTTAAGTC TTGTTCTGGA 18 TTGCTGTTTT CAGAAGAGAT TTTTAACATC TGTTTTTCTT TGTAGTCAGA AAGTAACTGG 24 CAAATTACAT GATGATGACT AGAAACAGCA TACTCTCTGG CCGTCTTTCC AGATCTTGAG 30 AAGATACATC AACATTTTGC TCAAGTAGAG GGCTGACTAT ACTTGCTGAT CCACAACATA 36 CAGCAAGTAT GAGAGCAGTT CTTCCATATC TATCCAGCGC ATTTAAATTC GCTTTTTTCT 42 TGATTAAAAA TTTCACCACT TGCTGTTTTT GCTCATGTAT ACCAAGTAGC AGTGGTGTGA 48 GGCCATGCTT GTTTTTTGAT TCGATATCAG CACCGTATAA GAGCAGTGCT TTGGCCATTA 54 ATTTATCTTC ATTGTAGACA GCATAGTGTA GAGTGGTATT TCCATACTCA TCTGGAATAT 60 TTGGATCAGT GCCATGTTCC AGCAACATTA ACGCACATTC ATCTTCCTGG CATTGTACGG 66 CCTTTGTCAG AGCTGTCCTC TTTTTGTTGT CAAGGACATT AAGTTGACAT CGTCTGTCCA 72 GCACGAGTTT TACTACTTCT GAATTCCCAT TGGCAGAGGC CAGATGTAGA GCAGTCCTCT 78 TTTGCTTGTC CCTCTTGTTC ACATCCGTGT CCCTGAGCAT GACGATGAGA TCCTTTCTGG 840 GGACTTTACC CCACCAGGCA GCTCTGTGGA GCTTGTCCAG ATCTTCTCCA TGGACGTGGT 900 ACCTGGGATC CATGAAGGCG CTGTCATCGT AGTCTCCCCA AGCGACCACG TTGCTCTTGC 960 CGCTCCCCTG CAGCAGGGGA AGCAGTGGCA GCACCACTTG CACCTCTTGC TCCCAAGCGT 1020 CTTCACAGAG GAGTCGTTGT GGTCTCCAGA AGTGCCCACG TTGCTCTTGC CGCTCCCCCT 1080 GTCCATCCAG GGAGGAAGAA ATGCAGGAAA TGAAAGATGC ATGCACGATG GTATACTCCT 1140 CAGCCATCAA ACTTCTGGAC AGCAGGTCAC TTCCAGCAAG GTGGAGAAAG CTGTCCACCC 1200 ACAGAGGATG AGATCCAGAA ACCACAATAT CCATTCACAA ACAAACACTT TTCAGCCAGA 1260 CACAGGTACT GAAATCATGT CATCTGCGGC AACATGGTGG AACCTACCCA ATCACACATC 1320 AAGAGATGAA GACACTGCAG TATATCTGCA CAACGTAATA CTCTTCATCC ATAACAAAAT 1380 AATATAATTT TCCTCTGGAG CCATATGGAT GAACTATGAA GGAAGAACTC CCCGAAGAAG 1440 CCAGTCGCAG AGAAGCCACA CTGAAGCTCT GTCCTCAGCC ATCAGCGCCA CGGACAGGAR 1500 TGTGTTTCTT CCCCAGTGAT GCAGCCTCAA GTTATCCCGA AGCTGCCGCA GCACACGGTG 1560 GCTCCTGAGA AACACCCCAG CTCTTCCGGT CTAACACAGG CAAGTCAATA AATGTGATAA 1620 TCACATAAAC AGAATTAAAA GCAAAGTCAC ATAAGCATCT CAACAGACAC AGAAAAGGCA 1680 TTTGACAAAA TCCAGCATCC TTGTATTTAT TGTTGCAGTT CTCAGAGGAA ATGCTTCTAA 1740 CTTTTCCCCA TTTAGTATTA TGTTGGCTGT GGGCTTGTCA TAGGTGGTTT TTATTACTTT 1800 AAGGTATGTC CCTTCTATGC CTGTTTTGCT GAGGGTTTTA ATTCTCGTGC C 1851 (2) IN TRAINING FOR SEQ ID NO: 293: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 668 base pairs (B) TI PO: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 293: CTTGAGCTTC CAAATAYGGA AGACTGGCCC TTACACASGT CAATGTTAAA ATGAATGCAT 60 TTCAGTATTT TGAAGATAAA ATTRGTAGAT CTATACCTTG TTTTTTGATT CGATATCAGC 120 ACCRTATAAG AGCAGTGCTT TGGCCATTAA TTTATCTTTC ATTRTAGACA GCRTAGTGYA 180 GAGTGGTATT TCCATACTCA TCTGGAATAT TTGGATCAGT GCCATGTTCC AGCAACATTA 240 ACGCACATTC ATCTTCCTGG CATTGTACGG CCTGTCAGTA TTAGACCCAA AAACAAATTA 300 CATATCTTAG GAATTCAAAA TAACATTCCA CAGCTTTCAC CAACTAGTTA TATTTAAAGG 360 AGAAAACTCA TTTTTATGCC ATGTATTGAA ATCAAACCCA CCTCATGCTG ATATAGTTGG 420 CTACTGCATA CCTTTATCAG AGCTGTCCTC TTTTTGTTGT CAAGGACATT AAGTTGACAT 480 CGTCTGTCCA sCAGGAGTTT TACTACTTCT GAATTCCCAT TGGCAGAGGC CAGATGTAGA 540 GCAGTCCTAT GAGAGTGAGA AGACTTTTTA GGAAATTGTA GTGCACTAGC TACAGCCATA 600 GCAATGATTC ATGTAACTGC AAACACTGAA TAGCCTGCTA TTACTCTGCC TTCAAAAAAA 660 AAAAAAAA 668 (2) INFORMATION FOR SEQ ID NO: 294: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1 512 base pairs (B) TI PO: nucleic acid (C) FI LAM ENTO: simple (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 294: GGGTCGCCCA GGGGGSGCGT GGGCTTTCCT CGGGTGGGTG TGGGTTTTCC CTGGGTGGGG 60 TGGGCTGGGC TRGAATCCCC TGCTGGGGTT GGCAGGTTTT GGCTGGGATT GACTTTTYTC 120 TTCAAACAGA TTGGAAACCC GGAGTTACCT GCTAGTTGGT GAAACTGGTT GGTAGACGCG 180 ATCTGTTGGC TACTACTGGC TTCTCCTGGC TGTTAAAAGC AGATGGTGGT TGAGGTTGAT 240 TCCATGCCGG CTGCTTCTTC TGTGAAGAAG CCATTTGGTC TCAGGAGCAA GATGGGCAAG 300 TGGTGCTGCC GTTGCTTCCC CTGCTGCAGG GAGAGCGGCA AGAGCAACGT GGGCACTTCT 360 GGAGACCACG ACGACTCTGC TATGAAGACA CTCAGGAGCA AGATGGGCAA GTGGTGCCGC 420 CACTGCTTCC CCTGCTGCAG GGGGAGTGGC AAGAGCAACG TGGGCGCTTC TGGAGACCAC 480 GACGAYTCTG CTATGAAGAC ACTCAGGAAC AAGATGGGCA AGTGGTGCTG CCACTGCTTC 540 CCCTGCTGCA GGGGGAGCRG CAAGAGCAAG GTGGGCGCTT GGGGAGACTA CGATGACAGT 600 GCCTTCATGG AGCCCAGGTA CCACGTCCGT GGAGAAGATC TGGACAAGCT CCACAGAGCT 660 GCCTGGTGGG GTAAAGTCCC CAGAAAGGAT CTCATCGTCA TGCTCAGC -. A CACTGACGTG 720 AACAAGAAGG ACAAGCAAAA GAGGACTGCT CTACATCTGG CCTCTGCCAA TGGGAATTCA 780 GAAGTAGTAA AACTCSTGCT GGACAGACGA TGTCAACTTA ATGTCCTTGA CAACAAAAAG 840 AGGACAGCTC TGAYAAAGGC CGTACAATGC CAGGAAGATG AATGTGCGTT AATGTTGCTG 900 GAACATGGCA CTGATCCAAA TATTCCAGAT GAGTATGGAA ATACCACTCT RCACTAYGCT 960 RTCTAYAATG AAGATAAATT AATGGCCAAA GCACTGCTCT TATAYGGTGC TGATATCGAA 1020 TCAAAAAACA AGGTATAGAT CTACTAATTT TATCTTCAAA ATACTGAAAT GCATTCATTT 1080 TAACATTGAC GTGTGTAAGG GCCAGTCTTC CGTATTTGGA AGCTCAAGCA TAACTTGAAT 1140 GAAAATATTT TGAAATGACC TAATTATCTM AGACTTTATT TTAAATATTG TTATTTTCAA 1200 AGAAGCATTA GAGGGTACAG TTTTTTTTTT TTAAATGCAC TTCTGGTAAA TACTTTTGTT 1260 GAAAACACTG AATTTGTAAA AGGTAATACT TACTATTTTT CAATTTTTCC CTCCTAGGAT 1320 TTTTTTTCCCC TAATGAATGT AAGATGGCAA AATTTGCCCT GAAATAGGTT TTACATGAAA 1380 ACTCCAAGAA AAGTTAAACA TGTTTCAGTG AATAGAGATC CTGCTCCTTT GGCAAGTTCC 1440 TAAAAAACAG TAATAGATAC GAGGTGATGC GCCTGTCAGT GGCAAGGTTT AAGATATTTC 1500 TGATCTCGTG CC 1512 (2) INFORMATION FOR SEQ ID NO: 295: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1853 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear ( xi) SEQUENCE DESCRITION: SEQ ID NO: 295: GGGTCGCCCA GGGGGSGCGT GGGCTTTCCT CGGGTGGGTG TGGGTTTTCC CTGGGTGGGG 60 TGGGCTGGGC TRGAATCCCC TGCTGGGGTT GGCAGGTTTT GGCTGGGATT GACTTTTYTC 120 TTCAAACAGA TTGGAAACCC GGAGTTACCT GCTAGTTGGT GAAACTGGTT GGTAGACGCG 180 ATCTGTTGGC TACTACTGGC TTCTCCTGGC TGTTAAAAGC AGATGGTGGT TGAGGTTGAT 240 TCCATGCCGG CTGCTTCTTC TGTGAAGAAG CCATTTGGTC TCAGGAGCAA GATGGGCAAG 300 TGGTGCTGCC GTTGCTTCCC CTGCTGCAGG GAGAGCGGCA AGAGCAACGT GGGCACTTCT 360 GGAGACCACG ACGACTCTGC TATGAAGACA CTCAGGAGCA AGATGGGCAA GTGGTGCCGC 420 CACTGCTTCC CCTGCTGCAG GGGGAGTGGC AAGAGCAACG TGGGCGCTTC TGGAGACCAC 480 GACGAYTCTG CTATGAAGAC ACTCAGGAAC AAGATGGGCA AGTGGTGCTG CCACTGCTTC 540 CCCTGCTGCA GGGGGAGCRG CAAGAGCAAG GTGGGCGCTT GGGGAGACTA CGATGACAGY 600 GCCTTCATGG AKCCCAGGTA CCACGTCCRT GGAGAAGATC TGGACAAGCT CCACAGAGCT 660 GCCTGGTGGG GTAAAGTCCC CAGAAAGGAT CTCATCGTCA TGCTCAGGGA CACKGAYGTG 720 AACAAGARGG ACAAGCAAAA GAGGACTGCT CTACATCTGG CCTCTGCCAA TGGGAATTCA 780 GAAGTAGTAA AACTCSTGCT GGACAGACGA TGTCAACTTA ATGTCCTTGA CAACAAAAAG 840 AGGACAGCTC TGAYAAAGGC CGTACAATGC CAGGAAGATG AATGTGCGTT AATGTTGCTG 900 GAACATGGCA CTGATCCAAA TATTCCAGAT GAGTATGGAA ATACCACTCT RCACTAYGCT 960 RTCTAYAATG AAGATAAATT AATGGCCAAA GCACTGCTCT TATAYGGTGC TGATATCGAA 1020 TCAAAAAACA AGCATGGCCT CACACCACTG YTACTTGGTR TACATGAGCA AAAACAGCAA 1080 GTSGTGAAAT TTTTAATYAA GAAAAAAGCG AATTTAAAAT GCRCTGGATA GATATGGAAG 1140 RACTGCTCTC ATACTTGCTG TATGTTGTGG ATCAGCAAGT ATAGTCAGCC YTCTACTTGA 1200 GCAAAATRTT GATGTATCTT CTCAAGATCT GGAAAGACGG CCAGAGAGTA TGCTGTTTCT 1260 AGTCATCATC ATGTAATTTG CCAGTTACTT TCTGACTACA AAGAAAAACA GATGTTAAAA 132 ATCTCTTCTG AAAACAGCAA TCCAGAACAA GACTTAAAGC TGACATCAGA GGAAGAGTCA 1380 CAAAGGCTTA AAGGAAGTGA AAACAGCCAG CCAGAGGCAT GGAAACTTTT AAATTTAAAC 1440 TTTTGGTTTA ATGTTTTTTT TTTTTGCCTT AATAATATTA GATAGTCCCA AATGAAATWA 1500 CCTATGAGAC TAGGCTTTGA GAATCAATAG ATTCTTTTTT TAAGAATCTT TTGGCTAGGA 1560 GCGGTGTCTC ACGCCTGTAA TTCCAGCACC TTGAGAGGCT GAGGTGGGCA GATCACGAGA 1620 TCAGGAGATC GAGACCATCC TGGCTAACAC GGTGAAACCC CATCTCTACT AAAAATACAA 1680 AAACTTAGCT GGGTGTGGTG GCGGGTGCCT GTAGTCCCAG CTACTCAGGA RGCTGAGGCA 1740 GGAGAATGGC ATGAACCCGG GAGGTGGAGG TTGCAGTGAG CCGAGATCCG CCACTACACT 1800 CCAGCCTGGG TGACAGAGCA AGACTCTGTC TCAAAAAAAA AAAAAAAAAA AAA 1853 (2) INFORMATION FOR SEQ ID NO: 296: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 2184 base pairs (B) TYPE: nucleic acid (C) FILAMENTO: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 296: GGCACGAGAA TTAAAACCCT CAGCAAAACA GGCATAGAAG GGACATACCT TAAAGTAATA 60 AAAACCACCT ATGACAAGCC CACAGCCAAC ATAATACTAA ATGGGGAAAA GTTAGAAGCA 120 TTTCCTCTGA GAACTGCAAC AATAAATACA AGGATGCTGG ATTTTGTCAA ATGCCTTTTC 180 TGTGTCTGTT GAGATGCTTA TGTGACTTTG CTTTTAATTC TGTTTATGTG ATTATCACAT 240 TTATTGACTT GCCTGTGTTA GACCGGAAGA sCTGGGGTGT TTCTCAGGAG CCACCGTGTG 300 CTGCGGCAGC TTCGGGATAA CTTGAGGCTG CATCACTGGG GAAGAAACAC AYTCCTGTCC 360 GTGGCGCTGA TGGCTGAGGA CAGAGCTTCA GTGTGGCTTC TCTGCGACTG GCTTCTTCGG 420 GGAGTTCTTC CTTCATAGTT CATCCATATG GCTCCAGAGG AAAATTATAT TATTTTGTTA 460 TGGATGAAGA GTATTACGTT GTGCAGATAT ACTGCAGTGT CTTCATCTCT TGATGTGTGA 540 TTGGGTAGGT TCCACCATGT TGCCGCAGAT GACATGATTT CAGTACCTGT GTCTGGCTGA 600 AAAGTGTTTG TTTGTGAATG GATATTGTGG TTTCTGGATC TCATCCTCTG TGGGTGGACA 660 GCTTTCTCCA CCTTGCTGGA AGTGACCTGC TGTCCAGAAG TTTGATGGCT GAGGAGTATA 720 CCATCGTGCA TGCATCTTTC ATTTCCTGCA TTTCTTCCTC CCTGGATGGA CAGGGGGAGC 780 GGCAAGAGCA ACGTGGGCAC TTCTGGAGAC CACAACGACT CCTCTGTGAA GACGCTTGGG 840 AGCAAGAGGT GCAAGTGGTG CTGCCACTGC TTCCCCTGCT GCAGGGGAGC GGCAAGAGCA 900 ACGTGGTCGC TTGGGGAGAC TACGATGACA GCGCCTTCAT GGATCCCAGG TACCACGTCC 960 ATGGAGAAGA TCTGGACAAG CTCCACAGAG CTGCCTGGTG GGGTAAAGTC CCCAGAAAGG 1020 ATCTCATCGT CATGCTCAGG GACACGGATG TGAACAAGAG GGACAAGCAA AAGAGGACTG 1080 CTCTACATCT GGCCTCTGCC AATGGGAATT CAGAAGTAGT AAAACTCGTG CTGGACAGAC 1140 GATGTCAACT TAATGTCCTT GACAACAAAA AGAGGACAGC TCTGACAAAG GCCGTACAAT 1200 GCCAGGAAGA TGAATGTGCG TTAATGTTGC TGGAACATGG CACTGATCCA AATATTCCAG 1260 ATGAGTATGG AAATACCACT CTACACTATG CTGTCTACAA TGAAGATAAA TTAATGGCCA 1320 AAGCACTGCT CTTATACGGT GCTGATATCG AATCAAAAAA CAAGCATGGC CTCACACCAC 1380 TGCTACTTGG TATACATGAG CAAAAACAGC AAGTGGTGAA ATTTTTAATC AAGAAAAAAG 1440 CGAATTTAAA TGCGCTGGAT AGATATGGAA GAACTGCTCT CATACTTGCT GTATGTTGTG 1500 GATCAGCAAG TATAGTCAGC CCTCTACTTG AGCAAAATGT TGATGTATCT TCTCAAGATC 1560 TGGAAAGACG GCCAGAGAGT ATGCTGTTTC TAGTCATCAT CATGTAATTT GCCAGTTACT 1620 TTCTGACTAC AAAGAAAAAC AGATGTTAAA AATCTCTTCT GAAAACAGCA ATCCAGAACA 1680 AGACTTAAAG CTGACATCAG AGGAAGAGTC ACAAAGGCTT AAAGGAAGTG AAAACAGCCA 1740 GCCAGAGGCA TGGAAACTTT TAAATTTAAA CTTTTGGTTT AATGTTTTTT TTTTTTGCCT 1800 TAATAATATT AGATAGTCCC AAATGAAATW ACCTATGAGA CTAGGCTTTG AGAATCAATA 1860 GATTCTTTTT TTAAGAATCT TTTGGCTAGs AGCGGTGTCT CACGCCTGTA ATTCCAGCAC 1920 CTTGAGAGGC TGAGGTGGGC AGATCACGAG ATCAGGAGAT CGAGACCATC CTGGCTAACA 1980 CGGTGAAACC CCATCTCTAC TAAAAATACA AAAACTTAGC TGGGTGTGGT GGCGGGTGCC 2040 TGTAGTCCCA GCTACTCAGG ARGCTGAGGC AGGAGAATGG CATGAACCCG GGAGGTGGAG 210 GTTGCAGTGA GCCGAGATCC GCCACTACAC TCCAGCCTGG GTGACAGAGC AAGACTCTGT 216 CTCAAAAAAA AAAAAAAAAA AAAA 218 (2) I NFORMATION FOR SEQ ID NO: 297: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1855 base pairs (B) TI PO: nucleic acid (C) FI LAMENT: simple (D) TOPOLOGY: linear (xi) SEQUENCE DESCRITION: SEQ ID NO: 297: TGCACGCATC GGCCAGTGTC TGTGCCACGT ACACTGACGC CCCCTGAGAT GTGCACGCCG 60 CACGCGCACG TTGCACGCGC GGCAGCGGCT TGGCTGGCTT GTAACGGCTT GCACGCGCAC 120 GCCGCCCCCG CATAACCGTC AGACTGGCCT GTAACGGCTT GCAGGCGCAC GCCGCACGCG 180 CGTAACGGCT TGGCTGCCCT GTAACGGCTT GCACGTGCAT GCTGCACGCG CGTTAACGGC 240 TTGGCTGGCA TGTAGCCGCT TGGCTTGGCT TTGCATTYTT TGCTKGGCTK GGCGTTGKTY 300 TCTTGGATTG CGCTTCCTC CTTGGATKGA CGTTTCCTCC TTGGATKGAC GTTTCYTYTY 360 TCGCGTTCCT TTGCTGGACT TGACCTTTTY TCTGCTGGGT TTGGCATTCC TTTGGGGTGG 420 GCTsGGTGTT TTCTCCGGGG GGGKTKGCCC TTCCTGGGGT GGGCGTGGGK CGCCCCCAGG 480 GGGCGTGGGC TTTCCCCGGG TGGGTGTGGG TTTTCCTGGG GTGGGGTGGs CTGTGCTGGG 540 ATCCCCCTGC TGGGGTTGGC AGGGATTGAC TTTTTCTTC AAACAGATTG GAAACCCGGA 600 GTAACNTGCT AGTTGGTGAA ACTGGTTGGT AGACGCGATC TGCTGGTACT ACTGTTTCTC 660 CTGGCTGTTA AAAGCAGATG GTGGCTGAGG TTGATTCAAT GCCGGCTGCT TCTTCTGTGA 720 AGAAGCCATT TGGTCTCAGG AGCAAGATGG GCAAGTGGTG CGCCACTGCT TCCCCTGCTG 780 CAGGGGGAGC GGCAAGAGCA ACGTGGGCAC TTCTGGAGAC CACAACGACT CCTCTGTGAA 840 GACGCTTGGG AGCAAGAGGT GCAAGTGGTG CTGCCCACTG CTTCCCCTGC TGCAGGGGAG 900 CGGCAAGAGC AACGTGGKCG CTTGGGGAGA CTACGATGAC AGCGCCTTCA TGGAKCCCAG 960 GTACCACGTC CRTGGAGAAG ATCTGGACAA GCTCCACAGA GCTGCCTGGT GGGGTAAAGT 1020 CCCCAGAAAG GATCTCATCG TCATGCTCAG GGACACTGAY GTGAACAAGA RGGACAAGCA 1080 AAAGAGGACT GCTCTACATC TGGCCTCTGC CAATGGGAAT TCAGAAGTAG TAAAACTCGT 1140 GCTGGACAGA CGATGTCAAC TTAATGTCCT TGACAACAAA AAGAGGACAG CTCTGACAAA 1200 GGCCGTACAA TGCCAGGAAG ATGAATGTGC GTTAATGTTG CTGGAACATG GCACTGATCC 1260 AAATATTCCA GATGAGTATG GAAATACCAC TCTACACTAT GCTGTCTACA ATGAAGATAA 1320 ATTAATGGCC AAAGCACTGC TCTTATACGG TGCTGATATC GAATCAAAAA ACAAGGTATA 1380 GATCTACTAA TTTTATCTTC AAAATACTGA AATGCATTCA TTTTAACATT GACGTGTGTA 1440 AGGGCCAGTC TTCCGTATTT GGAAGCTCAA GCATAACTTG AATGAAAATA TTTTGAAATG 1500 ACCTAATTAT CTAAGACTTT ATTTTAAATA TTGTTATTTT CAAAGAAGCA TTAGAGGGTA 1560 CAGTTTTTTT TTTTTAAATG CACTTCTGGT AAATACTTTT GTTGAAAACA CTGAATTTGT 1620 AAAAGGTAAT ACTTACTATT TTTCAATTTT TCCCTCCTAG GATTTTTTTC CCCTAATGAA 1680 TGTAAGATGG CAAAATTTGC CCTGAAATAG GTTTTACATG AAAACTCCAA GAAAAGTTAA 1740 ACATGTTTCA GTGAATAGAG ATCCTGCTCC TTTGGCAAGT TCCTAAAAAA CAGTAATAGA 1800 TACGAGGTGA TGCGCCTGTC AGTGGCAAGG TTTAAGATAT TTCTGATCTC GTGCC 1855

Claims (49)

1. An isolated DNA molecule, comprising: (a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-452, 154-166, 168-176 , 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268 , 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297; (b) a variant of said nucleotide sequence containing one or more substitutions, deletions, insertions and / or nucleotide modifications in no more than 20% of the nucleotide positions, such that the antigenic and / or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained; or (c) a nucleotide sequence encoding an epitope of a polypeptide encoded by at least one sequence selected from the group consisting of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-452, 154- 166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297.

2. An isolated DNA molecule encoding an epitope of a polypeptide, wherein said polypeptide is encoded by a nucleotide sequence that: (a) hybridizes to a sequence selected from the group consisting of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-452, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218. 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271 -273, 275, 276, 278, 280, 281, 284, 288 and 291 -297 under severe conditions; and (b) is at least 80% identical to a sequence selected from the group consisting of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-452, 1 54-166, 168-1 76 , 1 78-1 92, 1 94-1 98, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297.

3. An isolated DNA molecule encoding an epitope of a polypeptide, wherein said polypeptide is encoded by: (a) a nucleotide sequence transcribed from the SEQ sequence I D NO.141; or (b) a variant of said nucleotide sequence containing one or more substitutions, deletions, insertions and / or modifications of nucleotides in no more than 20% of the nucleotide positions, so that the antigenic and / or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained.

4. An isolated DNA or RNA molecule comprising a nucleotide sequence complementary to a DNA molecule according to any of claims 1-3.

5. A recombinant expression vector comprising a DNA molecule according to any of claims 1-3.

6. A host cell transformed or transfected with an expression vector according to claim 5.

7. A polypeptide comprising an amino acid sequence encoded by a DNA molecule according to any of claims 1 -3.

A polypeptide according to claim 7, wherein said polypeptide comprises an epitope of an amino acid sequence encoded by at least one nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3-26, 28-77 , 142, 143, 146-452, 1 54- 166, 168-176, 1 78-192, 1 94-1 98, 200-204, 206, 207, 209-214, 216, 218, 219, 221 -240 , 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271 -273, 275, 276, 278, 280, 281, 284, 288 and 291-297.

9. A monoclonal antibody that binds to a polypeptide according to claim 7.

10. A method for determining the presence of breast cancer in a patient comprising detecting, within a biological sample, at least one polypeptide according to the invention. claim 7, and hence determine the presence of breast cancer in the patient. eleven .

A method for determining the presence of breast cancer in a patient comprising detecting within a biological sample, at least one polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153 , 1 67, 177, 193, 1 99, 205, 208, 21 5, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize to them under severe conditions.

The method of claims 10 or 11, wherein the biological sample is a portion of a breast tumor.

The method of claim 10, wherein the step of detecting comprises contacting the biological sample with a monoclonal antibody according to claim 9.

14. The method of claim 1, wherein the step of detecting comprises contacting the biological sample with a monoclonal antibody that binds to a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 1 53, 167, 1777, 193, 199, 205, 208, 215, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize to them under severe conditions. 5.

A method for determining the presence of breast cancer in a patient comprising detecting, within a biological sample, an RNA molecule encoding at least one polypeptide according to claim 7, and from there determining the presence of cancer of Mom in the patient.

16. A method for determining the presence of breast cancer in a patient comprising detecting, within a biological sample, at least one RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78 -86, 144, 145, 153, 1 67, 1 77, 193, 1 99, 205, 208, 21 5, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize to the same under severe conditions; and from there to determine the presence of breast cancer in the patient.

17. The method of claims 1 5 or 16, wherein the biological sample is a portion of a breast tumor.

The method of claim 1, wherein the step of detecting comprises: (a) preparing cDNA from RNA molecules within the biological sample; and (b) specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide according to claim 7, and hence determining the presence of breast cancer in the patient.

The method of claim 16, wherein the step of detecting comprises: (a) preparing cDNA from RNA molecules within the biological sample; and (b) specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 1 53, 167, 1 77, 1 93, 1 99, 205, 208, 21 5, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285- 287, 289, 290 and sequences that hybridize thereto under severe conditions; and from there to determine the presence of breast cancer in the patient.

20. A method for monitoring the progression of breast cancer in a patient, comprising: (a) detecting an amount, in a biological sample, of at least one polypeptide according to claim 7 at a first point in time; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of polypeptide detected in the steps (a) and (b), and hence monitor the progression of breast cancer in the patient. twenty-one .

A method for monitoring the progression of breast cancer in a patient, comprising: (a) detecting in a biological sample an amount of at least one polypeptide at a first point in time, the polypeptide being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 1 53, 167, 1 77, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under severe conditions; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of polypeptides detected in steps (a) and (b), and hence monitoring the progression of breast cancer in the patient.

22. The method of claim 20 or 21, wherein the biological sample is a portion of a breast tumor.

The method of claim 20, wherein the step of detecting comprises contacting a portion of the biological sample with a monoclonal antibody according to claim 9.

24. The method of claim 21, wherein the step of detecting comprises contacting the biological sample with a monoclonal antibody that binds to a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86. , 144, 45, 1 53, 1 67, 1 77, 1 93, 1 99, 205, 208, 21 5, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under severe conditions.

The method of claim 20, wherein said polypeptide comprises an epitope of an amino acid sequence encoded by at least one nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3-26, 28-77, 142 , 143, 146-452, 154-166, 168-176, 178-1,292, 1 94-198, 200-204, 206, 207, 209-214, 216, 218, 21 9, 221-240, 243.245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271 -273, 275, 276, 278, 280, 281, 284, 288 and 291-297.

26. A method for monitoring the progression of breast cancer in a patient, comprising: (a) detecting an amount, within a biological sample, of at least one RNA molecule encoding a polypeptide according to claim 7 in a first point in time; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of RNA molecules detected in steps (a) and (b), and hence monitoring the progression of breast cancer in the patient.

The method of claim 25, wherein the step of detecting comprises: (a) preparing cDNA from RNA molecules within the biological sample; and (b) specifically amplifying cDNA molecules that are capable of encoding at least a portion of a polypeptide according to claim 7.

28. A method for monitoring the progression of breast cancer in a patient, comprising: (a) detecting an amount, within a biological sample, of a RNA molecule at a first point in time, the RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86 , 144, 145, 1 53, 167, 177, 193, 1 99, 205, 208, 21 5, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277 , 279, 282, 283, 285-287, 289, 290 and sequences that hybridize to them under severe conditions; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of RNA molecules detected in steps (a) and (b), and hence monitoring the progression of breast cancer in the patient.

29. A pharmaceutical composition, comprising a polypeptide according to claim 7 and a physiologically acceptable carrier.

30. A pharmaceutical composition for inhibiting the development of breast cancer, comprising a polypeptide and a physiologically acceptable carrier, the polypeptide being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 1 53 , 167, 1 77, 1 93, 1 99, 205, 208, 21 5, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under severe conditions.

31 A vaccine, comprising a polypeptide according to claim 7 and an immune response enhancer.

32. A vaccine, comprising a DNA molecule according to any of claims 1 -3.

33. A vaccine, comprising a recombinant expression vector comprising a DNA molecule according to any of claims 1-3.

34. A vaccine for inhibiting the development of breast cancer, comprising a polypeptide and an immune response enhancer, the polypeptide being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 1 67, 1 77, 1 93, 1 99, 205, 208, 215, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282 , 283, 285-287, 289, 290 and sequences that hybridize to them under severe conditions.

35. A pharmaceutical composition according to any of claims 29 or 30, for use in the manufacture of a medicament for inhibiting the development of breast cancer in a patient, comprising administering to a patient.

36. A vaccine according to any of claims 31-34, for use in the manufacture of a medicament for inhibiting the development of breast cancer in a patient.

37. A diagnostic set comprising: (a) one or more monoclonal antibodies according to claim 9; and (b) a detection reagent.

38. A diagnostic kit comprising: (a) one or more monoclonal antibodies that bind to a polypeptide encoded by a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID NO: 78-86, 144, 145, 153, 167 , 177, 1 93, 199, 205, 208, 215, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287 , 289, 290 and sequences that hybridize to them under severe conditions; and (b) a detection reagent.

39. The set of any of claims 37 or 38, wherein the monoclonal antibody (s) is immobilized on a solid support.

40. A diagnostic set comprising two polymerase chain reaction primers, at least one of the primers being specific for an RNA molecule according to claim 4.

41 The assembly of claim 40, wherein at least one of the polymerase chain reaction initiators comprises at least 10 contiguous nucleotides of an RNA molecule according to claim 4.

42. A diagnostic set comprising two reaction primers. in polymerase chain, at least one of the primers being specific for an RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177 , 193, 199, 205, 208, 215, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.

43. The assembly of claim 42, wherein at least one of the polymerase chain reaction primers comprises at least about 10 contiguous nucleotides of an RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of consists of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274 , 277, 279, 282, 283, 285-287, 289 and 290.

44. A diagnostic set comprising at least one oligonucleotide probe, the oligonucleotide probe containing at least about 15 contiguous nucleotides of a DNA molecule according to the invention. claim 4.

45. A diagnostic set comprising at least one oligonucleotide probe, the oligonucleotide probe comprising at least about 15 contiguous nucleotides of a DNA sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 1 77, 193, 1 99, 205, 208, 21 5, 21 7, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.

46. A diagnostic set comprising at least one oligonucleotide probe specific for a DNA molecule according to claim 4.

47. The set of the claim 46, wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA molecule according to claim 4.

48. A diagnostic set comprising at least one oligonucleotide probe specific for a DNA sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.

49. The assembly of claim 48, in wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215 , 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.